U.S. patent application number 15/907119 was filed with the patent office on 2018-10-18 for targeted therapeutic nucleosides and their use.
This patent application is currently assigned to Ionis Pharmaceuticals, Inc.. The applicant listed for this patent is Ionis Pharmaceuticals, Inc.. Invention is credited to Thazha P. Prakash, Punit P. Seth.
Application Number | 20180296684 15/907119 |
Document ID | / |
Family ID | 52689464 |
Filed Date | 2018-10-18 |
United States Patent
Application |
20180296684 |
Kind Code |
A1 |
Seth; Punit P. ; et
al. |
October 18, 2018 |
TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE
Abstract
Provided herein are compounds comprising one or more therapeutic
nucleosides and one or more targeting groups. In certain
embodiments, the compounds further comprise one or more
oligonucleotides. In certain embodiments, a targeting group
comprises one or more N-Acetylgalactosamine.
Inventors: |
Seth; Punit P.; (Carlsbad,
CA) ; Prakash; Thazha P.; (Carlsbad, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ionis Pharmaceuticals, Inc. |
Carlsbad |
CA |
US |
|
|
Assignee: |
Ionis Pharmaceuticals, Inc.
Carlsbad
CA
|
Family ID: |
52689464 |
Appl. No.: |
15/907119 |
Filed: |
February 27, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15021995 |
Mar 15, 2016 |
9943604 |
|
|
PCT/US2014/056630 |
Sep 19, 2014 |
|
|
|
15907119 |
|
|
|
|
61880813 |
Sep 20, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/7068 20130101;
A61K 47/549 20170801; C07H 19/20 20130101; A61K 31/7064 20130101;
C12N 2320/32 20130101; A61K 45/06 20130101; A61K 31/7008 20130101;
A61K 31/711 20130101; C12N 2310/113 20130101; C12N 15/111 20130101;
C12N 2310/351 20130101; C07H 19/10 20130101; A61K 31/713 20130101;
A61K 31/706 20130101; A61K 31/7125 20130101; A61K 31/712 20130101;
A61K 47/61 20170801; A61K 31/7052 20130101; C12N 2310/14 20130101;
A61K 31/7072 20130101; C12N 2310/11 20130101; A61K 31/7115
20130101; A61K 31/713 20130101; A61K 2300/00 20130101; A61K 31/7125
20130101; A61K 2300/00 20130101; A61K 31/712 20130101; A61K 2300/00
20130101; A61K 31/7115 20130101; A61K 2300/00 20130101; A61K 31/711
20130101; A61K 2300/00 20130101; A61K 31/7072 20130101; A61K
2300/00 20130101 |
International
Class: |
A61K 47/61 20170101
A61K047/61; A61K 45/06 20060101 A61K045/06; C07H 19/10 20060101
C07H019/10; C07H 19/20 20060101 C07H019/20; C12N 15/11 20060101
C12N015/11; A61K 47/54 20170101 A61K047/54; A61K 31/7125 20060101
A61K031/7125; A61K 31/711 20060101 A61K031/711; A61K 31/7115
20060101 A61K031/7115; A61K 31/712 20060101 A61K031/712; A61K
31/713 20060101 A61K031/713; A61K 31/7072 20060101
A61K031/7072 |
Claims
1.-235. (canceled)
236. A compound consisting of a targeting group and 2-50 linked
therapeutic nucleosides, wherein the targeting group comprises at
least one cell-targeting ligand.
237. The compound of claim 236, wherein the targeting group
comprises three cell-targeting ligands.
238. The compound of claim 236 or 237, wherein each cell-targeting
ligand is N-acetylgalactosamine.
239. The compound of claim 236, wherein the targeting group
comprises a structure represented by formula I below: ##STR00226##
wherein: A is a cell-targeting ligand; B is a tether; C is a
branching group; D is a targeting group linker; E is a cleavable
moiety; n is 1, 2, 3, 4, or 5; and m is 0 or 1.
240. The compound of claim 236, wherein at least one therapeutic
nucleoside comprises a modified furanosyl ring, wherein the
modified furanosyl ring of the at least one therapeutic nucleoside
comprises a 2' or 3' substituent independently selected from
hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl,
alkoxy, CF3, and ester.
241. The compound of claim 236, wherein at least one therapeutic
nucleoside comprises the following structure: ##STR00227## wherein
R.sub.3 is hydroxyl or the targeting group; and R4 and R5 are each
independently selected from phenoxy, NHCH(CH3)C(O)OiPr, alkoxy,
alkylamino, hydroxyl, an internucleoside linking group linking the
therapeutic nucleoside to another therapeutic nucleoside, and the
targeting group; provided that exactly one of R3, R4, and R5 is the
targeting group.
242. The compound of claim 236, wherein one terminal therapeutic
nucleoside comprises the following structure: ##STR00228## wherein
B is a modified or unmodified nucleobase; X is O or CCH2; Y is
CR.sub.6R.sub.7; and R.sub.6 is the targeting group, hydrogen,
hydroxyl, or O-L-valinyl ester; R.sub.7 is hydrogen, hydroxyl, or
O-L-valinyl ester; and wherein if R.sub.6 is not the targeting
group, the terminal therapeutic nucleoside is linked to a compound
comprising a targeting group.
243. The compound of claim 236, wherein at least one therapeutic
nucleoside is an antiviral nucleoside.
244. The compound of claim 243, wherein at least one antiviral
nucleoside inhibits a viral polymerase.
245. The compound of claim 243, wherein at least one antiviral
nucleoside is selected from among an anti-HCV nucleoside and an
anti-HBV nucleoside.
246. A pharmaceutical composition comprising a compound of claim
236 or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable carrier or diluent.
247. A compound consisting of a targeting group, 1-50 linked
therapeutic nucleosides, and an antisense compound; wherein the
targeting group comprises at least one cell-targeting ligand;
wherein the therapeutic nucleosides are linked by cleavable bonds
to each other and to the antisense compound; wherein said
therapeutic nucleosides are cleaved from each other and from the
antisense compound upon cellular uptake; and wherein the antisense
compound consists of 8-30 linked nucleosides.
248. The compound of claim 247, wherein the cell-targeting ligand
is N-acetylgalactosamine.
249. The compound of claim 247, wherein the cleavable bond is
selected from among an amide, a polyamide, an ester, an ether, a
phosphodiester, a phosphate ester, a phosphonate, a
phosphoramidate, a carbamate, a disulfide, or a peptide.
250. The compound of claim 247, wherein the antisense compound
comprises at least one modified nucleoside comprising a
modification at the 2' position selected from MOE, OMe, cEt, and
LNA.
251. The compound of claim 247, wherein the antisense oligomeric
compound is complementary to a target viral RNA or a target human
RNA that is involved in virus pathogenicity.
252. The compound of claim 247, wherein at least one therapeutic
nucleoside(s) comprises the following structure: ##STR00229##
wherein for each therapeutic nucleoside with this structure, R3 is
hydroxyl or a targeting group; and R4 and R5 are each phenoxy,
NHCH(CH3)C(O)OiPr, alkoxy, alkylamino, hydroxyl, a targeting group,
or an internucleoside linking group linking the therapeutic
nucleoside to another therapeutic nucleoside or to the antisense
compound; with the proviso that the compound has exactly one
targeting group.
253. The compound of claim 247, wherein each internucleoside
linkage linking two therapeutic nucleosides to one another is an
unmodified phosphodiester internucleoside linkage.
254. A pharmaceutical composition comprising a compound of claim
247 or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable carrier or diluent.
Description
SEQUENCE LISTING
[0001] The present application is being filed along with a Sequence
Listing in electronic format. The Sequence Listing is provided as a
file entitled CORE0119USC1SEQ_ST25.txt, created on Feb. 27, 2018,
which is 8 Kb in size. The information in the electronic format of
the sequence listing is incorporated herein by reference in its
entirety.
BACKGROUND OF THE INVENTION
[0002] Certain therapeutic nucleosides are known in the art. For
example, certain modified nucleosides posess antiviral activity.
For example, certain such nucleosides inhibit viral poymerases,
such as Hepatitis C Virus (HCV) NS5b polymerase. See e.g., U.S.
Pat. No. 7,105,499.
[0003] In certain instances, certain chemical moieties, when
attached to a parent compound, enhance entry of such parent
compound into a cell. In certain such instances, entry is
particularly increased for a particular cell type. For example, it
has been reported that N-acetyl galactoseamine (GalNAc), when
attached through certain linkers to an siRNA compound can increase
uptake of such siRNA compound into liver cells.
[0004] Antisense compounds have been described previously. The
principle behind antisense technology is that an antisense compound
hybridizes to a target nucleic acid and modulates the amount,
activity, and/or function of the target nucleic acid. For example
in certain instances, antisense compounds result in altered
transcription or translation of a target. Such modulation of
expression can be achieved by, for example, target mRNA degradation
or occupancy-based inhibition. An example of modulation of RNA
target function by degradation is RNase H-based degradation of the
target RNA upon hybridization with a DNA-like antisense compound.
Another example of modulation of gene expression by target
degradation is RNA interference (RNAi). RNAi refers to
antisense-mediated gene silencing through a mechanism that utilizes
the RNA-induced siliencing complex (RISC).
[0005] Chemical modifications increasing potency of therapeutic
nucleosides and/or antisense compounds allow administration of
lower doses, which reduces the potential for toxicity, as well as
decreasing overall cost of therapy.
SUMMARY OF THE INVENTION
[0006] In certain embodiments, the present disclosure provides
therapeutic agents comprising at least one therapeutic nucleoside
and at least one targeting group. Certain such therapeutic agents
also comprise one or more oligomeric compound, such as an antisense
compound. Certain therapeutic agents are represented by the
formula:
(Targeting Group).sub.p-(Therapeutic Nucleoside).sub.n-(Oligomeric
Compound).sub.m;
[0007] wherein
[0008] p is 0-10;
[0009] n is from 1-50; and
[0010] m is 0 or 1;
[0011] provided that if n is 1 and m is 0, then p is not 0.
[0012] In such embodiments, the targeting group may be attached to
any position of at least one target nucleoside.
[0013] Such attachment may be through a cleavable moiety, such as a
cleavable bond or a cleavable nucleoside. In embodiments comprising
more than one therapeutic nucleoside (i.e., where n is >1) such
therapeutic nucleosides may be linked together by cleavable
moieties, such as cleavable bonds or cleavable nucleosides. The
therapeutic nucleoside may attach to either the 3' or the 5' end of
the oligomeric compound and may be attached by a cleavable moiety,
such as a cleavable bond or cleavable nucleoside. In certain
embodiments, the oligomeric compound is an antisense compound.
[0014] Certain therapeutic agents are represented by the
formula:
(Targeting Group).sub.p-(Oligomeric Compound).sub.m-(Therapeutic
Nucleoside).sub.n;
[0015] wherein
[0016] p is 0-10;
[0017] n is from 1-50; and
[0018] m is 0 or 1;
[0019] provided that if n is 1 and m is 0, then p is not 0.
[0020] In such embodiments, the targeting group may be attached to
either the 3' or the 5' end of the oligomeric compound and may be
attached by a cleavable moiety, such as a cleavable bond or
cleavable nucleoside. The oligomeric compound may attach to any
position of at least one therapeutic nucleoside. Such attachment
may comprise a cleavable moiety, such as a cleavable bond or
cleavable nucleoside. In embodiments comprising more than one
therapeutic nucleoside (where n is >1) such therapeutic
nucleosides may be linked together by cleavable moieties, such as
cleavable bonds or cleavable nucleosides. In certain embodiments,
the oligomeric compound is an antisense compound.
[0021] In certain embodiments, the therapeutic nucleoside and the
oligomeric compound both treat the same disease or condition. In
certain such embodiments, the disease or condition is a viral
infection. In certain such embodiments, the viral infection
comprises infection in the liver. In certain such embodiments, the
disease or condition is Hepatitis B infection. In certain
embodiments, the disease or condition is Hepatitis C infection.
[0022] In certain embodiments, the targeting group comprises a
ligand for a cell surface receptor. For example, in certain
embodiments, the targeting group comprises at least one N-acetyl
galactoseamine, which has been described as a ligand for the
asiaglycoprotein receptor. In certain embodiments the targeting
group increases uptake of the therapeutic compound (with or without
an oligomeric compound) into cells. In certain such embodiments,
uptake is particularly increased in certain cells or cell-types.
For example, cells that express a receptor that is recognized by a
ligand of the targeting group. Asiaglycoprotein receptors are
expressed on hepatocytes, so compounds comprising GalNac ligands
are preferentially taken up by hepatocytes. In certain embodiments,
once inside a cell, the targeting group is cleaved from the one or
more therapeutic nucleosides. Further, in certain embodiments
comprising more than one therapeutic nucleoside, such therapeutic
nucleosides are cleaved from one another. Thus, after uptake and
cleavage, free individual therapeutic nucleosides are present in
the cell. In certain embodiments, compounds further comprise an
oligomeric compound. Such oligomeric compound may be
single-stranded or double-stranded and may be an antisense
compound, such as a RISC compound or RNase H compound; an siRNA,
ssRNA, shRNA, or ASO.
[0023] In embodiments comprising more than one therapeutic
nucleoside, the targeting group may be absent. That is, in certain
embodiments, the invention provides 2-50 linked therapeutic
nucleosides. In certain such embodiments, the therapeutic
nucleosides are linked by cleavable bonds. In certain embodiments,
such 2-50 linked therapeutic nucleosides lacking a targeting group
are bound to an oligomeric compound, such as an antisense
compound.
[0024] Certain therapeutic agents of the present invention are
characterized as follows:
##STR00001##
[0025] In certain embodiments, therapeutic agents are provided
having the structure:
##STR00002##
[0026] In certain embodiments, therapeutic agents are provided
having the structure:
##STR00003##
[0027] The present disclosure provides the following non-limiting
numbered embodiments: [0028] Embodiment 1. A compound comprising a
targeting group and at least one therapeutic nucleoside. [0029]
Embodiment 2. The compound of embodiment 1, wherein the targeting
group comprises at least one cell-targeting ligand. [0030]
Embodiment 3. The compound of embodiment 1, wherein the targeting
group comprises 1-4 cell-targeting ligands. [0031] Embodiment 4.
The compound of embodiment 3 comprising 3 cell-targeting ligands.
[0032] Embodiment 5. The compound of any of embodiments 1-4,
wherein each cell-targeting ligand is N-acetylgalactosamine. [0033]
Embodiment 6. The compound of embodiment 5, wherein the
N-acetylgalactosamine is attached to the compound via the galactose
Cl oxygen. [0034] Embodiment 7. The compound of any of embodiments
1-6, wherein the targeting group comprises a targeting group
linker. [0035] Embodiment 8. The compound of embodiment 7, wherein
the targeting group linker comprises one or more groups selected
from among: phosphate, amide, ether, ester, pyrrolidine, disulfide,
and methylene. [0036] Embodiment 9. The compound of embodiment 8,
wherein the targeting group linker comprises a structure selected
from among:
##STR00004## ##STR00005##
[0037] wherein n and m are independently selected from 1, 2, 3, 4,
5, 6, 7, 8, 9, or 10. [0038] Embodiment 10. The compound of any of
embodiments 1-9, wherein the targeting group comprises a branching
group. [0039] Embodiment 11. The compound of embodiment 10, wherein
the branching group comprises one or more groups selected from
among: amino acid, amino alcohol, alkoxy, and amine. [0040]
Embodiment 12. The compound of embodiment 10 or 11, wherein the
branching group has a structure selected from among:
[0040] ##STR00006## [0041] Embodiment 13. The compound of any of
embodiments 1-12, wherein the targeting group comprises at least
one tether. [0042] Embodiment 14. The compound of embodiment 13,
wherein at least one tether comprises one or more groups selected
from among: amino acid, amide, methylene, phosphate, carbonyl, and
piperidine. [0043] Embodiment 15. The compound of embodiment 14,
wherein at least one tether has a structure selected from
among:
##STR00007##
[0044] wherein n, m, and q are independently selected from 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10. [0045] Embodiment 16. The compound of any
of embodiments 1-15, wherein the targeting group comprises a
cleavable moiety. [0046] Embodiment 17. The compound of embodiment
16, wherein the cleavable moiety is a non-therapeutic nucleoside.
[0047] Embodiment 18. The compound of embodiment 17, wherein the
cleavable non-therapeutic nucleoside is attached to the targeting
group linker via a cleavable bond. [0048] Embodiment 19. The
compound of embodiment 17 or 18, wherein the non-therapeutic
nucleoside comprises a 2' substituent selected from among: H, OH,
MOE, F, and OMe. [0049] Embodiment 20. The compound of any of
embodiments 1-19, wherein the targeting group comprises a group
comprises a structure represented by formula I below:
##STR00008##
[0050] wherein:
[0051] A is a cell-targeting ligand;
[0052] B is a tether;
[0053] C is a branching group;
[0054] D is a targeting group linker;
[0055] E is a cleavable moiety;
[0056] n is 1, 2, 3, 4, or 5; and
[0057] m is 0 or 1. [0058] Embodiment 21. The compound of any of
embodiments 1-20, wherein the targeting group increases potency of
the therapeutic nucleoside. [0059] Embodiment 22. The compound of
any of embodiments 1-20, wherein the targeting group increases in
delivery or uptake of the therapeutic nucleoside in liver cells.
[0060] Embodiment 23. The compound of embodiment 22, wherein the
liver cells are hepatocytes. [0061] Embodiment 24. The compound of
embodiment 22 or 23, wherein the cells are in an animal. [0062]
Embodiment 25. The compound of any of embodiments 1-24, wherein at
least one therapeutic nucleoside comprises a modified or unmodified
pyrimidine nucleobase. [0063] Embodiment 26. The compound of any of
embodiments 1-25, wherein at least one therapeutic nucleoside
comprises a modified or unmodified purine nucleobase. [0064]
Embodiment 27. The compound of any of embodiments 1-26, wherein at
least one therapeutic nucleoside comprises a modified furanosyl
ring. [0065] Embodiment 28. The compound of embodiment 27, wherein
the modified furanosyl ring of the at least one therapeutic
nucleoside comprises a 2' or 3' substituent independently selected
from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl,
alkoxy, CF.sub.3, and ester. [0066] Embodiment 29. The compound of
any of embodiments 27-28, wherein the modified furanosyl ring of
the at least one therapeutic nucleoside comprises a 5' substituent
independently selected from hydrogen, hydroxyl, ester, phosphate,
phosphate ester, and phosphoramidate. [0067] Embodiment 30. The
compound of any of embodiments 27-29, wherein the modified
furanosyl ring of the at least one therapeutic nucleoside comprises
a 4' substituent comprising an azido group. [0068] Embodiment 31.
The compound of any of embodiments 27-30, wherein the modified
furanosyl ring of the at least one therapeutic nucleoside comprises
a 2' substituent that is other than H or OH. [0069] Embodiment 32.
The compound of embodiment 31, wherein at least one 2' substituent
of the modified furanosyl ring of at least one therapeutic
nucleoside is selected from F and methyl. [0070] Embodiment 33. The
compound of embodiment 32, wherein neither 2' substituent is H or
OH. [0071] Embodiment 34. The compound of any of embodiments 27-33,
wherein the 2' substituents are methyl and hydroxyl. [0072]
Embodiment 35. The compound of any of embodiments 27-33, wherein
the 2' substituents are methyl and fluoro. [0073] Embodiment 36.
The compound of embodiment 35, wherein absolute configuration of
the chiral center at the 2' position is R. [0074] Embodiment 37.
The compound of any of embodiments 27-36, wherein the 3'
substituents of the modified furanosyl ring of at least one
therapeutic nucleoside are hydrogen and hydroxyl. [0075] Embodiment
38. The compound of any of embodiments 27-37, wherein the 5'
substituents of the modified furanosyl ring of at least one
therapeutic nucleoside comprise OP(O)R.sub.1R.sub.2, wherein
R.sub.1 and R.sub.2 are each independently hydroxyl, phenoxy,
naphthalenoxy, OiPr, NHbenzyl, NHCH(CH.sub.3)C(O)OiPr, and
NHCH(CH.sub.3)C(O)OCH.sub.2t-butyl. [0076] Embodiment 39. The
compound of any of embodiments 1-38, wherein the therapeutic
nucleoside comprises the following structure:
[0076] ##STR00009## [0077] wherein R.sub.3 is hydroxyl or the
targeting group; and [0078] Bx is a modified or unmodified
nucleobase. [0079] Embodiment 40. The compound of embodiment 39,
wherein the therapeutic nucleoside comprises the following
structure:
[0079] ##STR00010## [0080] wherein R.sub.3 is hydroxyl or the
targeting group; and [0081] R.sub.4 and R.sub.5 are each
independently selected from phenoxy, NHCH(CH.sub.3)C(O)OiPr,
alkoxy, alkylamino, hydroxyl, an internucleoside linking group
linking the therapeutic nucleoside to another nucleoside or to an
oligomeric compound, and the targeting group; provided that at
least one of R.sub.3, R.sub.4, and R.sub.5 is a targeting group.
[0082] Embodiment 41. The compound of any of embodiments 1-38,
wherein the therapeutic nucleoside comprises the following
structure:
[0082] ##STR00011## [0083] wherein B is a modified or unmodified
nucleobase; [0084] X is O or CCH.sub.2; [0085] Y is S or
CR.sub.6R.sub.7; and [0086] R.sub.6 and R.sub.7 are each
independently selected from hydrogen, hydroxyl, O-L-valinyl ester,
and the targeting group. [0087] Embodiment 42. The compound of
embodiment 41, wherein the modified or unmodified nucleobase is
selected from among: adenine, uracil, cytosine, 5-methylcytosine,
guanine, thymine, and 5-fluorocytosine. [0088] Embodiment 43. The
compound of any of embodiments 1-42, wherein at least one
therapeutic nucleoside comprises an acyclic sugar surrogate. [0089]
Embodiment 44. The compound of embodiment 43, wherein the
therapeutic nucleoside comprising an acyclic sugar surrogate
comprises a purine nucleobase linked to a phosphonate via the sugar
surrogate. [0090] Embodiment 45. The compound of embodiment 44,
wherein the targeting group is attached to the phosphonate. [0091]
Embodiment 46. The compound of any of embodiments 1-45, wherein at
least one therapeutic nucleoside is an antiviral nucleoside. [0092]
Embodiment 47. The compound of embodiment 46, wherein the at least
one anti-viral nucleoside inhibits a viral polymerase. [0093]
Embodiment 48. The compound of embodiment 46 or 47, wherein at
least one antiviral nucleoside is an anti-HCV nucleoside. [0094]
Embodiment 49. The compound of embodiment 46 or 47, wherein the at
least one antiviral nucleoside is an anti-HBV nucleoside. [0095]
Embodiment 50. The compound of any of embodiments 1-49, wherein the
compound comprises one therapeutic nucleoside. [0096] Embodiment
51. The compound of any of embodiments 1-49, wherein the compound
comprises 2-50 therapeutic nucleosides. [0097] Embodiment 52. The
compound of embodiment 51, wherein the therapeutic nucleosides are
all the same as one another. [0098] Embodiment 53. The compound of
embodiment 51, wherein at least 2 therapeutic nucleosides are
different from one another. [0099] Embodiment 54. The compound of
any of embodiments 51-53, wherein at least one internucleoside
linkage linking two therapeutic nucleosides to one another is an
unmodified phosphodiester internucleoside linkage. [0100]
Embodiment 55. The compound of any of embodiments 51-54, wherein
each internucleoside linkage linking two therapeutic nucleosides to
one another is an unmodified phosphodiester internucleoside
linkage. [0101] Embodiment 56. The compound of any of embodiments
1-55, wherein the targeting group is attached to the therapeutic
nucleoside by a cleavable bond. [0102] Embodiment 57. The compound
of embodiment 56, wherein the cleavable bond is selected from among
an amide, a polyamide, an ester, an ether, a phosphodiester, a
phosphate ester, a phosphonate, a phosphoramidate, a carbamate, a
disulfide, or a peptide. [0103] Embodiment 58. The compound of any
of embodiments 1-57, wherein a targeting group is attached to the
3' position of a therapeutic nucleoside. [0104] Embodiment 59. The
compound of any of embodiments 1-58, wherein a targeting group is
attached to the 5' position of a therapeutic nucleoside. [0105]
Embodiment 60. The compound of any of embodiments 1-59 comprising
an oligomeric compound. [0106] Embodiment 61. The compound of
embodiment 60, wherein the oligomeric compound is single-stranded.
[0107] Embodiment 62. The compound of embodiment 60, wherein the
oligomeric compound is double- stranded. [0108] Embodiment 63. The
compound of any of embodiments 60-62, wherein the oligomeric
compound comprises a modified oligonucleotide consisting of 8-30
linked nucleosides. [0109] Embodiment 64. The compound of
embodiment 63, wherein the modified oligonucleotide comprises at
least one modified nucleoside comprising a modified sugar. [0110]
Embodiment 65. The compound of embodiment 64, wherein the modified
oligonucleotide comprises at least one modified nucleoside
comprising a modification at the 2' position selected from MOE,
OMe, cEt, and LNA. [0111] Embodiment 66. The compound of any of
embodiments 63-65, wherein the modified oligonucleotide comprises a
region of alternating sugar motif, comprising at least three
alternating regions of 2'-OMe nucleosides and 2'-F nucleosides,
wherein each region consists of 1-4 nucleosides. [0112] Embodiment
67. The compound of any of embodiments 63-65 wherein the modified
oligonucleotide is a gapmer. [0113] Embodiment 68. The compound of
any of embodiments 63-67, wherein the modified oligonucleotide
comprises at least one phosphorothioate internucleoside linkage.
[0114] Embodiment 69. The compound of any of embodiments 63-68,
wherein the modified oligonucleotide is an antisense compound.
[0115] Embodiment 70. The compound of embodiment 69, wherein the
antisense compound is an RNase H compound. [0116] Embodiment 71.
The compound of embodiment 69, wherein the antisense compound is an
RNAi oligomeric compound. [0117] Embodiment 72. The compound of any
of embodiments 69-71, wherein the antisense oligomeric compound is
complementary to a target viral RNA or a target human RNA that is
involved in virus pathogenicity. [0118] Embodiment 73. The compound
of embodiment 72, wherein the target RNA is an HCV RNA or a human
RNA involved in HCV pathogenicity. [0119] Embodiment 74. The
compound of embodiment 73, wherein the target RNA is a transcript
of HCV F-transactivated protein 1. [0120] Embodiment 75. The
compound of embodiment 72, wherein the target RNA is an HBV RNA or
a human RNA involved in HBV pathogenicity. [0121] Embodiment 76.
The compound of embodiment 75, wherein the target RNA is a
transcript of HBV associated factor, HBV pX associated protein-8,
or HBV pre-s2 binding protein. [0122] Embodiment 77. The compound
of any of embodiments 69-76, wherein the antisense oligomeric
compound is complementary to a target microRNA. [0123] Embodiment
78. The compound of embodiment 77, wherein the target microRNA is
miR-122. [0124] Embodiment 79. The compound of embodiment 77,
wherein the target microRNA is miR-221 or miR-21. [0125] Embodiment
80. The compound of any of embodiments 60-79, wherein the
therapeutic nucleoside is directly linked to the oligomeric
compound. [0126] Embodiment 81. The compound of embodiment 80,
wherein the therapeutic nucleoside is directly linked to the 3' end
of the oligomeric compound. [0127] Embodiment 82. The compound of
embodiment 80, wherein the therapeutic nucleoside is directly
linked to the 5' end of the oligomeric compound. [0128] Embodiment
83. The compound of any of embodiments 60-82, wherein the
therapeutic nucleoside and the oligomeric compound are linked via a
phosphate group. [0129] Embodiment 84. The compound of any of
embodiments 60-82, wherein the targeting group is directly attached
to one end of the oligomeric compound, and the therapeutic
nucleoside is directly attached to the opposite end of the
oligomeric compound. [0130] Embodiment 85. The compound of any of
embodiments 60-82, wherein the targeting group is directly attached
to one end of the therapeutic nucleoside, and the oligomeric
compound is attached to the opposite end of the therapeutic
nucleoside. [0131] Embodiment 86. A compound of any of embodiments
1-85 having the formula:
##STR00012##
[0131] wherein: [0132] A is a cell-targeting ligand; [0133] B is a
tether; [0134] C is a branching group; [0135] D is a targeting
group linker; [0136] E is a cleavable moiety; [0137] T is a
therapeutic nucleoside; [0138] Z is an oligomeric compound; [0139]
n is 1, 2, 3, 4, or 5; [0140] m is 0 or 1; and [0141] q is 1-50.
[0142] Embodiment 87. A pharmaceutical composition comprising a
compound of any of embodiments 1-86 or a pharmaceutically
acceptable salt thereof and a pharmaceutically acceptable carrier
or diluent. [0143] Embodiment 88. A method of treating an
RNA-dependent virus infection comprising administering to a mammal
in need of such treatment a therapeutically effective amount of a
compound of any of embodiments 1-87. [0144] Embodiment 89. A method
of embodiment 88, wherein the RNA-dependent virus is an RNA virus.
[0145] Embodiment 90. A method of embodiment 89, wherein the
RNA-dependent RNA virus is HCV. [0146] Embodiment 91. A method of
embodiment 88, wherein the RNA-dependent virus is a DNA virus.
[0147] Embodiment 92. A method of embodiment 91, wherein the
RNA-dependent DNA virus is HBV. [0148] Embodiment 93. The use of
the compound of any of embodiments 1-87 in the treatment of an
RNA-dependent virus infection. [0149] Embodiment 94. The use of the
compound of any of embodiments 1-87 in the manufacture of a
medicament for the treatment of an RNA-dependent virus infection.
[0150] Embodiment 95. The use of embodiment 93 or 94, wherein the
RNA-dependent virus is an RNA virus. [0151] Embodiment 96. The use
of embodiment 95, wherein the RNA-dependent RNA virus is HCV.
[0152] Embodiment 97. The use of embodiment 93 or 94, wherein the
RNA-dependent virus is a DNA virus. [0153] Embodiment 98. The use
of embodiment 97, wherein the RNA-dependent DNA virus is HBV.
[0154] Embodiment 99. A compound comprising at least one
therapeutic nucleoside and at least one additional moiety selected
from a targeting group and an oligomeric compound. [0155]
Embodiment 100. The compound of embodiment 99 comprising a
targeting group. [0156] Embodiment 101. The compound of embodiment
100, wherein the targeting group comprises at least one
cell-targeting ligand. [0157] Embodiment 102. The compound of
embodiment 100, wherein the targeting group comprises 1-4
cell-targeting ligands. [0158] Embodiment 103. The compound of
embodiment 102 comprising exactly 1 cell-targeting ligand. [0159]
Embodiment 104. The compound of embodiment 102 comprising exactly 2
cell-targeting ligands. [0160] Embodiment 105. The compound of
embodiment 102 comprising exactly 3 cell-targeting ligands. [0161]
Embodiment 106. The compound of any of embodiments 101-105, wherein
each cell-targeting ligand is N-acetylgalactosamine. [0162]
Embodiment 107. The compound of embodiment 106, wherein the
N-acetylgalactosamine is attached to the compound via the galactose
Cl oxygen. [0163] Embodiment 108. The compound of any of
embodiments 99-107, wherein the targeting group comprises a
targeting group linker. [0164] Embodiment 109. The compound of
embodiment 108, wherein the targeting group linker comprises one or
more groups selected from among: phosphate, amide, ether, ester,
pyrrolidine, disulfide, and methylene. [0165] Embodiment 110. The
compound of embodiment 108, wherein the targeting group linker
comprises a structure selected from among:
##STR00013## ##STR00014##
[0166] wherein n and m are independently selected from 1, 2, 3, 4,
5, 6, 7, 8, 9, or 10. [0167] Embodiment 111. The compound of
embodiment 108, wherein the targeting group linker comprises a
structure selected from among:
##STR00015##
[0168] wherein each n is independently selected from 1, 2, 3, 4, 5,
6, 7, 8, 9, or 10. [0169] Embodiment 112. The compound of any of
embodiments 99-102 or 104-111, wherein the targeting group
comprises a branching group. [0170] Embodiment 113. The compound of
embodiment 112, wherein the branching group comprises one or more
groups selected from among: amino acid, amino alcohol, alkoxy, and
amine. [0171] Embodiment 114. The compound of embodiment 112 or
113, wherein the branching group has a structure selected from
among:
[0171] ##STR00016## [0172] Embodiment 115. The compound of
embodiment 112 or 113, wherein the branching group has a structure
selected from among:
[0172] ##STR00017## [0173] Embodiment 116. The compound of any of
embodiments 99-115, wherein the targeting group comprises at least
one tether. [0174] Embodiment 117. The compound of embodiment 116,
wherein the at least one tether comprises one or more groups
selected from among: amino acid, amide, methylene, phosphate,
carbonyl, and piperidine. [0175] Embodiment 118. The compound of
embodiment 116, wherein the at least one tether has a structure
selected from among:
##STR00018##
[0176] wherein n, m, and q are independently selected from 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10. [0177] Embodiment 119. The compound of
embodiment 116, wherein the at least one tether has a structure
selected from among:
##STR00019##
[0178] wherein each n is independently selected from 1, 2, 3, 4, 5,
6, 7, 8, 9, or 10. [0179] Embodiment 120. The compound of any of
embodiments 99-119, wherein the compound comprises a cleavable
moiety. [0180] Embodiment 121. The compound of embodiment 120,
wherein the cleavable moiety is a phosphodiester. [0181] Embodiment
122. The compound of embodiment 120, wherein the cleavable moiety
is a non-therapeutic nucleoside. [0182] Embodiment 123. The
compound of embodiment 122, wherein the cleavable non-therapeutic
nucleoside is attached to the targeting group linker via a
cleavable bond. [0183] Embodiment 124. The compound of embodiment
122 or 123, wherein the non-therapeutic nucleoside comprises a 2'
substituent selected from among: H, OH, MOE, F, and OMe. [0184]
Embodiment 125. The compound of any of embodiments 99-124, wherein
the targeting group comprises a group comprises a structure
represented by formula:
##STR00020##
[0185] wherein:
[0186] A is a cell-targeting ligand;
[0187] B is a tether;
[0188] C is a branching group;
[0189] D is a targeting group linker;
[0190] E is a cleavable moiety;
[0191] n is 1, 2, 3, 4, or 5;
[0192] t is 0 or 1;
[0193] q is 0 or 1; and
[0194] m is 0 or 1. [0195] Embodiment 126. The compound of any of
embodiments 99-125, wherein the targeting group increases potency
of the therapeutic nucleoside. [0196] Embodiment 127. The compound
of any of embodiments 99-125, wherein the targeting group increases
in delivery or uptake of the therapeutic nucleoside in liver cells.
[0197] Embodiment 128. The compound of embodiment 127, wherein the
liver cells are hepatocytes. [0198] Embodiment 129. The compound of
embodiment 127 or 128, wherein the cells are in an animal. [0199]
Embodiment 130. The compound of any of embodiments 99-129, wherein
at least one therapeutic nucleoside comprises a modified or
unmodified pyrimidine nucleobase. [0200] Embodiment 131. The
compound of any of embodiments 99-129, wherein at least one
therapeutic nucleoside comprises a modified or unmodified purine
nucleobase. [0201] Embodiment 132. The compound of any of
embodiments 99-131, wherein at least one therapeutic nucleoside
comprises a modified furanosyl ring. [0202] Embodiment 133. The
compound of embodiment 132, wherein the modified furanosyl ring of
the at least one therapeutic nucleoside comprises a 2' or 3'
substituent independently selected from hydrogen, halogen,
hydroxyl, amino, alkyl, alkenyl, alkynyl, alkoxy, CF.sub.3, and
ester. [0203] Embodiment 134. The compound of any of embodiments
132-133, wherein the modified furanosyl ring of the at least one
therapeutic nucleoside comprises a 5' substituent independently
selected from hydrogen, hydroxyl, ester, phosphate, phosphate
ester, and phosphoramidate. [0204] Embodiment 135. The compound of
any of embodiments 132-134, wherein the modified furanosyl ring of
the at least one therapeutic nucleoside comprises a 4' substituent
comprising an azido group. [0205] Embodiment 136. The compound of
any of embodiments 132-135, wherein the modified furanosyl ring of
the at least one therapeutic nucleoside comprises a 2' substituent
that is other than H or OH. [0206] Embodiment 137. The compound of
embodiment 136, wherein at least one 2' substituent of the modified
furanosyl ring of at least one therapeutic nucleoside is selected
from F and methyl. [0207] Embodiment 138. The compound of any of
embodiments 136-137, wherein neither 2' substituent is H or OH.
[0208] Embodiment 139. The compound of any of embodiments 132-137,
wherein the 2' substituents are methyl and hydroxyl. [0209]
Embodiment 140. The compound of any of embodiments 132-138, wherein
the 2' substituents are methyl and fluoro. [0210] Embodiment 141.
The compound of embodiment 140, wherein absolute configuration of
the chiral center at the 2' position is R. [0211] Embodiment 142.
The compound of any of embodiments 132-141, wherein the 3'
substituents of the modified furanosyl ring of at least one
therapeutic nucleoside are hydrogen and hydroxyl. [0212] Embodiment
143. The compound of any of embodiments 132-142, wherein the 5'
substituents of the modified furanosyl ring of at least one
therapeutic nucleoside comprise OP(O)R.sub.1R.sub.2, wherein
R.sub.1 and R.sub.2 are each independently hydroxyl, phenoxy,
naphthalenoxy, OiPr, NHbenzyl, NHCH(CH.sub.3)C(O)OiPr, and
NHCH(CH.sub.3)C(O)OCH.sub.2t-butyl. [0213] Embodiment 144. The
compound of any of embodiments 99-134, 136-138, or 140-143, wherein
the therapeutic nucleoside comprises the following structure:
[0213] ##STR00021## [0214] wherein R.sub.3 is hydroxyl or the
targeting group; and
[0215] Bx is a modified or unmodified nucleobase. [0216] Embodiment
145. The compound of embodiment 144, wherein the therapeutic
nucleoside comprises the following structure:
[0216] ##STR00022## [0217] wherein R.sub.3 is hydroxyl or the
targeting group; and [0218] R.sub.4 and R.sub.5 are each
independently selected from phenoxy, NHCH(CH.sub.3)C(O)OiPr,
alkoxy, alkylamino, hydroxyl, an internucleoside linking group
linking the therapeutic nucleoside to another nucleoside or to an
oligomeric compound, and the targeting group; [0219] provided that
at least one of R.sub.3, R.sub.4, and R.sub.5 is a targeting group.
[0220] Embodiment 146. The compound of any of embodiments 99-132 or
134, wherein the therapeutic nucleoside comprises the following
structure:
[0220] ##STR00023## [0221] wherein B is a modified or unmodified
nucleobase; [0222] X is O or CCH.sub.2; [0223] Y is S or
CR.sub.6R.sub.7; and [0224] R.sub.6 and R.sub.7 are each
independently selected from hydrogen, hydroxyl, O-L-valinyl ester,
and the targeting group. [0225] Embodiment 147. The compound of
embodiment 146, wherein the modified or unmodified nucleobase is
selected from among: adenine, uracil, cytosine, 5-methylcytosine,
guanine, thymine, and 5-fluorocytosine. [0226] Embodiment 148. The
compound of any of embodiments 99-131, wherein at least one
therapeutic nucleoside comprises an acyclic sugar surrogate. [0227]
Embodiment 149. The compound of embodiment 148, wherein the
therapeutic nucleoside comprising an acyclic sugar surrogate
comprises a purine nucleobase linked to a phosphonate via the sugar
surrogate. [0228] Embodiment 150. The compound of embodiment 149,
wherein the targeting group is attached to the phosphonate. [0229]
Embodiment 151. The compound of any of embodiments 99-150, wherein
at least one therapeutic nucleoside is an antiviral nucleoside.
[0230] Embodiment 152. The compound of embodiment 145, wherein the
at least one anti-viral nucleoside inhibits a viral polymerase.
[0231] Embodiment 153. The compound of embodiment 151 or 152,
wherein at least one antiviral nucleoside is an anti-HCV
nucleoside. [0232] Embodiment 154. The compound of embodiment 151
or 152, wherein the at least one antiviral nucleoside is an
anti-HBV nucleoside. [0233] Embodiment 155. The compound of any of
embodiments 99-154, wherein the compound comprises exactly one
therapeutic nucleoside. [0234] Embodiment 156. The compound of any
of embodiments 99-154, wherein the compound comprises 2-50
therapeutic nucleosides. [0235] Embodiment 157. The compound of
embodiment 156, wherein the therapeutic nucleosides are all the
same as one another. [0236] Embodiment 158. The compound of
embodiment 156, wherein at least 2 therapeutic nucleosides are
different from one another. [0237] Embodiment 159. The compound of
any of embodiments 156-158, wherein the therapeutic nucleosides are
arranged according to the following formula:
##STR00024##
[0238] Wherein
[0239] each B is independently a cleavable moiety;
[0240] each C is independently a therapeutic nucleoside;
[0241] y is 0 or 1;
[0242] z is 1-50;
[0243] each t is independently 0 or 1;
[0244] p is 0 or 1;
[0245] provided that if z is 1, p is not 0. [0246] Embodiment 160.
The compound of embodiment 159, wherein y is 1 and each t is 1.
[0247] Embodiment 161. The compound of any of embodiments 159-160,
wherein each B comprises a non-therapeutic nucleoside. [0248]
Embodiment 162. The compound of any of embodiments 159-160, wherein
each B consists of a cleavable bond. [0249] Embodiment 163. The
compound of any of embodiments 159-160, wherein each B is a
phosphodiester. [0250] Embodiment 164. The compound of any of
embodiments 156-163, wherein at least one internucleoside linkage
linking two nucleosides to one another is an unmodified
phosphodiester internucleoside linkage. [0251] Embodiment 165. The
compound of any of embodiments 156-163, wherein each
internucleoside linkage linking two nucleosides to one another is
an unmodified phosphodiester internucleoside linkage. [0252]
Embodiment 166. The compound of any of embodiments 99-165, wherein
the targeting group is attached to the therapeutic nucleoside by a
cleavable bond. [0253] Embodiment 167. The compound of embodiment
166, wherein the cleavable bond is selected from among an amide, a
polyamide, an ester, an ether, a phosphodiester, a phosphate ester,
a phosphonate, a phosphoramidate, a carbamate, a disulfide, or a
peptide. [0254] Embodiment 168. The compound of any of embodiments
99-167, wherein a targeting group is attached to the 3' position of
a therapeutic nucleoside. [0255] Embodiment 169. The compound of
any of embodiments 99-167, wherein a targeting group is attached to
the 5' position of a therapeutic nucleoside. [0256] Embodiment 170.
The compound of any of embodiments 99-169 comprising an oligomeric
compound. [0257] Embodiment 171. The compound of embodiment 170,
wherein the oligomeric compound is single-stranded. [0258]
Embodiment 172. The compound of embodiment 170, wherein the
oligomeric compound is double-stranded. [0259] Embodiment 173. The
compound of any of embodiments 170-172, wherein the oligomeric
compound comprises a modified oligonucleotide consisting of 8-30
linked nucleosides. [0260] Embodiment 174. The compound of
embodiment 173, wherein the modified oligonucleotide comprises at
least one modified nucleoside comprising a modified sugar. [0261]
Embodiment 175. The compound of embodiment 174, wherein the
modified oligonucleotide comprises at least one modified nucleoside
comprising a modification at the 2' position selected from MOE,
OMe, cEt, and LNA. [0262] Embodiment 176. The compound of any of
embodiments 173-175, wherein the modified oligonucleotide comprises
a region of alternating sugar motif, comprising at least three
alternating regions of 2'-OMe nucleosides and 2'-F nucleosides,
wherein each region consists of 1-4 nucleosides. [0263] Embodiment
177. The compound of any of embodiments 173-175 wherein the
modified oligonucleotide is a gapmer. [0264] Embodiment 178. The
compound of any of embodiments 173-177, wherein the modified
oligonucleotide comprises at least one phosphorothioate
internucleoside linkage. [0265] Embodiment 179. The compound of any
of embodiments 173-178, wherein the modified oligonucleotide is an
antisense compound. [0266] Embodiment 180. The compound of
embodiment 179, wherein the antisense compound is an RNase H
compound. [0267] Embodiment 181. The compound of embodiment 179,
wherein the antisense compound is an RNAi oligomeric compound.
[0268] Embodiment 182. The compound of any of embodiments 179-181,
wherein the antisense oligomeric compound is complementary to a
target viral RNA or a target human RNA that is involved in virus
pathogenicity. [0269] Embodiment 183. The compound of embodiment
182, wherein the target RNA is an HCV RNA or a human RNA involved
in HCV pathogenicity. [0270] Embodiment 184. The compound of
embodiment 183, wherein the target RNA is a transcript of HCV
F-transactivated protein 1. [0271] Embodiment 185. The compound of
embodiment 182, wherein the target RNA is an HBV RNA or a human RNA
involved in HBV pathogenicity. [0272] Embodiment 186. The compound
of embodiment 185, wherein the target RNA is a transcript of HBV
associated factor, HBV pX associated protein-8, or HBV pre-s2
binding protein. [0273] Embodiment 187. The compound of any of
embodiments 179-186, wherein the antisense oligomeric compound is
complementary to a target microRNA. [0274] Embodiment 188. The
compound of embodiment 187, wherein the target microRNA is miR-122.
[0275] Embodiment 189. The compound of embodiment 187, wherein the
target microRNA is miR-221 or miR-21. [0276] Embodiment 190. The
compound of any of embodiments 170-189, wherein the therapeutic
nucleoside is directly linked to the oligomeric compound. [0277]
Embodiment 191. The compound of embodiment 190, wherein the at
least one therapeutic nucleoside is directly linked to the 3' end
of the oligomeric compound. [0278] Embodiment 192. The compound of
embodiment 190, wherein the at least one therapeutic nucleoside is
directly linked to the 5' end of the oligomeric compound. [0279]
Embodiment 193. The compound of any of embodiments 170-192, wherein
the at least one therapeutic nucleoside and the oligomeric compound
are linked via a phosphate group. [0280] Embodiment 194. The
compound of any of embodiments 170-192, wherein the at least one
therapeutic nucleoside and the oligomeric compound are linked via a
non-therapeutic nucleoside. [0281] Embodiment 195. The compound of
any of embodiments 170-194, wherein the targeting group is directly
attached to one end of the oligomeric compound, and the therapeutic
nucleoside is directly attached to the opposite end of the
oligomeric compound. [0282] Embodiment 196. The compound of any of
embodiments 170-194, wherein the targeting group is directly
attached to one end of the therapeutic nucleoside, and the
oligomeric compound is attached to the opposite end of the
therapeutic nucleoside. [0283] Embodiment 197. A compound having
the formula:
[0283] ##STR00025## [0284] Embodiment 198. A compound having the
formula:
##STR00026##
[0285] wherein R.dbd.H, miR-122, or 1-49 therapeutic nucleosides.
[0286] Embodiment 199. A compound of any of embodiments 99-198
having the formula:
[0286]
A.sub.x-B.sub.y-(C-(B).sub.t).sub.z-C.sub.p-D.sub.q-E.sub.r-(F-G)-
.sub.s [0287] a. wherein [0288] b. A is an oligomeric compound;
[0289] c. each B is independently a cleavable moiety [0290] d. each
C is independently a therapeutic nucleoside [0291] e. D is a target
group linker [0292] f. E is a branching group [0293] g. each F is a
tether; [0294] h. each G is a ligand; [0295] i. x is 0 or 1; [0296]
j. y is 0 or 1; [0297] k. z is 1-20; [0298] each t is independently
0 or 1; [0299] m. is 0 or 1; [0300] n. q is 0 or 1; [0301] o. r is
0 or 1; and [0302] p. s is 0-5; and
[0303] provided that if z is 1, then at least one of x and s is
other than 0. [0304] Embodiment 200. A pharmaceutical composition
comprising a compound of any of embodiments 99-199 or a
pharmaceutically acceptable salt thereof and a pharmaceutically
acceptable carrier or diluent. [0305] Embodiment 201. A method of
treating an RNA-dependent virus infection comprising administering
to a mammal in need of such treatment a therapeutically effective
amount of a compound of any of embodiments 99-199. [0306]
Embodiment 202. The method of embodiment 201, wherein the
RNA-dependent virus is an RNA virus. [0307] Embodiment 203. The
method of embodiment 202, wherein the RNA-dependent RNA virus is
HCV. [0308] Embodiment 204. The method of embodiment 201, wherein
the RNA-dependent virus is a DNA virus. [0309] Embodiment 205. The
method of embodiment 204, wherein the RNA-dependent DNA virus is
HBV.
[0310] Embodiment 206. The use of the compound of any of
embodiments 99-199 in the treatment of an RNA-dependent virus
infection. [0311] Embodiment 207. The use of the compound of any of
embodiments 99-199 in the manufacture of a medicament for the
treatment of an RNA-dependent virus infection. [0312] Embodiment
208. The use of embodiment 206 or 207, wherein the RNA-dependent
virus is an RNA virus. [0313] Embodiment 209. The use of embodiment
208, wherein the RNA-dependent RNA virus is HCV. [0314] Embodiment
210. The use of embodiment 206 or 207, wherein the RNA-dependent
virus is a DNA virus. [0315] Embodiment 211. The use of embodiment
210, wherein the RNA-dependent DNA virus is HBV.
DETAILED DESCRIPTION
[0316] It is to be understood that both the foregoing general
description and the following detailed description are exemplary
and explanatory only and are not restrictive of the disclosure.
Herein, the use of the singular includes the plural unless
specifically stated otherwise. As used herein, the use of "or"
means "and/or" unless stated otherwise. Furthermore, the use of the
term "including" as well as other forms, such as "includes" and
"included", is not limiting. Also, terms such as "element" or
"component" encompass both elements and components comprising one
unit and elements and components that comprise more than one
subunit, unless specifically stated otherwise.
[0317] The section headings used herein are for organizational
purposes only and are not to be construed as limiting the subject
matter described. All documents, or portions of documents, cited in
this application, including, but not limited to, patents, patent
applications, articles, books, and treatises, are hereby expressly
incorporated by reference in their entirety for any purpose.
A. Definitions
[0318] Unless specific definitions are provided, the nomenclature
used in connection with, and the procedures and techniques of,
analytical chemistry, synthetic organic chemistry, and medicinal
and pharmaceutical chemistry described herein are those well known
and commonly used in the art. Standard techniques may be used for
chemical synthesis, and chemical analysis. Certain such techniques
and procedures may be found for example in "Carbohydrate
Modifications in Antisense Research" Edited by Sangvi and Cook,
American Chemical Society, Washington D.C., 1994; "Remington's
Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa.,
21.sup.st edition, 2005; and "Antisense Drug Technology,
Principles, Strategies, and Applications" Edited by Stanley T.
Crooke, CRC Press, Boca Raton, Fla.; and Sambrook et al.,
"Molecular Cloning, A laboratory Manual," 2.sup.nd Edition, Cold
Spring Harbor Laboratory Press, 1989, which are hereby incorporated
by reference for any purpose. Where permitted, all patents,
applications, published applications and other publications and
other data referred to throughout in the disclosure are
incorporated by reference herein in their entirety.
[0319] Unless otherwise indicated, the following terms have the
following meanings:
[0320] As used herein, "nucleoside" means a compound comprising a
nucleobase moiety and a sugar moiety. Nucleosides include, but are
not limited to, naturally occurring nucleosides (as found in DNA
and RNA) and modified nucleosides. Nucleosides may be linked to a
phosphate moiety.
[0321] As used herein, "chemical modification" means a chemical
difference in a compound when compared to a naturally occurring
counterpart. Chemical modifications of oligonucleotides include
nucleoside modifications (including sugar moiety modifications and
nucleobase modifications) and internucleoside linkage
modifications. In reference to an oligonucleotide, chemical
modification does not include differences only in nucleobase
sequence.
[0322] As used herein, "nucleotide" means a nucleoside further
comprising a phosphate linking group. As used herein, "linked
nucleosides" may or may not be linked by phosphate linkages and
thus includes, but is not limited to "linked nucleotides." As used
herein, "linked nucleosides" are nucleosides that are connected in
a continuous sequence (i.e. no additional nucleosides are present
between those that are linked).
[0323] As used herein, "nucleobase" means a group of atoms that can
be linked to a sugar moiety to create a nucleoside that is capable
of incorporation into an oligonucleotide, and wherein the group of
atoms is capable of bonding with a complementary naturally
occurring nucleobase of another oligonucleotide or nucleic acid.
Nucleobases may be naturally occurring or may be modified.
[0324] As used herein the terms, "unmodified nucleobase" or
"naturally occurring nucleobase" means the naturally occurring
heterocyclic nucleobases of RNA or DNA: the purine bases adenine
(A) and guanine (G), and the pyrimidine bases thymine (T), cytosine
(C) (including 5-methyl C), and uracil (U).
[0325] As used herein, "modified nucleobase" means any nucleobase
that is not a naturally occurring nucleobase.
[0326] As used herein, "modified nucleoside" means a nucleoside
comprising at least one chemical modification compared to naturally
occurring RNA or DNA nucleosides. Modified nucleosides comprise a
modified sugar moiety and/or a modified nucleobase.
[0327] As used herein, "furanosyl" means a structure comprising a
5-membered ring comprising four carbon atoms and one oxygen
atom.
[0328] As used herein, "naturally occurring sugar moiety" means a
ribofuranosyl as found in naturally occurring RNA or a
deoxyribofuranosyl as found in naturally occurring DNA.
[0329] As used herein, "sugar moiety" means a naturally occurring
sugar moiety or a modified sugar moiety of a nucleoside.
[0330] As used herein, "modified sugar moiety" means a substituted
sugar moiety or a sugar surrogate.
[0331] As used herein, "substituted sugar moiety" means a furanosyl
that is not a naturally occurring sugar moiety. Substituted sugar
moieties include, but are not limited to furanosyls comprising
substituents at the 2'-position, the 3'-position, the 5'-position
and/or the 4'-position. Certain substituted sugar moieties are
bicyclic sugar moieties.
[0332] As used herein, "2'-substituted sugar moiety" means a
furanosyl comprising a substituent at the 2'-position other than H
or OH. Unless otherwise indicated, a 2'-substituted sugar moiety is
not a bicyclic sugar moiety (i.e., the 2'-substituent of a
2'-substituted sugar moiety does not form a bridge to another atom
of the furanosyl ring.
[0333] As used herein, "MOE" means
--OCH.sub.2CH.sub.2OCH.sub.3.
[0334] As used herein, "2'-F nucleoside" refers to a nucleoside
comprising a sugar comprising fluorine at the 2' position. Unless
otherwise indicated, the fluorine in a 2'-F nucleoside is in the
ribo position (replacing the OH of a natural ribose).
[0335] As used herein the term "sugar surrogate" means a structure
that does not comprise a furanosyl and that is capable of replacing
the naturally occurring sugar moiety of a nucleoside, such that the
resulting nucleoside sub-units are capable of linking together
and/or linking to other nucleosides to form an oligomeric compound.
Such structures include rings comprising a different number of
atoms than furanosyl (e.g., 4, 6, or 7-membered rings); replacement
of the oxygen of a furanosyl with a non-oxygen atom (e.g., carbon,
sulfur, or nitrogen); both a change in the number of atoms and a
replacement of the oxygen; or an acyclic structure. Such structures
may also comprise substitutions corresponding to those described
for substituted sugar moieties (e.g., 6-membered carbocyclic
bicyclic sugar surrogates optionally comprising additional
substituents). Sugar surrogates also include more complex sugar
replacements (e.g., the non-ring systems of peptide nucleic acid).
Sugar surrogates include without limitation morpholinos,
cyclohexenyls and cyclohexitols.
[0336] As used herein, "bicyclic sugar moiety" means a modified
sugar moiety comprising a 4 to 7 membered ring (including but not
limited to a furanosyl) comprising a bridge connecting two atoms of
the 4 to 7 membered ring to form a second ring, resulting in a
bicyclic structure. In certain embodiments, the 4 to 7 membered
ring is a sugar ring. In certain embodiments the 4 to 7 membered
ring is a furanosyl. In certain such embodiments, the bridge
connects the 2'-carbon and the 4'-carbon of the furanosyl.
[0337] As used herein, "bicyclic nucleoside" or "BNA" means a
nucleoside comprising a bicyclic sugar moiety.
[0338] As used herein, "constrained ethyl nucleoside" or "cEt"
means a nucleoside comprising a bicyclic sugar moiety comprising a
4'-CH(CH.sub.3)--O-2'bridge.
[0339] As used herein, "locked nucleic acid nucleoside" or "LNA"
means a nucleoside comprising a bicyclic sugar moiety comprising a
4'-CH.sub.2--O-2'bridge. As used herein, "2'-substituted
nucleoside" means a nucleoside comprising a substituent at the
2'-position other than H or OH. Unless otherwise indicated, a
2'-substituted nucleoside is not a bicyclic nucleoside.
[0340] As used herein, "deoxynucleoside" means a nucleoside
comprising 2'-H furanosyl sugar moiety, as found in naturally
occurring deoxyribonucleosides (DNA). In certain embodiments, a
2'-deoxynucleoside may comprise a modified nucleobase or may
comprise an RNA nucleobase (e.g., uracil).
[0341] As used herein, "oligonucleotide" means an oligomeric
compound comprising a plurality of linked nucleosides. In certain
embodiments, an oligonucleotide comprises one or more unmodified
ribonucleosides (RNA) and/or unmodified deoxyribonucleosides (DNA)
and/or one or more modified nucleosides.
[0342] As used herein, "modified oligonucleotide" means an
oligonucleotide comprising at least one modified nucleoside and/or
at least one modified internucleoside linkage.
[0343] As used herein, "linkage" or "linking group" means a group
of atoms that link together two or more other groups of atoms.
[0344] As used herein "internucleoside linkage" means a covalent
linkage between adjacent nucleosides in an oligonucleotide.
[0345] As used herein "naturally occurring internucleoside linkage"
means a 3' to 5' phosphodiester linkage.
[0346] As used herein, "modified internucleoside linkage" means any
internucleoside linkage other than a naturally occurring
internucleoside linkage.
[0347] As used herein, "terminal internucleoside linkage" means the
linkage between the last two nucleosides of an oligonucleotide or
defined region thereof.
[0348] As used herein, "phosphorus linking group" means a linking
group comprising a phosphorus atom. Phosphorus linking groups
include without limitation groups having the formula:
##STR00027##
wherein:
[0349] R.sub.a and R.sub.d are each, independently, O, S, CH.sub.2,
NH, or NJ1 wherein J.sub.1 is C.sub.1-C.sub.6 alkyl or substituted
C.sub.1-C.sub.6 alkyl;
[0350] R.sub.b is O or S;
[0351] R.sub.c is OH, SH, C.sub.1-C.sub.6 alkyl, substituted
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, substituted
C.sub.1-C.sub.6 alkoxy, amino or substituted amino; and
[0352] J.sub.1 is R.sub.b is O or S.
Phosphorus linking groups include without limitation,
phosphodiester, phosphorothioate, phosphorodithioate, phosphonate,
phosphoramidate, phosphorothioamidate, thionoalkylphosphonate,
phosphotriesters, thionoalkylphosphotriester and
boranophosphate.
[0353] As used herein, "internucleoside phosphorus linking group"
means a phosphorus linking group that directly links two
nucleosides.
[0354] As used herein, "non-internucleoside phosphorus linking
group" means a phosphorus linking group that does not directly link
two nucleosides. In certain embodiments, a non-internucleoside
phosphorus linking group links a nucleoside to a group other than a
nucleoside. In certain embodiments, a non-internucleoside
phosphorus linking group links two groups, neither of which is a
nucleoside.
[0355] As used herein, "neutral linking group" means a linking
group that is not charged. Neutral linking groups include without
limitation phosphotriesters, methylphosphonates, MMI
(--CH.sub.2--N(CH.sub.3)--O--), amide-3
(--CH.sub.2--C(.dbd.O)--N(H)--), amide-4
(--CH.sub.2--N(H)--C(.dbd.O)--), formacetal (--O--CH.sub.2--O--),
and thioformacetal (--S--CH.sub.2--O--). Further neutral linking
groups include nonionic linkages comprising siloxane
(dialkylsiloxane), carboxylate ester, carboxamide, sulfide,
sulfonate ester and amides (See for example: Carbohydrate
Modifications in Antisense Research; Y. S. Sanghvi and P. D. Cook
Eds. ACS Symposium Series 580; Chapters 3 and 4, (pp. 40-65)).
Further neutral linking groups include nonionic linkages comprising
mixed N, O, S and CH.sub.2 component parts.
[0356] As used herein, "internucleoside neutral linking group"
means a neutral linking group that directly links two
nucleosides.
[0357] As used herein, "non-internucleoside neutral linking group"
means a neutral linking group that does not directly link two
nucleosides. In certain embodiments, a non-internucleoside neutral
linking group links a nucleoside to a group other than a
nucleoside. In certain embodiments, a non-intemucleoside neutral
linking group links two groups, neither of which is a
nucleoside.
[0358] As used herein, "oligomeric compound" means a polymeric
structure comprising two or more sub-structures. In certain
embodiments, an oligomeric compound comprises an oligonucleotide.
In certain embodiments, an oligomeric compound comprises one or
more conjugate groups and/or terminal groups. In certain
embodiments, an oligomeric compound consists of an oligonucleotide.
Oligomeric compounds also include naturally occurring nucleic
acids. In certain embodiments, an oligomeric compound comprises a
backbone of one or more linked monomeric subunits where each linked
monomeric subunit is directly or indirectly attached to a
heterocyclic base moiety. In certain embodiments, oligomeric
compounds may also include monomeric subunits that are not linked
to a heterocyclic base moiety, thereby providing abasic sites. In
certain embodiments, the linkages joining the monomeric subunits,
the sugar moieties or surrogates and the heterocyclic base moieties
can be independently modified. In certain embodiments, the
linkage-sugar unit, which may or may not include a heterocyclic
base, may be substituted with a mimetic such as the monomers in
peptide nucleic acids.
[0359] As used herein, "terminal group" means one or more atom
attached to either, or both, the 3' end or the 5' end of an
oligonucleotide. In certain embodiments a terminal group is a
conjugate group. In certain embodiments, a terminal group comprises
one or more terminal group nucleosides.
[0360] As used herein, "targeting group" means a group of atoms
which, when bound to a nucleoside or oligomeric compound, modifies
one or more properties of such nucleoside or oligomeric compound,
including but not limited to pharmacodynamic, pharmacokinetic,
binding, absorption, cellular distribution, cellular uptake, and/or
clearance properties.
[0361] In certain instances, targeting groups are shown herein as
radicals, providing a bond for forming covalent attachment to a
nucleoside or oligomeric compound such as an oligonucleotide. In
certain embodiments, the point of attachment is the oxygen atom of
a 3'-hydroxyl group of a nucleoside or of the 3' terminal
nucleoside of an oligomeric compound. In certain embodiments, the
point of attachment is the oxygen atom of a 5'-hydroxyl group of
the nucleoside or of a 5' terminal nucleoside of an oligomeric
compound. In certain embodiments, the bond for forming attachment
of the targeting group to the nucleoside or oligomeric compound is
a cleavable bond. In certain such embodiments, such cleavable bond
constitutes all or part of a cleavable moiety.
[0362] As used herein, "targeting group linker" or "linker" in the
context of a targeting group means a portion of a targeting group
comprising any atom or group of atoms and which covalently links
(1) an oligomeric compound to another portion of the targeting
group or (2) two or more portions of the targeting group to one
another.
[0363] As used herein, "branching group" means a portion of a
targeting group comprising any atom or group of atoms which
covalently link a single moiety to two or more separate moieties.
In certain embodiments, a branching group links a single oligomeric
compound or nucleoside to two or more portions of a targeting
group. In certain embodiments, a branching group links a single
portion of a targeting group to two or more other portions of the
targeting group.
[0364] As used herein, "tether" means a portion of a targeting
group comprising any atom or group of atoms that covalently links a
cell targeting ligand to either (1) an oligomeric compound or
nucleoside or (2) another portion of the targeting group.
[0365] As used herein, "cell-targeting ligand" means a moiety that
binds a cell. In certain embodiments, cell-targeting ligands are
selective for one or more particular cell type. In certain
embodiments, cell-targeting moieties selectively bind a receptor,
such as a cell surface receptor.
[0366] As used herein, "cleavable bond" means any chemical bond
capable of being split under conditions where such splitting is
desired. In certain embodiments, a cleavable bond is split when a
compound is administered to an animal and/or after entry into a
cell. In certain embodiments, a cleavable bond is selected from
among: an amide, a polyamide, an ester, an ether, a phosphodiester,
a phosphate ester, a phosphonate, a phosphoramidate, a carbamate, a
di-sulfide, or a peptide.
[0367] As used herein, "cleavable moiety" means a cleavable bond or
group of atoms that comprises one or more cleavable bond. In
certain embodiments, a cleavable moiety includes a nucleoside with
a cleavable bond linked to the 3' position of the furanosyl ring.
In certain embodiments, the cleavable moiety includes a nucleoside
with a cleavable bond linked to the 5' position of the furanosyl
ring. In certain embodiments, the cleavable moiety includes a
nucleoside with cleavable bonds linked to both the 3' and 5'
positions of the furanosyl ring. In certain embodiments, the
cleavable moiety is a phosphodiester.
[0368] As used herein, "carbohydrate cluster" means a compound
having one or more carbohydrate residues attached to a scaffold or
linker group. (see, e.g., Maier et al., "Synthesis of Antisense
Oligonucleotides Conjugated to a Multivalent Carbohydrate Cluster
for Cellular Targeting," Bioconjugate Chemistry, 2003, (14): 18-29,
which is incorporated herein by reference in its entirety, or
Rensen et al., "Design and Synthesis of Novel
N-Acetylgalactosamine-Terminated Glycolipids for Targeting of
Lipoproteins to the Hepatic Asiaglycoprotein Receptor," J. Med.
Chem. 2004, (47): 5798-5808, for examples of carbohydrate conjugate
clusters).
[0369] As used herein, "modified carbohydrate" means any
carbohydrate having one or more chemical modifications relative to
naturally occurring carbohydrates.
[0370] As used herein, "carbohydrate derivative" means any compound
which may be synthesized using a carbohydrate as a starting
material or intermediate.
[0371] As used herein, "carbohydrate" means a naturally occurring
carbohydrate, a modified carbohydrate, or a carbohydrate
derivative.
[0372] As used herein "protecting group" means any compound or
protecting group known to those having skill in the art.
Non-limiting examples of protecting groups may be found in
"Protective Groups in Organic Chemistry", T. W. Greene, P. G. M.
Wuts, ISBN 0-471-62301-6, John Wiley & Sons, Inc, New York,
which is incorporated herein by reference in its entirety.
[0373] As used herein, "single-stranded" means an oligomeric
compound that is not hybridized to its complement and which lacks
sufficient self-complementarity to form a stable self-duplex.
[0374] As used herein, "double-stranded" means either a pair of
separate oligomeric compounds that are hybridized to one another or
a single self-complementary oligomeric compound that forms a
hairpin structure. In certain embodiments, a double-stranded
oligomeric compound comprises a first and a second oligonucleotide.
Such double-stranded compounds may have one or more or
non-hybridizing nucleosides at one or both ends of one or both
strands (overhangs) and/or one or more internal non-hybridizing
nucleosides (mismatches) provided there is sufficient
complementarity to maintain hybridization under physiologically
relevant conditions.
[0375] As used herein, "antisense compound" means a compound
comprising or consisting of an oligonucleotide at least a portion
of which is complementary to a target nucleic acid to which it is
capable of hybridizing, resulting in at least one antisense
activity. Antisense compounds may be single- or double-stranded.
Antisnese compounds may comprise non-hypbridizing moieties, such as
conjugates and/or terminal groups.
[0376] As used herein, "antisense activity" means any detectable
and/or measurable change attributable to the hybridization of an
antisense compound to its target nucleic acid.
[0377] As used herein, "gapmer" means an oligonucleotide comprising
a gap segment of linked nucleosides that is positioned between 5'
and 3' wing segments of linked nucleosides. The gap and wing
segments are distinguished by the types of nucleosides they
contain. In certain embodiments, the gap contains
deoxyribonucleosides. In certain embodiments, the wings contain
ribonucleosides and/or 2' modified nucleosides.
[0378] As used herein, "RNase H compound" means an antisense
compound wherein at least some of the antisense activity of the
antisense compound is attributable to hybridization of the
antisense compound to a target nucleic acid and subsequent cleavage
of the target nucleic acid by RNase H.
[0379] As used herein, "RNAi oligomeric compound" means an
antisense compound wherein at least some of the antisense activity
of the antisense compound is attributable to the RNA Induced
Silencing Complex (RISC).
[0380] As used herein, "detecting" or "measuring" means that a test
or assay for detecting or measuring is performed. Such detection
and/or measuring may result in a value of zero. Thus, if a test for
detection or measuring results in a finding of no activity
(activity of zero), the step of detecting or measuring the activity
has nevertheless been performed.
[0381] As used herein, "detectable and/or measureable activity"
means an activity that is not zero.
[0382] As used herein, "essentially unchanged" means little or no
change in a particular parameter, particularly relative to another
parameter which changes much more. In certain embodiments, a
parameter is essentially unchanged when it changes less than 5%. In
certain embodiments, a parameter is essentially unchanged if it
changes less than two-fold while another parameter changes at least
ten-fold. For example, in certain embodiments, an antisense
activity is a change in the amount of a target nucleic acid. In
certain such embodiments, the amount of a non-target nucleic acid
is essentially unchanged if it changes much less than the target
nucleic acid does, but the change need not be zero.
[0383] As used herein, "expression" means the process by which a
gene ultimately results in a protein. Expression includes, but is
not limited to, transcription, post-transcriptional modification
(e.g., splicing, polyadenylation, addition of 5'-cap), and
translation.
[0384] As used herein, "target nucleic acid" means a nucleic acid
to which an antisense compound is intended to hybridize to result
in a desired antisense activity. Antisense compounds have
sufficient complementarity to their target nucleic acids to allow
hybridization under physiological conditions.
[0385] As used herein, "nucleobase complementarity" or
"complementarity" when in reference to nucleobases means a
nucleobase that is capable of base pairing with another nucleobase.
For example, in DNA, adenine (A) is complementary to thymine (T).
For example, in RNA, adenine (A) is complementary to uracil (U). In
certain embodiments, complementary nucleobase means a nucleobase of
an antisense compound that is capable of base pairing with a
nucleobase of its target nucleic acid. For example, if a nucleobase
at a certain position of an antisense compound is capable of
hydrogen bonding with a nucleobase at a certain position of a
target nucleic acid, then the position of hydrogen bonding between
the oligonucleotide and the target nucleic acid is considered to be
complementary at that nucleobase pair. Nucleobases comprising
certain modifications may maintain the ability to pair with a
counterpart nucleobase and thus, are still capable of nucleobase
complementarity.
[0386] As used herein, "non-complementary" in reference to
nucleobases means a pair of nucleobases that do not form hydrogen
bonds with one another.
[0387] As used herein, "complementary" in reference to oligomeric
compounds (e.g., linked nucleosides, oligonucleotides, or nucleic
acids) means the capacity of such oligomeric compounds or regions
thereof to hybridize to another oligomeric compound or region
thereof through nucleobase complementarity. Complementary
oligomeric compounds need not have nucleobase complementarity at
each nucleoside. Rather, some mismatches are tolerated. In certain
embodiments, complementary oligomeric compounds or regions are
complementary at 70% of the nucleobases (70% complementary). In
certain embodiments, complementary oligomeric compounds or regions
are 80% complementary. In certain embodiments, complementary
oligomeric compounds or regions are 90% complementary. In certain
embodiments, complementary oligomeric compounds or regions are 95%
complementary. In certain embodiments, complementary oligomeric
compounds or regions are 100% complementary.
[0388] As used herein, "mismatch" means a nucleobase of a first
oligomeric compound that is not capable of pairing with a
nucleobase at a corresponding position of a second oligomeric
compound, when the first and second oligomeric compound are
aligned. Either or both of the first and second oligomeric
compounds may be oligonucleotides.
[0389] As used herein, "hybridization" means the pairing of
complementary oligomeric compounds (e.g., an antisense compound and
its target nucleic acid). While not limited to a particular
mechanism, the most common mechanism of pairing involves hydrogen
bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen
hydrogen bonding, between complementary nucleobases.
[0390] As used herein, "specifically hybridizes" means the ability
of an oligomeric compound to hybridize to one nucleic acid site
with greater affinity than it hybridizes to another nucleic acid
site.
[0391] As used herein, "fully complementary" in reference to an
oligonucleotide or portion thereof means that each nucleobase of
the oligonucleotide or portion thereof is capable of pairing with a
nucleobase of a complementary nucleic acid or contiguous portion
thereof. Thus, a fully complementary region comprises no mismatches
or unhybridized nucleobases in either strand.
[0392] As used herein, "percent complementarity" means the
percentage of nucleobases of an oligomeric compound that are
complementary to an equal-length portion of a target nucleic acid.
Percent complementarity is calculated by dividing the number of
nucleobases of the oligomeric compound that are complementary to
nucleobases at corresponding positions in the target nucleic acid
by the total length of the oligomeric compound.
[0393] As used herein, "percent identity" means the number of
nucleobases in a first nucleic acid that are the same type
(independent of chemical modification) as nucleobases at
corresponding positions in a second nucleic acid, divided by the
total number of nucleobases in the first nucleic acid.
[0394] As used herein, "modulation" means a change of amount or
quality of a molecule, function, or activity when compared to the
amount or quality of a molecule, function, or activity prior to
modulation. For example, modulation includes the change, either an
increase (stimulation or induction) or a decrease (inhibition or
reduction) in gene expression. As a further example, modulation of
expression can include a change in splice site selection of
pre-mRNA processing, resulting in a change in the absolute or
relative amount of a particular splice-variant compared to the
amount in the absence of modulation.
[0395] As used herein, "chemical motif" means a pattern of chemical
modifications in an oligonucleotide or a region thereof. Motifs may
be defined by modifications at certain nucleosides and/or at
certain linking groups of an oligonucleotide.
[0396] As used herein, "nucleoside motif" means a pattern of
nucleoside modifications in an oligonucleotide or a region thereof.
The linkages of such an oligonucleotide may be modified or
unmodified. Unless otherwise indicated, motifs herein describing
only nucleosides are intended to be nucleoside motifs. Thus, in
such instances, the linkages are not limited.
[0397] As used herein, "sugar motif" means a pattern of sugar
modifications in an oligonucleotide or a region thereof.
[0398] As used herein, "linkage motif" means a pattern of linkage
modifications in an oligonucleotide or region thereof. The
nucleosides of such an oligonucleotide may be modified or
unmodified. Unless otherwise indicated, motifs herein describing
only linkages are intended to be linkage motifs. Thus, in such
instances, the nucleosides are not limited.
[0399] As used herein, "nucleobase modification motif" means a
pattern of modifications to nucleobases along an oligonucleotide.
Unless otherwise indicated, a nucleobase modification motif is
independent of the nucleobase sequence.
[0400] As used herein, "sequence motif" means a pattern of
nucleobases arranged along an oligonucleotide or portion thereof.
Unless otherwise indicated, a sequence motif is independent of
chemical modifications and thus may have any combination of
chemical modifications, including no chemical modifications.
[0401] As used herein, "type of modification" in reference to a
nucleoside or a nucleoside of a "type" means the chemical
modification of a nucleoside and includes modified and unmodified
nucleosides. Accordingly, unless otherwise indicated, a "nucleoside
having a modification of a first type" may be an unmodified
nucleoside.
[0402] As used herein, "differently modified" mean chemical
modifications or chemical substituents that are different from one
another, including absence of modifications. Thus, for example, a
MOE nucleoside and an unmodified DNA nucleoside are "differently
modified," even though the DNA nucleoside is unmodified. Likewise,
DNA and RNA are "differently modified," even though both are
naturally-occurring unmodified nucleosides. Nucleosides that are
the same but for comprising different nucleobases are not
differently modified. For example, a nucleoside comprising a 2'-OMe
modified sugar and an unmodified adenine nucleobase and a
nucleoside comprising a 2'-OMe modified sugar and an unmodified
thymine nucleobase are not differently modified.
[0403] As used herein, "the same type of modifications" refers to
modifications that are the same as one another, including absence
of modifications. Thus, for example, two unmodified DNA nucleosides
have "the same type of modification," even though the DNA
nucleoside is unmodified. Such nucleosides having the same type
modification may comprise different nucleobases.
[0404] As used herein, "separate regions" means portions of an
oligonucleotide wherein the chemical modifications or the motif of
chemical modifications of any neighboring portions include at least
one difference to allow the separate regions to be distinguished
from one another.
[0405] As used herein the term "mono or polycyclic ring system" is
meant to include all ring systems selected from single or
polycyclic radical ring systems wherein the rings are fused or
linked and is meant to be inclusive of single and mixed ring
systems individually selected from aliphatic, alicyclic, aryl,
heteroaryl, aralkyl, arylalkyl, heterocyclic, heteroaryl,
heteroaromatic and heteroarylalkyl. Such mono and poly cyclic
structures can contain rings that each have the same level of
saturation or each, independently, have varying degrees of
saturation including fully saturated, partially saturated or fully
unsaturated. Each ring can comprise ring atoms selected from C, N,
O and S to give rise to heterocyclic rings as well as rings
comprising only C ring atoms which can be present in a mixed motif
such as for example benzimidazole wherein one ring has only carbon
ring atoms and the fused ring has two nitrogen atoms. The mono or
polycyclic ring system can be further substituted with substituent
groups such as for example phthalimide which has two .dbd.O groups
attached to one of the rings. Mono or polycyclic ring systems can
be attached to parent molecules using various strategies such as
directly through a ring atom, fused through multiple ring atoms,
through a substituent group or through a bifunctional linking
moiety.
[0406] As used herein, "therapeutic agent" means a compound which
is capable of producing a desired result when administered to an
animal. Therapeutic agents may be in the most active form when
delivered or may be prodrugs or polyprodrugs.
[0407] As used herein, "prodrug" means an inactive or less active
form of a compound which, when administered to a subject, is
metabolized to form the active, or more active, compound. In
certain embodiments, a prodrug comprises a targeting group and at
least one active compound.
[0408] As used herein, "poly-prodrug" means a prodrug comprising
more than one active compound.
[0409] As used herein, "substituent" and "substituent group," means
an atom or group that replaces the atom or group of a named parent
compound. For example a substituent of a modified nucleoside is any
atom or group that differs from the atom or group found in a
naturally occurring nucleoside (e.g., a modified 2'-substuent is
any atom or group at the 2'-position of a nucleoside other than H
or OH). Substituent groups can be protected or unprotected. In
certain embodiments, compounds of the present disclosure have
substituents at one or at more than one position of the parent
compound. Substituents may also be further substituted with other
substituent groups and may be attached directly or via a linking
group such as an alkyl or hydrocarbyl group to a parent
compound.
[0410] Likewise, as used herein, "substituent" in reference to a
chemical functional group means an atom or group of atoms that
differs from the atom or a group of atoms normally present in the
named functional group. In certain embodiments, a substituent
replaces a hydrogen atom of the functional group (e.g., in certain
embodiments, the substituent of a substituted methyl group is an
atom or group other than hydrogen which replaces one of the
hydrogen atoms of an unsubstituted methyl group). Unless otherwise
indicated, groups amenable for use as substituents include without
limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl
(--C(O)R.sub.aa), carboxyl (--C(O)O--R.sub.aa), aliphatic groups,
alicyclic groups, alkoxy, substituted oxy (--O--R.sub.aa), aryl,
aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino
(--N(R.sub.bb)(R.sub.cc)), imino(.dbd.NR.sub.bb), amido
(--C(O)N--(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(O)R.sub.aa), azido
(--N.sub.3), nitro (--NO.sub.2), cyano (--CN), carbamido
(--OC(O)N(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(O)OR.sub.aa),
ureido (--N(R.sub.bb)C(O)N(R.sub.bb)(R.sub.cc)), thioureido
(--N(R.sub.bb)C(S)N(R.sub.bb)(R.sub.cc)), guanidinyl
(--N(R.sub.bb)C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc)), amidinyl
(--C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc) or
--N(R.sub.bb)C(.dbd.NR.sub.bb)(R.sub.aa)), thiol (--SR.sub.bb),
sulfinyl (--S(O)R.sub.bb), sulfonyl (--S(O).sub.2R.sub.bb) and
sulfonamidyl (--S(O).sub.2N(R.sub.bb)(R.sub.cc) or
--N(R.sub.bb)S(O).sub.2R.sub.bb). Wherein each R.sub.aa, R.sub.bb
and R.sub.cc is, independently, H, an optionally linked chemical
functional group or a further substituent group with a preferred
list including without limitation, alkyl, alkenyl, alkynyl,
aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic,
heterocyclic and heteroarylalkyl. Selected substituents within the
compounds described herein are present to a recursive degree.
[0411] As used herein, "alkyl," as used herein, means a saturated
straight or branched hydrocarbon radical containing up to twenty
four carbon atoms. Examples of alkyl groups include without
limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl,
octyl, decyl, dodecyl and the like. Alkyl groups typically include
from 1 to about 24 carbon atoms, more typically from 1 to about 12
carbon atoms (C.sub.1-C.sub.12 alkyl) with from 1 to about 6 carbon
atoms being more preferred.
[0412] As used herein, "alkenyl," means a straight or branched
hydrocarbon chain radical containing up to twenty four carbon atoms
and having at least one carbon-carbon double bond. Examples of
alkenyl groups include without limitation, ethenyl, propenyl,
butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and
the like. Alkenyl groups typically include from 2 to about 24
carbon atoms, more typically from 2 to about 12 carbon atoms with
from 2 to about 6 carbon atoms being more preferred. Alkenyl groups
as used herein may optionally include one or more further
substituent groups.
[0413] As used herein, "alkynyl," means a straight or branched
hydrocarbon radical containing up to twenty four carbon atoms and
having at least one carbon-carbon triple bond. Examples of alkynyl
groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl,
and the like. Alkynyl groups typically include from 2 to about 24
carbon atoms, more typically from 2 to about 12 carbon atoms with
from 2 to about 6 carbon atoms being more preferred. Alkynyl groups
as used herein may optionally include one or more further
substituent groups.
[0414] As used herein, "acyl," means a radical formed by removal of
a hydroxyl group from an organic acid and has the general Formula
--C(O)--X where X is typically aliphatic, alicyclic or aromatic.
Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic
sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic
phosphates, aliphatic phosphates and the like. Acyl groups as used
herein may optionally include further substituent groups.
[0415] As used herein, "alicyclic" means a cyclic ring system
wherein the ring is aliphatic. The ring system can comprise one or
more rings wherein at least one ring is aliphatic. Preferred
alicyclics include rings having from about 5 to about 9 carbon
atoms in the ring. Alicyclic as used herein may optionally include
further substituent groups. As used herein, "aliphatic" means a
straight or branched hydrocarbon radical containing up to twenty
four carbon atoms wherein the saturation between any two carbon
atoms is a single, double or triple bond. An aliphatic group
preferably contains from 1 to about 24 carbon atoms, more typically
from 1 to about 12 carbon atoms with from 1 to about 6 carbon atoms
being more preferred. The straight or branched chain of an
aliphatic group may be interrupted with one or more heteroatoms
that include nitrogen, oxygen, sulfur and phosphorus. Such
aliphatic groups interrupted by heteroatoms include without
limitation, polyalkoxys, such as polyalkylene glycols, polyamines,
and polyimines. Aliphatic groups as used herein may optionally
include further substituent groups.
[0416] As used herein, "alkoxy" means a radical formed between an
alkyl group and an oxygen atom wherein the oxygen atom is used to
attach the alkoxy group to a parent molecule. Examples of alkoxy
groups include without limitation, methoxy, ethoxy, propoxy,
isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy,
neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein may
optionally include further substituent groups.
[0417] As used herein, "aminoalkyl" means an amino substituted
C.sub.1-C.sub.12 alkyl radical. The alkyl portion of the radical
forms a covalent bond with a parent molecule. The amino group can
be located at any position and the aminoalkyl group can be
substituted with a further substituent group at the alkyl and/or
amino portions.
[0418] As used herein, "aralkyl" and "arylalkyl" mean an aromatic
group that is covalently linked to a C.sub.1-C.sub.12 alkyl
radical. The alkyl radical portion of the resulting aralkyl (or
arylalkyl) group forms a covalent bond with a parent molecule.
Examples include without limitation, benzyl, phenethyl and the
like. Aralkyl groups as used herein may optionally include further
substituent groups attached to the alkyl, the aryl or both groups
that form the radical group.
[0419] As used herein, "aryl" and "aromatic" mean a mono- or
polycyclic carbocyclic ring system radicals having one or more
aromatic rings. Examples of aryl groups include without limitation,
phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
Preferred aryl ring systems have from about 5 to about 20 carbon
atoms in one or more rings. Aryl groups as used herein may
optionally include further substituent groups.
[0420] As used herein, "halo" and "halogen," mean an atom selected
from fluorine, chlorine, bromine and iodine.
[0421] As used herein, "heteroaryl," and "heteroaromatic," mean a
radical comprising a mono- or poly-cyclic aromatic ring, ring
system or fused ring system wherein at least one of the rings is
aromatic and includes one or more heteroatoms. Heteroaryl is also
meant to include fused ring systems including systems where one or
more of the fused rings contain no heteroatoms. Heteroaryl groups
typically include one ring atom selected from sulfur, nitrogen or
oxygen. Examples of heteroaryl groups include without limitation,
pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl,
thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl,
thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl,
benzooxazolyl, quinoxalinyl and the like. Heteroaryl radicals can
be attached to a parent molecule directly or through a linking
moiety such as an aliphatic group or hetero atom. Heteroaryl groups
as used herein may optionally include further substituent
groups.
[0422] As used herein, "therapeutic nucleoside" means a nucleoside
that provides a therapeutic benefit when administered to a
subject.
[0423] As used herein, "non-therapeutic nucleoside" means a
nucleoside that does not provide a therapeutic benefit when
administered to a subject. In certain embodiments, a prodrug may
comprise a non-therapeutic nucleoside. In such embodiments, the
presence of the non-therapeutic nucleoside may increase the
activity of the active compound, but is not itself directly
responsible for the therapeutic activity.
[0424] As used herein, the term "therapeutically effective amount"
refers to an amount of a pharmaceutical agent that provides a
therapeutic benefit to an animal.
[0425] As used herein, the term "treatment" or "treating" refers to
administering a composition of the invention to effect an
alteration or improvement of the disease or condition. Prevention,
amelioration, and/or treatment may require administration of
multiple doses at regular intervals, or prior to onset of the
disease or condition to alter the course of the disease or
condition. Moreover, a single agent may be used in a single
individual for each prevention, amelioration, and treatment of a
condition or disease sequentially, or concurrently.
[0426] As used herein, the term "pharmaceutical agent" refers to a
substance that provides a therapeutic benefit when administered to
a subject. In certain embodiments, a pharmaceutical agent comprises
a prodrug.
[0427] As used herein, "pharmaceutically acceptable carrier or
diluent" means any substance suitable for use in administering to
an animal. In certain embodiments, a pharmaceutically acceptable
carrier or diluent is sterile saline. In certain embodiments, such
sterile saline is pharmaceutical grade saline.
[0428] As used herein, "administering" means providing a
pharmaceutical agent to an animal, and includes, but is not limited
to administering by a medical professional and
self-administering.
[0429] As used herein, the term "pharmaceutical composition" refers
to a mixture of substances suitable for administering to an
individual. For example, a pharmaceutical composition may comprise
a therapeutic agents and a sterile aqueous solution.
[0430] As used herein, the term "animal" refers to a human or
non-human animal, including, but not limited to, mice, rats,
rabbits, dogs, cats, pigs, and non-human primates, including, but
not limited to, monkeys and chimpanzees.
B. Certain Thereapeutic Agents
[0431] In certain embodiments, the invention provides therapeutic
agents comprising at least one therapeutic nucleoside and at least
one targeting group. In certain embodiments, the invention provides
therapeutic agents comprising at least one therapeutic nucleoside
and at least one targeting group and at least one oligomeric
compound, such as an antisense compound. In certain embodiments,
the invention provides therapeutic agents comprising at least two
therapeutic nucleosides. In certain embodiments, the invention
provides therapeutic agents comprising at least two therapeutic
nucleosides and at least one targeting group. In certain
embodiments, the invention provides therapeutic agents comprising
at least two therapeutic nucleoside and at least one targeting
group and at least one oligomeric compound.
[0432] a. Certain Therapeutic Nucleosides
[0433] Certain therapeutic nucleosides suitable for use in the
present invention have been described. See for example, L. P.
Jordheim, D. Durantel, and C. Dumontet, "Advances in the
development of nucleoside and nucleotide analogues for cancer and
viral diseases" Nature Reviews Drug Discovery 12,447-464 (2013).
Such therapeutic nucleosides include, but are not limited to
therapeutic nucleosides for use in treating cancer and viral
infections, including but not limited to HIV, HCV, and HBV
infections.
[0434] i. Certain Antiviral Therapeutic Nucleosides
[0435] In certain embodiments, the therapeutic nucleosides used in
the present invention are antiviral therapeutic nucleosides. For
example, in certain embodiments, the therapeutic nucleoside
comprises the following structure:
##STR00028## [0436] wherein R.sub.3 is hydroxyl or a cleavable
moiety with additional substituents; and [0437] Bx is a modified or
unmodified nucleobase.
[0438] In certain such embodiments, the therapeutic nucleoside
comprises the following structure:
##STR00029##
[0439] wherein R.sub.3 is hydroxyl or the targeting group; and
[0440] R.sub.4 and R.sub.5 are each independently selected from
phenoxy, NHCH(CH.sub.3)C(O)OiPr, alkoxy, alkylamino, hydroxyl, an
internucleoside linking group linking the therapeutic nucleoside to
another nucleoside or to an oligomeric compound, and the targeting
group; [0441] provided that at least one of R.sub.3, R.sub.4, and
R.sub.5 is a targeting group.
[0442] In certain embodiments, the therapeutic nucleoside comprises
the following structure:
##STR00030##
[0443] wherein B is a modified or unmodified nucleobase;
[0444] X is 0 or CCH.sub.2;
[0445] Y is S or CR.sub.6R.sub.7; and
[0446] R.sub.6 and R.sub.7 are each independently selected from
hydrogen, hydroxyl, O-L-valinyl ester, and the targeting group.
[0447] In certain such embodiments, the modified or unmodified
nucleobase is selected from among: adenine, uracil, cytosine,
5-methylcytosine, guanine, thymine, and 5-fluorocytosine.
[0448] In certain embodiments, a therapeutic nucleoside comprises
an acyclic sugar surrogate.
1. Certain Anti-HBV Therapeutic Nucleosides
[0449] In certain embodiments, the therapeutic nucleoside can be
used to treat HBV infections. In certain embodiments, the
therapeutic nucleoside is Telbivudine. In certain embodiments, the
therapeutic nucleoside is Entecavir. In certain embodiments, the
therapeutic nucleoside is Lamivudine. In certain embodiments, the
therapeutic nucleoside is Adefovir dipivoxil. In certain
embodiments, the therapeutic nucleoside is Tenofovir disoproxil
fumarate. In certain embodiments, the therapeutic nucleoside is
Sovaldi. In certain embodiments, a method of treating HBV infection
comprises administering a combination of therapeutic nucleosides or
a combination of at least one therapeutic nucleoside with at least
one non-nucleoside therapeutic agent.
2. Certain Anti-HCV Therapeutic Nucleosides
[0450] In certain embodiments, the therapeutic nucleoside can be
used to treat HCV infections. In certain embodiments, the
therapeutic nucleoside is IDX21437. In certain embodiments, the
therapeutic nucleoside is IDX21459. In certain embodiments, the
therapeutic nucleoside is Ribavirin. In certain embodiments, the
therapeutic nucleoside is Taribavirin. In certain embodiments, the
therapeutic nucleoside is Mericitabine. In certain embodiments, the
therapeutic nucleoside is ASL-2200. In certain embodiments, the
therapeutic nucleoside is Sovaldi. In certain embodiments, a method
of treating HCV infection comprises administering a combination of
therapeutic nucleosides or a combination of at least one
therapeutic nucleoside with at least one non-nucleoside therapeutic
agent.
[0451] b. Certain Targeting Groups
[0452] In certain embodiments, therapeutic agents comprise at least
one targeting group. In certain embodiments, such targeting group
comprises at least one ligand. In certain embodiments, a targeting
group comprises a carbohydrate or carbohydrate cluster. In certain
embodiments, a targeting group comprises more than one ligand. In
certain such embodiments, the targeting group comprises a branching
group to allow attachment of more than one ligand. In certain
embodiments, a targeting group is attached to a therapeutic
nucleoside by a cleavable moiety, such as a cleavable bond or
cleavable nucleoside. In certain such embodiments, such cleavable
moiety allows the targeting group to be cleaved from the remainder
of the therapeutic agent. In certain embodiments, the cleavable
moiety is a cleavable bond. In certain embodiments, the cleavable
moiety is a group of atoms comprising at least one cleavable bond.
In certain embodiments, the targeting group comprises one or more
tether and/or one or more target group linker. In certain such
embodiments, such groups are designed to provide suitable
separation among functional groups to allow desired interactions,
for example interaction of ligands with cell surface receptors. The
various portions of targeting groups are discussed separately
below. One may use such portions in any combination, including
omitting certain portions, to create various targeting groups.
[0453] 1. Certain Ligands
[0454] In certain embodiments, the present disclosure provides
targeting group comprising at least one ligand. In certain
embodiments, each ligand is covalently attached to a tether. In
certain embodiments, each ligand is selected to have an affinity
for at least one type of receptor on a target cell. In certain
embodiments, ligands are selected that have an affinity for at
least one type of receptor on the surface of a mammalian liver
cell. In certain embodiments, ligands are selected that have an
affinity for the hepatic asialoglycoprotein receptor (ASGP-R). In
certain embodiments, each ligand is a carbohydrate. In certain
embodiments, each ligand is, independently selected from galactose,
N-acetyl galactoseamine, mannose, glucose, glucosamone and fucose.
In certain embodiments, each ligand is N-acetyl galactoseamine
(GalNAc). In certain embodiments, the targeting moiety comprises 2
to 6 ligands. In certain embodiments, the targeting moiety
comprises 3 ligands. In certain embodiments, the targeting moiety
comprises 3 N-acetyl galactoseamine ligands.
[0455] In certain embodiments, the ligand is a carbohydrate,
carbohydrate derivative, modified carbohydrate, multivalent
carbohydrate cluster, polysaccharide, modified polysaccharide, or
polysaccharide derivative. In certain embodiments, the ligand is an
amino sugar or a thio sugar. For example, amino sugars may be
selected from any number of compounds known in the art, for example
glucosamine, sialic acid, .alpha.-D-galactosamine,
N-Acetylgalactosamine (GalNAc),
2-acetamido-2-deoxy-D-galactopyranose,
2-Amino-3-O--[(R)-1-carboxyethyl]-2-deoxy-.beta.-D-glucopyranose
(.beta.-muramic acid), 2-Deoxy-2-methylamino-L-glucopyranose,
4,6-Dideoxy-4-formamido-2,3-di-O-methyl-D-mannopyranose,
2-Deoxy-2-sulfoamino-D-glucopyranose and N-sulfo-D-glucosamine, and
N-Glycoloyl-.alpha.-neuraminic acid. For example, thio sugars may
be selected from the group consisting of
5-Thio-.beta.-D-glucopyranose, Methyl
2,3,4-tri-O-acetyl-1-thio-6-O-trityl-.alpha.-D-glucopyranoside,
4-Thio-.beta.-D-galactopyranose, and ethyl
3,4,6,7-tetra-O-acetyl-2-deoxy-1,5-dithio-.alpha.-D-gluco-heptopyranoside-
.
[0456] In certain embodiments one or more ligand has a structure
selected from among:
##STR00031##
[0457] wherein each R.sub.1 is selected from OH and
NHCOCH.sub.3.
[0458] In certain embodiments one or more ligand has a structure
selected from among:
##STR00032##
[0459] In certain embodiments one or more ligand has a structure
selected from among:
##STR00033##
[0460] In certain embodiments one or more ligand has a structure
selected from among:
##STR00034##
[0461] 2. Certain Tethers
[0462] In certain embodiments, one or more ligand is attached to
the remainder of the targeting group through a tether. In certain
embodiments, tethers attach a ligand directly to a therapeutic
nucleoside. In certain embodiments, a tether attaches a ligand to a
branching group or a targeting group linker.
[0463] In certain embodiments, each tether is a linear aliphatic
group comprising one or more groups selected from alkyl, ether,
thioether, disulfide, amide and polyethylene glycol groups in any
combination. In certain embodiments, each tether is a linear
aliphatic group comprising one or more groups selected from alkyl,
substituted alkyl, ether, thioether, disulfide, amide,
phosphodiester and polyethylene glycol groups in any combination.
In certain embodiments, each tether is a linear aliphatic group
comprising one or more groups selected from alkyl, ether and amide
groups in any combination. In certain embodiments, each tether is a
linear aliphatic group comprising one or more groups selected from
alkyl, substituted alkyl, phosphodiester, ether and amide groups in
any combination. In certain embodiments, each tether is a linear
aliphatic group comprising one or more groups selected from alkyl
and phosphodiester in any combination.
[0464] In certain embodiments, each tether comprises at least one
phosphorus linking group or neutral linking group. In certain
embodiments, the tether includes one or more cleavable bond. In
certain embodiments, the tether is attached to the branching group
through either an amide or an ether group. In certain embodiments,
the tether is attached to the branching group through a
phosphodiester group. In certain embodiments, the tether is
attached to the branching group through a phosphorus linking group
or neutral linking group. In certain embodiments, the tether is
attached to the branching group through an ether group. In certain
embodiments, the tether is attached to the ligand through either an
amide or an ether group. In certain embodiments, the tether is
attached to the ligand through an ether group. In certain
embodiments, the tether is attached to the ligand through either an
amide or an ether group. In certain embodiments, the tether is
attached to the ligand through an ether group.
[0465] In certain embodiments, each tether comprises from about 8
to about 20 atoms in chain length between the ligand and the
branching group. In certain embodiments, each tether group
comprises from about 10 to about 18 atoms in chain length between
the ligand and the branching group. In certain embodiments, each
tether group comprises about 13 atoms in chain length.
[0466] In certain embodiments, a tether has a structure selected
from among:
##STR00035## [0467] wherein each n is, independently, from 1 to 20;
and [0468] each p is from 1 to about 6.
[0469] In certain embodiments, a tether has a structure selected
from among:
##STR00036##
[0470] In certain embodiments, a tether has a structure selected
from among:
##STR00037## [0471] wherein each n is, independently, from 1 to
20.
[0472] In certain embodiments, a tether has a structure selected
from among:
##STR00038## [0473] wherein L is either a phosphorus linking group
or a neutral linking group; [0474] Z.sub.1 is C(.dbd.O)O--R.sub.2;
[0475] Z.sub.2 is H, C.sub.1-C.sub.6 alkyl or substituted
C.sub.1-C.sub.6 alky; [0476] R.sub.2 is H, C.sub.1-C.sub.6 alkyl or
substituted C.sub.1-C.sub.6 alky; and [0477] each m.sub.1 is,
independently, from 0 to 20 wherein at least one m.sub.1 is greater
than 0 for each tether.
[0478] In certain embodiments, a tether has a structure selected
from among:
##STR00039##
[0479] In certain embodiments, a tether has a structure selected
from among:
##STR00040## [0480] wherein Z2 is H or CH.sub.3; and [0481] each
m.sub.1 is, independently, from 0 to 20 wherein at least one
m.sub.1 is greater than 0 for each tether.
[0482] In certain embodiments, a tether comprises a phosphorus
linking group. In certain embodiments, a tether does not comprise
any amide bonds. In certain embodiments, a tether comprises a
phosphorus linking group and does not comprise any amide bonds.
[0483] 3. Certain Branching Groups In certain embodiments, the
targeting groups comprise more than one tethered or untethered
ligand.
[0484] Certain such targeting groups comprise one or more branching
groups to accommodate such more that one ligand. In certain
embodiments, the branching group attaches two or more tethers or
ligands to a target group linker; to a cleavable moiety; or
directly to a therapeutic nucleoside.
[0485] In certain embodiments, the branching group comprises a
branched aliphatic group comprising groups selected from alkyl,
amide, disulfide, polyethylene glycol, ether, thioether and
hydroxylamino groups. In certain embodiments, the branching group
comprises groups selected from alkyl, amide and ether groups. In
certain embodiments, the branching group comprises groups selected
from alkyl and ether groups. In certain embodiments, the branching
group comprises a mono or polycyclic ring system. In certain
embodiments, the branching group comprises one or more cleavable
bond. In certain embodiments, the targeting group does not include
a branching group.
[0486] In certain embodiments, a branching group has a structure
selected from among:
##STR00041## ##STR00042## ##STR00043## [0487] wherein each n is,
independently, from 1 to 20; [0488] j is from 1 to 3; and [0489] m
is from 2 to 6.
[0490] In certain embodiments, a branching group has a structure
selected from among:
##STR00044## ##STR00045## [0491] wherein each n is, independently,
from 1 to 20; and [0492] m is from 2 to 6.
[0493] In certain embodiments, a branching group has a structure
selected from among:
##STR00046## ##STR00047## ##STR00048##
[0494] In certain embodiments, a branching group has a structure
selected from among:
##STR00049## [0495] wherein each A.sub.1 is independently, O, S,
C.dbd.O or NH; and [0496] each n is, independently, from 1 to
20.
[0497] In certain embodiments, a branching group has a structure
selected from among:
##STR00050## [0498] wherein each A.sub.1 is independently, O, S,
C.dbd.O or NH; and [0499] each n is, independently, from 1 to
20.
[0500] In certain embodiments, a branching group has a structure
selected from among:
##STR00051## [0501] wherein A.sub.1 is O, S, C.dbd.Oor NH; and
[0502] each n is, independently, from 1 to 20.
[0503] In certain embodiments, a branching group has a structure
selected from among:
##STR00052##
[0504] In certain embodiments, a branching group has a structure
selected from among:
##STR00053##
[0505] In certain embodiments, a branching group has a structure
selected from among:
##STR00054##
[0506] 4. Certain Targeting Group Linkers
[0507] In certain embodiments, the targeting groups comprise a
targeting group linker. In certain such embodiments, the targeting
group linker is covalently bound to a branching group and a
cleavable moiety. In certain embodiments, the targeting group
linker is covalently bound to a branching group and to the
therapeutic nucleoside. In certain embodiments, the linker is
covalently bound to a cell-targeting moiety. In certain
embodiments, the targeting group linker further comprises a
covalent attachment to a solid support. In certain embodiments, the
targeting group linker further comprises a covalent attachment to a
protein binding moiety. In certain embodiments, the targeting group
linker further comprises a covalent attachment to a solid support
and further comprises a covalent attachment to a protein binding
moiety. In certain embodiments, the targeting group linker includes
multiple positions for attachment of tethered ligands. In certain
embodiments, the targeting group linker includes multiple positions
for attachment of tethered ligands and is not attached to a
branching group. In certain embodiments, the linker further
comprises one or more cleavable bond. In certain embodiments, the
targeting group does not include a targeting group linker.
[0508] In certain embodiments, the targeting group linker includes
at least a linear group comprising groups selected from alkyl,
amide, disulfide, polyethylene glycol, ether, thioether (--S--) and
hydroxylamino (--O--N(H)--) groups. In certain embodiments, the
linear group comprises groups selected from alkyl, amide and ether
groups. In certain embodiments, the linear group comprises groups
selected from alkyl and ether groups. In certain embodiments, the
linear group comprises at least one phosphorus linking group. In
certain embodiments, the linear group comprises at least one
phosphodiester group. In certain embodiments, the linear group
includes at least one neutral linking group. In certain
embodiments, the linear group is covalently attached to the
cell-targeting moiety and the cleavable moiety. In certain
embodiments, the linear group is covalently attached to the
cell-targeting moiety and the antisense compound. In certain
embodiments, the linear group is covalently attached to the
cell-targeting moiety, the cleavable moiety and a solid support. In
certain embodiments, the linear group is covalently attached to the
cell-targeting moiety, the cleavable moiety, a solid support and a
protein binding moiety. In certain embodiments, the linear group
includes one or more cleavable bond.
[0509] In certain embodiments, the targeting group linker includes
the linear group covalently attached to a scaffold group. In
certain embodiments, the scaffold includes a branched aliphatic
group comprising groups selected from alkyl, amide, disulfide,
polyethylene glycol, ether, thioether and hydroxylamino groups. In
certain embodiments, the scaffold includes a branched aliphatic
group comprising groups selected from alkyl, amide and ether
groups. In certain embodiments, the scaffold includes at least one
mono or polycyclic ring system. In certain embodiments, the
scaffold includes at least two mono or polycyclic ring systems. In
certain embodiments, the linear group is covalently attached to the
scaffold group and the scaffold group is covalently attached to the
cleavable moiety and the linker. In certain embodiments, the linear
group is covalently attached to the scaffold group and the scaffold
group is covalently attached to the cleavable moiety, the linker
and a solid support. In certain embodiments, the linear group is
covalently attached to the scaffold group and the scaffold group is
covalently attached to the cleavable moiety, the linker and a
protein binding moiety. In certain embodiments, the linear group is
covalently attached to the scaffold group and the scaffold group is
covalently attached to the cleavable moiety, the linker, a protein
binding moiety and a solid support. In certain embodiments, the
scaffold group includes one or more cleavable bond.
[0510] In certain embodiments, the targeting group linker includes
a protein binding moiety. In certain embodiments, the protein
binding moiety is a lipid such as for example including but not
limited to cholesterol, cholic acid, adamantane acetic acid,
1-pyrene butyric acid, dihydrotestosterone,
1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group,
hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl
group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid,
O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine), a
vitamin (e.g., folate, vitamin A, vitamin E, biotin, pyridoxal), a
peptide, a carbohydrate (e.g., monosaccharide, disaccharide,
trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide),
an endosomolytic component, a steroid (e.g., uvaol, hecigenin,
diosgenin), a terpene (e.g., triterpene, e.g., sarsasapogenin,
friedelin, epifriedelanol derivatized lithocholic acid), or a
cationic lipid. In certain embodiments, the protein binding moiety
is a C16 to C22 long chain saturated or unsaturated fatty acid,
cholesterol, cholic acid, vitamin E, adamantane or
1-pentafluoropropyl.
[0511] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00055## ##STR00056## [0512] wherein each n is, independently,
from 1 to 20; and p is from 1 to 6.
[0513] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00057## ##STR00058## [0514] wherein each n is, independently,
from 1 to 20.
[0515] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00059## ##STR00060## [0516] wherein n is from 1 to 20.
[0517] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00061## ##STR00062##
[0518] wherein each L is, independently, a phosphorus linking group
or a neutral linking group; and [0519] each n is, independently,
from 1 to 20.
[0520] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00063## ##STR00064## ##STR00065## ##STR00066##
[0521] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00067## ##STR00068##
[0522] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00069## ##STR00070##
[0523] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00071## [0524] wherein n is from 1 to 20.
[0525] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00072##
[0526] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00073##
[0527] In certain embodiments, a targeting group linker has a
structure selected from among:
##STR00074##
[0528] In certain embodiments, the targeting group linker has the
structure:
##STR00075##
[0529] ii. Certain Targeting Groups
[0530] In certain embodiments, targeting groups comprise any
combination of the structural features above. In certain such
embodiments, targeting groups have the following structure:
##STR00076## [0531] wherein each n is, independently, from 1 to
20.
[0532] In certain such embodiments, targeting groups have the
following structure:
##STR00077##
[0533] In certain such embodiments, targeting groups have the
following structure:
##STR00078## [0534] wherein each n is, independently, from 1 to 20;
[0535] Z is H or a linked solid support; [0536] Q is an antisense
compound; [0537] X is O or S; and [0538] Bx is a heterocyclic base
moiety.
[0539] In certain such embodiments, targeting groups have the
following structure:
##STR00079##
[0540] In certain such embodiments, targeting groups have the
following structure:
##STR00080##
[0541] In certain such embodiments, targeting groups have the
following structure:
##STR00081## [0542] wherein each n is, independently, from 1 to
6.
[0543] In certain such embodiments, targeting groups have the
following structure:
##STR00082##
[0544] In certain such embodiments, targeting groups have the
following structure:
##STR00083## [0545] wherein each n is, independently, from 1 to
6.
[0546] In certain such embodiments, targeting groups have the
following structure:
##STR00084##
[0547] In certain such embodiments, targeting groups have the
following structure:
##STR00085## [0548] wherein each n is, independently, from 1 to
6.
[0549] In certain such embodiments, targeting groups have the
following structure:
##STR00086##
[0550] In certain embodiments, targeting groups do not comprise a
pyrrolidine.
[0551] Additional target groups may be found in the art, sometimes
referred to as conjugate groups in the context of oligonucleotides.
Representative United States patents, United States patent
application publications, and international patent application
publications that teach the preparation of certain of the above
noted therapeutic agents, target groups, conjugated antisense
compounds, tethers, linkers, branching groups, ligands, cleavable
moieties as well as other modifications include without limitation,
U.S. Pat. No. 5,994,517, U.S. Pat. No. 6,300,319, U.S. Pat. No.
6,660,720, U.S. Pat. No. 6,906,182, U.S. Pat. No. 7,262,177, U.S.
Pat. No. 7,491,805, U.S. Pat. No. 8,106,022, U.S. Pat. No.
7,723,509, US 2006/0148740, US 2011/0123520, WO 2013/033230 and WO
2012/037254, each of which is incorporated by reference herein in
its entirety.
[0552] Representative publications that teach the preparation of
certain of the above noted targeting groups, tethers, linkers,
branching groups, ligands, cleavable moieties as well as other
modifications include without limitation, BIESSEN et al., "The
Cholesterol Derivative of a Triantennary Galactoside with High
Affinity for the Hepatic Asialoglycoprotein Receptor: a Potent
Cholesterol Lowering Agent" J. Med. Chem. (1995) 38:1846-1852,
BIESSEN et al., "Synthesis of Cluster Galactosides with High
Affinity for the Hepatic Asialoglycoprotein Receptor" J. Med. Chem.
(1995) 38:1538-1546, LEE et al., "New and more efficient
multivalent glyco-ligands for asialoglycoprotein receptor of
mammalian hepatocytes" Bioorganic & Medicinal Chemistry (2011)
19:2494-2500, RENSEN et al., "Determination of the Upper Size Limit
for Uptake and Processing of Ligands by the Asialoglycoprotein
Receptor on Hepatocytes in Vitro and in Vivo" J. Biol. Chem. (2001)
276(40):37577-37584, RENSEN et al., "Design and Synthesis of Novel
N-Acetylgalactosamine-Terminated Glycolipids for Targeting of
Lipoproteins to the Hepatic Asialoglycoprotein Receptor" J. Med.
Chem. (2004) 47:5798-5808, SLIEDREGT et al., "Design and Synthesis
of Novel Amphiphilic Dendritic Galactosides for Selective Targeting
of Liposomes to the Hepatic Asialoglycoprotein Receptor" J. Med.
Chem. (1999) 42:609-618, and Valentijn et al., "Solid-phase
synthesis of lysine-based cluster galactosides with high affinity
for the Asialoglycoprotein Receptor" Tetrahedron, 1997, 53(2),
759-770, each of which is incorporated by reference herein in its
entirety.
[0553] c. Certain Cleavable Moieties
[0554] In certain embodiments, a therapeutic agent comprises one or
more cleavable moieties. In certain embodiments, a targeting group
is attached to a therapeutic nucleoside via a cleavable moiety. In
certain embodiments, two or more therapeutic nucleosides are joined
together by a cleavable moiety. In certain embodiments, a cleavable
moiety is a cleavable bond. In certain embodiments, a cleavable
moiety comprises a cleavable bond. In certain embodiments a
cleavable moiety is a cleavable nucleoside. In certain such
embodiments, a cleavable nucleoside is a modified or unmodified
nucleoside attached through a cleavable bond, such as a
phosphodiester bond.
[0555] In certain embodiments, the cleavable moiety comprises a
phosphate or phosphodiester. In certain embodiments, the cleavable
moiety is a cleavable nucleoside or nucleoside analog. In certain
embodiments, the nucleoside or nucleoside analog comprises an
optionally protected heterocyclic base selected from a purine,
substituted purine, pyrimidine or substituted pyrimidine. In
certain embodiments, the cleavable moiety is a nucleoside
comprising an optionally protected heterocyclic base selected from
uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine,
4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine
and 2-N-isobutyrylguanine. In certain embodiments, the cleavable
moiety is 2'-deoxy nucleoside that is attached to the 3' position
of the antisense compound by a phosphodiester linkage and is
attached to the linker by a phosphodiester or phosphorothioate
linkage. In certain embodiments, the cleavable moiety is 2'-deoxy
adenosine that is attached to the 3' position of the antisense
compound by a phosphodiester linkage and is attached to the linker
by a phosphodiester or phosphorothioate linkage. In certain
embodiments, the cleavable moiety is 2'-deoxy adenosine that is
attached to the 3' position of the antisense compound by a
phosphodiester linkage and is attached to the linker by a
phosphodiester linkage.
[0556] In certain embodiments, the cleavable moiety is attached to
the 3' position of the antisense compound. In certain embodiments,
the cleavable moiety is attached to the 5' position of the
antisense compound. In certain embodiments, the cleavable moiety is
attached to a 2' position of the antisense compound. In certain
embodiments, the cleavable moiety is attached to the antisense
compound by a phosphodiester linkage. In certain embodiments, the
cleavable moiety is attached to the linker by either a
phosphodiester or a phosphorothioate linkage. In certain
embodiments, the cleavable moiety is attached to the linker by a
phosphodiester linkage.
[0557] In certain embodiments, the cleavable moiety is cleaved
after the complex has been administered to an animal only after
being internalized by a targeted cell. Inside the cell the
cleavable moiety is cleaved thereby releasing the active antisense
compound. While not wanting to be bound by theory it is believed
that the cleavable moiety is cleaved by one or more nucleases
within the cell. In certain embodiments, the one or more nucleases
cleave the phosphodiester linkage between the cleavable moiety and
the linker. In certain embodiments, the cleavable moiety has a
structure selected from among the following:
##STR00087##
wherein each of Bx, Bx.sub.1, Bx.sub.2, and Bx.sub.3 is
independently a heterocyclic base moiety. In certain embodiments,
the cleavable moiety has a structure selected from among the
following:
##STR00088##
In certain embodiments, the cleavable moiety has the structure:
##STR00089##
[0558] C. Certain Oligomeric Compounds
[0559] In certain embodiments, therapeutic agents comprise one or
more oligomeric compound. In certain such embodiments, such
oligomeric compound comprises or consists of an antisense compound.
Such antisense compounds comprise linked nucleosides, each
nucleoside comprising a sugar moiety and a nucleobase. The
structure of such antisense compounds may be considered in terms of
chemical features (e.g., modifications and patterns of
modifications) and nucleobase sequence (e.g., sequence of antisense
compound, identity and sequence of target nucleic acid).
[0560] i. Certain Chemistry Features
[0561] In certain embodiments, antisense compound comprise one or
more modification. In certain such embodiments, antisense compounds
comprise one or more modified nucleosides and/or modified
internucleoside linkages. In certain embodiments, modified
nucleosides comprise a modified sugar moiety and/or modified
nucleobase.
[0562] 1. Certain Sugar Moieties
[0563] In certain embodiments, compounds of the disclosure comprise
one or more modified nucleosides comprising a modified sugar
moiety. Such compounds comprising one or more sugar-modified
nucleosides may have desirable properties, such as enhanced
nuclease stability or increased binding affinity with a target
nucleic acid relative to an oligonucleotide comprising only
nucleosides comprising naturally occurring sugar moieties. In
certain embodiments, modified sugar moieties are substituted sugar
moieties. In certain embodiments, modified sugar moieties are sugar
surrogates. Such sugar surrogates may comprise one or more
substitutions corresponding to those of substituted sugar moieties.
In certain embodiments, modified sugar moieties are substituted
sugar moieties comprising one or more non-bridging sugar
substituent, including but not limited to substituents at the 2'
and/or 5' positions. Examples of sugar substituents suitable for
the 2'-position, include, but are not limited to: 2'-F,
2'-OCH.sub.3 ("OMe" or "O-methyl"), and 2'-O(CH.sub.2)20CH.sub.3
("MOE"). In certain embodiments, sugar substituents at the 2'
position is selected from allyl, amino, azido, thio, O-allyl,
O--C.sub.1-C.sub.10 alkyl, O--C.sub.1-C.sub.10 substituted alkyl;
OCF.sub.3, O(CH.sub.2).sub.2SCH.sub.3,
O(CH.sub.2).sub.2--O--N(Rm)(Rn), and
O--CH.sub.2--C(.dbd.O)--N(Rm)(Rn), where each Rm and Rn is,
independently, H or substituted or unsubstituted C.sub.1-C.sub.10
alkyl. Examples of sugar substituents at the 5 `-position, include,
but are not limited to:, 5`-methyl (R or S); 5'-vinyl, and
5'-methoxy. In certain embodiments, substituted sugars comprise
more than one non-bridging sugar substituent, for example,
2'-F-5'-methyl sugar moieties (see,e.g., PCT International
Application WO 2008/101157, for additional 5',2'-bis substituted
sugar moieties and nucleosides).
[0564] Nucleosides comprising 2'-substituted sugar moieties are
referred to as 2'-substituted nucleosides. In certain embodiments,
a 2'-substituted nucleoside comprises a 2'-substituent group
selected from halo, allyl, amino, azido, SH, CN, OCN, CF.sub.3,
OCF.sub.3, O, S, or N(R.sub.m)-alkyl; O, S, or N(R.sub.m)-alkenyl;
O, S or N(R.sub.m)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl,
aralkyl, O-alkaryl, O-aralkyl, O(CH.sub.2).sub.2SCH.sub.3,
O--(CH.sub.2).sub.2--O--N(R.sub.m)(R.sub.n) or
O--H.sub.2--C(.dbd.O)--N(R.sub.m)(R.sub.n), where each R.sub.m and
R.sub.n is, independently, H, an amino protecting group or
substituted or unsubstituted C.sub.1-C.sub.10 alkyl. These
2'-substituent groups can be further substituted with one or more
substituent groups independently selected from hydroxyl, amino,
alkoxy, carboxy, benzyl, phenyl, nitro (NO.sub.2), thiol,
thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and
alkynyl.
[0565] In certain embodiments, a 2'-substituted nucleoside
comprises a 2'-substituent group selected from F, NH.sub.2,
N.sub.3, OCF.sub.3, O--CH.sub.3, O(CH.sub.2).sub.3NH.sub.2,
CH.sub.2--CH.dbd.CH.sub.2, O--CH.sub.2--CH.dbd.CH.sub.2,
OCH.sub.2CH.sub.2OCH.sub.3, O(CH.sub.2).sub.2SCH.sub.3,
O--(CH.sub.2).sub.2--O--N(R.sub.m)(R.sub.n),
O(CH.sub.2).sub.2(CH.sub.2).sub.2N(CH.sub.3).sub.2, and
N-substituted acetamide
(O--CH.sub.2--C(.dbd.O)--N(R.sub.m)(R.sub.n) where each R.sub.m and
R.sub.n is, independently, H, an amino protecting group or
substituted or unsubstituted C.sub.1-C.sub.10 alkyl.
[0566] In certain embodiments, a 2'-substituted nucleoside
comprises a sugar moiety comprising a 2'-substituent group selected
from F, OCF.sub.3, O--CH.sub.3, OCH.sub.2CH.sub.2OCH.sub.3,
O(CH.sub.2)2SCH.sub.3, O--(CH.sub.2).sub.2--O--N(CH.sub.3).sub.2,
--O(CH.sub.2).sub.2O(CH.sub.2).sub.2N(CH.sub.3).sub.2, and
O--CH.sub.2--C(.dbd.O)--N(H)CH.sub.3.
[0567] In certain embodiments, a 2'-substituted nucleoside
comprises a sugar moiety comprising a 2'-substituent group selected
from F, O--CH.sub.3, and OCH.sub.2CH.sub.2OCH.sub.3.
[0568] Certain modified sugar moieties comprise a bridging sugar
substituent that forms a second ring resulting in a bicyclic sugar
moiety. In certain such embodiments, the bicyclic sugar moiety
comprises a bridge between the 4' and the 2' furanose ring atoms.
Examples of such 4' to 2' sugar substituents, include, but are not
limited to: -[C(R.sub.a)(R.sub.b)]--,
--[C(R.sub.a)(R.sub.b)].sub.n--O--, --C(R.sub.aR.sub.b)--N(R)--O--
or, --C(R.sub.aR.sub.b)--O--N(R)--; 4'-CH.sub.2-2',
4'-(CH.sub.2).sub.2-2', 4'-(CH.sub.2).sub.3-2', 4'-(CH.sub.2)--O-2'
(LNA); 4'-(CH.sub.2)--S-2'; 4'-(CH.sub.2).sub.2--O-2' (ENA);
4'-CH(CH.sub.3)--O-2' (cEt) and 4'-CH(CH.sub.2OCH.sub.3)--O-2', and
analogs thereof (see, e.g., U.S. Pat. No. 7,399,845, issued on Jul.
15, 2008); 4'-C(CH.sub.3)(CH.sub.3)--O-2'and analogs thereof, (see,
e.g., WO2009/006478, published Jan. 8, 2009);
4'-CH.sub.2--N(OCH.sub.3)-2' and analogs thereof (see, e.g.,
WO2008/150729, published Dec. 11, 2008);
4'-CH.sub.2--O--N(CH.sub.3)-2' (see, e.g., US2004/0171570,
published Sep. 2, 2004); 4'-CH.sub.2--O--N(R)-2', and
4'-CH.sub.2--N(R)--O-2'-, wherein each R is, independently, H, a
protecting group, or C.sub.1-C.sub.12 alkyl;
4'-CH.sub.2--N(R)--O2', wherein R is H, C.sub.1-C.sub.12 alkyl, or
a protecting group (see, U.S. Pat. No. 7,427,672, issued on Sep.
23, 2008); 4'-CH.sub.2--C(H)(CH.sub.3)-2' (see, e.g.,
Chattopadhyaya, et al., J. Org. Chem.,2009, 74, 118-134); and
4'-CH.sub.2--C(.dbd.CH.sub.2)-2' and analogs thereof (see,
published PCT International Application WO 2008/154401, published
on Dec. 8, 2008).
[0569] In certain embodiments, such 4' to 2' bridges independently
comprise from 1 to 4 linked groups independently selected from
--[C(R.sub.d)(R.sub.b).sub.n--, --C(R.sub.a).dbd.C(R.sub.b)--,
--C(R.sub.a).dbd.N--, --C(.dbd.NR.sub.a)--, --C(.dbd.O)--,
--C(.dbd.S)--, --O--, --Si(R.sub.a).sub.2--, --S(.dbd.O)--, and
--N(R.sub.a)--;
[0570] wherein:
[0571] x is 0, 1, or 2;
[0572] n is 1, 2, 3, or 4;
[0573] each R.sub.a and R.sub.b is, independently, H, a protecting
group, hydroxyl, C.sub.1-C.sub.12 alkyl, substituted
C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, substituted
C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, substituted
C.sub.2-C.sub.12 alkynyl, C.sub.5-C.sub.20 aryl, substituted
C.sub.5-C.sub.20 aryl, heterocycle radical, substituted heterocycle
radical, heteroaryl, substituted heteroaryl, C.sub.5-C.sub.7
alicyclic radical, substituted C.sub.5-C.sub.7 alicyclic radical,
halogen, OJ.sub.1, NJ.sub.1J.sub.2, SJ.sub.1, N.sub.3, COOJ, acyl
(C(.dbd.O)--H), substituted acyl, CN, sulfonyl
(S(.dbd.O).sub.2-J.sub.1), or sulfoxyl (S(.dbd.O)-J.sub.1); and
[0574] each J.sub.1 and J.sub.2 is, independently, H,
C.sub.1-C.sub.12 alkyl, substituted C.sub.1-C.sub.12 alkyl,
C.sub.2-C.sub.12 alkenyl, substituted C.sub.2-C.sub.12 alkenyl,
C.sub.2-C.sub.12 alkynyl, substituted C.sub.2-C.sub.12 alkynyl,
C.sub.5-C.sub.20 aryl, substituted C.sub.5-C.sub.20 aryl, acyl
(C(.dbd.O)--H), substituted acyl, a heterocycle radical, a
substituted heterocyle radical, C.sub.1-C.sub.12 aminoalkyl,
substituted C.sub.1-C.sub.12 aminoalkyl, or a protecting group.
[0575] Nucleosides comprising bicyclic sugar moieties are referred
to as bicyclic nucleosides or BNAs. Bicyclic nucleosides include,
but are not limited to, (A) .alpha.-L-Methyleneoxy
(4'-CH.sub.2--O-2') BNA, (B) .beta.-D-Methyleneoxy
(4'-CH.sub.2--O-2') BNA (also referred to as locked nucleic acid or
LNA), (C) Ethyleneoxy (4'-(CH.sub.2).sub.2--O-2') BNA, (D) Aminooxy
(4'-CH.sub.2--O--N(R)-2') BNA, (E) Oxyamino
(4'-CH.sub.2--N(R)--O-2') BNA, (F) Methyl(methyleneoxy)
(4'-CH(CH.sub.3)--O-2') BNA (also referred to as constrained ethyl
or cEt), (G) methylene-thio (4'-CH.sub.2--S-2') BNA, (H)
methylene-amino (4'-CH.sub.2--N(R)-2') BNA, (I) methyl carbocyclic
(4'-CH.sub.2--CH(CH.sub.3)-2') BNA, and (J) propylene carbocyclic
(4'-(CH.sub.2).sub.3-2') BNA as depicted below.
##STR00090## ##STR00091##
wherein Bx is a nucleobase moiety and R is, independently, H, a
protecting group, or C.sub.1-C.sub.12 alkyl.
[0576] Additional bicyclic sugar moieties are known in the art, for
example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et
al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc.
Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg.
Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem.,
1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc.,
129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., Curr. Opinion
Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001,
8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243;
U.S. Pat. Nos. 7,053,207, 6,268,490, 6,770,748, 6,794,499,
7,034,133, 6,525,191, 6,670,461, and 7,399,845; WO 2004/106356, WO
1994/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent
Publication Nos. US2004/0171570, US2007/0287831, and
US2008/0039618; U.S. patent Ser. Nos. 12/129,154, 60/989,574,
61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and
61/099,844; and PCT International Applications Nos.
PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922.
[0577] In certain embodiments, bicyclic sugar moieties and
nucleosides incorporating such bicyclic sugar moieties are further
defined by isomeric configuration. For example, a nucleoside
comprising a 4'-2' methylene-oxy bridge, may be in the .alpha.-L
configuration or in the .beta.-D configuration. Previously,
.alpha.-L-methyleneoxy (4'-CH.sub.2--O-2') bicyclic nucleosides
have been incorporated into antisense compounds that showed
antisense activity (Frieden et al., Nucleic Acids Research, 2003,
21, 6365-6372).
[0578] In certain embodiments, substituted sugar moieties comprise
one or more non-bridging sugar substituent and one or more bridging
sugar substituent (e.g., 5'-substituted and 4'-2' bridged sugars).
(see, PCT International Application WO 2007/134181, published on
Nov. 22, 2007, wherein LNA is substituted with, for example, a
5'-methyl or a 5'-vinyl group).
[0579] In certain embodiments, modified sugar moieties are sugar
surrogates. In certain such embodiments, the oxygen atom of the
naturally occuring sugar is substituted, e.g., with a sulfer,
carbon or nitrogen atom. In certain such embodiments, such modified
sugar moiety also comprises bridging and/or non-bridging
substituents as described above. For example, certain sugar
surogates comprise a 4'-sulfer atom and a substitution at the
2'-position (see,e.g., published U.S. Patent Application
US2005/0130923, published on Jun. 16, 2005) and/or the 5' position.
By way of additional example, carbocyclic bicyclic nucleosides
having a 4'-2' bridge have been described (see, e.g., Freier et
al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et
al., J. Org. Chem., 2006, 71, 7731-7740).
[0580] In certain embodiments, sugar surrogates comprise rings
having other than 5-atoms. For example, in certain embodiments, a
sugar surrogate comprises a six-membered tetrahydropyran. Such
tetrahydropyrans may be further modified or substituted.
Nucleosides comprising such modified tetrahydropyrans include, but
are not limited to, hexitol nucleic acid (HNA), anitol nucleic acid
(ANA), manitol nucleic acid (MNA) (see Leumann, C J. Bioorg. &
Med. Chem. (2002) 10:841-854), fluoro HNA (F-HNA), and those
compounds having Formula VI:
##STR00092##
wherein independently for each of said at least one tetrahydropyran
nucleoside analog of Formula VII:
[0581] Bx is a nucleobase moiety;
[0582] T.sub.3 and T.sub.4 are each, independently, an
internucleoside linking group linking the tetrahydropyran
nucleoside analog to the antisense compound or one of T.sub.3 and
T.sub.4 is an internucleoside linking group linking the
tetrahydropyran nucleoside analog to the antisense compound and the
other of T.sub.3 and T.sub.4 is H, a hydroxyl protecting group, a
linked conjugate group, or a 5' or 3'-terminal group; q.sub.1,
q.sub.2, q.sub.3, q.sub.4, q.sub.5, q.sub.6 and q.sub.7 are each,
independently, H, C.sub.1-C.sub.6 alkyl, substituted
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, substituted
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, or substituted
C.sub.2-C.sub.6 alkynyl; and
[0583] each of R.sub.1 and R.sub.2 is independently selected from
among: hydrogen, halogen, substituted or unsubstituted alkoxy,
NJ.sub.1J.sub.2, SJ.sub.1, N.sub.3, OC(.dbd.X)J.sub.1,
OC(.dbd.X)NJ.sub.1J.sub.2, NJ.sub.3C(.dbd.X)NJ.sub.1J.sub.2, and
CN, wherein X is O, S or NJ.sub.1, and each J.sub.1, J.sub.2, and
J.sub.3 is, independently, H or C.sub.1-C.sub.6 alkyl.
[0584] In certain embodiments, the modified THP nucleosides of
Formula VI are provided wherein q.sub.1, q.sub.2, q.sub.3, q.sub.4,
q.sub.5, q.sub.6 and q.sub.7 are each H. In certain embodiments, at
least one of q.sub.1, q.sub.2, q.sub.3, q.sub.4, q.sub.5, q.sub.6
and q.sub.7 is other than H. In certain embodiments, at least one
of q.sub.1, q.sub.2, q.sub.3, q.sub.4, q.sub.5, q.sub.6 and q.sub.7
is methyl. In certain embodiments, THP nucleosides of Formula VI
are provided wherein one of R.sub.1 and R.sub.2 is F. In certain
embodiments, R.sub.1 is fluoro and R.sub.2 is H, R.sub.1 is methoxy
and R.sub.2 is H, and R.sub.1 is methoxyethoxy and R.sub.2 is
H.
[0585] Many other bicyclo and tricyclo sugar surrogate ring systems
are also known in the art that can be used to modify nucleosides
for incorporation into antisense compounds (see, e.g., review
article: Leumann, J. C, Bioorganic & Medicinal Chemistry, 2002,
10, 841-854).
[0586] Combinations of modifications are also provided without
limitation, such as 2'-F-5'-methyl substituted nucleosides (see PCT
International Application WO 2008/101157 Published on Aug. 21, 2008
for other disclosed 5', 2'-bis substituted nucleosides) and
replacement of the ribosyl ring oxygen atom with S and further
substitution at the 2'-position (see published U.S. Patent
Application US2005-0130923, published on Jun. 16, 2005) or
alternatively 5'-substitution of a bicyclic nucleic acid (see PCT
International Application WO 2007/134181, published on Nov. 22,
2007 wherein a 4'-CH.sub.2--O-2' bicyclic nucleoside is further
substituted at the 5' position with a 5'-methyl or a 5'-vinyl
group). The synthesis and preparation of carbocyclic bicyclic
nucleosides along with their oligomerization and biochemical
studies have also been described (see, e.g., Srivastava et al., J.
Am. Chem. Soc. 2007, 129(26), 8362-8379).
[0587] In certain embodiments, the present disclosure provides
oligonucleotides comprising modified nucleosides. Those modified
nucleotides may include modified sugars, modified nucleobases,
and/or modified linkages. The specific modifications are selected
such that the resulting oligonucleotides possess desireable
characteristics. In certain embodiments, oligonucleotides comprise
one or more RNA-like nucleosides. In certain embodiments,
oligonucleotides comprise one or more DNA-like nucleotides.
2. Certain Nucleobase Modifications
[0588] In certain embodiments, nucleosides of the present
disclosure comprise one or more unmodified nucleobases. In certain
embodiments, nucleosides of the present disclosure comprise one or
more modified nucleobases.
[0589] In certain embodiments, modified nucleobases are selected
from: universal bases, hydrophobic bases, promiscuous bases,
size-expanded bases, and fluorinated bases as defined herein.
5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6
substituted purines, including 2-aminopropyladenine,
5-propynyluracil; 5-propynylcytosine; 5-hydroxymethyl cytosine,
xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl
derivatives of adenine and guanine, 2-propyl and other alkyl
derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and
2-thiocytosine, 5-halouracil and cytosine, 5-propynyl
(--C.ident.C--CH.sub.3) uracil and cytosine and other alkynyl
derivatives of pyrimidine bases, 6-azo uracil, cytosine and
thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino,
8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines
and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and
other 5-substituted uracils and cyto-sines, 7-methylguanine and
7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and
8-azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and
3-deazaadenine, universal bases, hydrophobic bases, promiscuous
bases, size-expanded bases, and fluorinated bases as defined
herein. Further modified nucleobases include tricyclic pyrimidines
such as phenoxazine cytidine([5,4-b][1,4]benzoxazin-2(3H)-one),
phenothiazine cytidine
(1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a
substituted phenoxazine cytidine (e.g.
9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),
carbazole cytidine (2H-pyrimido[4,5 -b]indol2-one), pyridoindole
cytidine (H-pyrido[3',2'4,5]pyrrolo[2,3-d]pyrimidin-2-one).
Modified nucleobases may also include those in which the purine or
pyrimidine base is replaced with other heterocycles, for example
7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.
Further nucleobases include those disclosed in U.S. Pat. No.
3,687,808, those disclosed in The Concise Encyclopedia Of Polymer
Science And Engineering, Kroschwitz, J. I., Ed., John Wiley &
Sons, 1990, 858-859; those disclosed by Englisch et al., Angewandte
Chemie, International Edition, 1991, 30, 613; and those disclosed
by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications,
Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288.
[0590] Representative United States patents that teach the
preparation of certain of the above noted modified nucleobases as
well as other modified nucleobases include without limitation, U.S.
Pat. Nos. 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273;
5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177;
5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617;
5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and
6,005,096, certain of which are commonly owned with the instant
application, and each of which is herein incorporated by reference
in its entirety.
3. Certain Internucleoside Linkages
[0591] In certain embodiments, the present disclosure provides
oligonucleotides comprising linked nucleosides. In such
embodiments, nucleosides may be linked together using any
internucleoside linkage. The two main classes of internucleoside
linking groups are defined by the presence or absence of a
phosphorus atom. Representative phosphorus containing
internucleoside linkages include, but are not limited to,
phosphodiesters (PO), phosphotriesters, methylphosphonates,
phosphoramidate, and phosphorothioates (PS).
[0592] Representative non-phosphorus containing internucleoside
linking groups include, but are not limited to,
methylenemethylimino (--CH.sub.2--N(CH.sub.3)--O--CH.sub.2-),
thiodiester (--O--C(O)--S--, thionocarbamate (--O--C(O)(NH)--S--);
siloxane (--O--Si(H).sub.2--O--); and N,N'-dimethylhydrazine
(--CH.sub.2--N(CH.sub.3)--N(CH.sub.3)--). Modified linkages,
compared to natural phosphodiester linkages, can be used to alter,
typically increase, nuclease resistance of the oligonucleotide. In
certain embodiments, internucleoside linkages having a chiral atom
can be prepared as a racemic mixture, or as separate enantiomers.
Representative chiral linkages include, but are not limited to,
alkylphosphonates and phosphorothioates. Methods of preparation of
phosphorous-containing and non-phosphorous-containing
internucleoside linkages are well known to those skilled in the
art.
[0593] The oligonucleotides described herein contain one or more
asymmetric centers and thus give rise to enantiomers,
diastereomers, and other stereoisomeric configurations that may be
defined, in terms of absolute stereochemistry, as (R) or (S),
.alpha. or .beta. such as for sugar anomers, or as (D) or (L) such
as for amino acids etc. Included in the antisense compounds
provided herein are all such possible isomers, as well as their
racemic and optically pure forms.
[0594] Neutral internucleoside linkages include without limitation,
phosphotriesters, methylphosphonates, MMI
(3.sup.1-CH.sub.2--N(CH.sub.3)--O-5'), amide-3
(3'-CH.sub.2--C(.dbd.O)--N(H)-5'), amide-4
(3'-CH.sub.2--N(H)--C(.dbd.O)-5'), formacetal
(3'-O--CH.sub.2--O-5'), and thioformacetal (3'-S--CH.sub.2--O-5').
Further neutral internucleoside linkages include nonionic linkages
comprising siloxane (dialkylsiloxane), carboxylate ester,
carboxamide, sulfide, sulfonate ester and amides (See for example:
Carbohydrate Modifications in Antisense Research; Y. S. Sanghvi and
P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4,
40-65). Further neutral internucleoside linkages include nonionic
linkages comprising mixed N, O, S and CH.sub.2 component parts.
4. Certain Motifs
[0595] In certain embodiments, antisense compounds comprise one or
more modified nucleoside (e.g., nucleoside comprising a modified
sugar and/or modified nucleobase) and/or one or more modified
internucleoside linkage. The pattern of such modifications on an
oligonucleotide is referred to herein as a motif. In certain
embodiments, sugar, nucleobase, and linkage motifs are independent
of one another.
a. Certain Sugar Motifs
[0596] In certain embodiments, oligonucleotides comprise one or
more type of modified sugar moieties and/or naturally occurring
sugar moieties arranged along an oligonucleotide or region thereof
in a defined pattern or sugar modification motif. Such motifs may
include any of the sugar modifications discussed herein and/or
other known sugar modifications.
[0597] In certain embodiments, the oligonucleotides comprise or
consist of a region having a gapmer sugar motif, which comprises
two external regions or "wings" and a central or internal region or
"gap." The three regions of a gapmer sugar motif (the 5'-wing, the
gap, and the 3'-wing) form a contiguous sequence of nucleosides
wherein at least some of the sugar moieties of the nucleosides of
each of the wings differ from at least some of the sugar moieties
of the nucleosides of the gap. Specifically, at least the sugar
moieties of the nucleosides of each wing that are closest to the
gap (the 3'-most nucleoside of the 5'-wing and the 5'-most
nucleoside of the 3'-wing) differ from the sugar moiety of the
neighboring gap nucleosides, thus defining the boundary between the
wings and the gap. In certain embodiments, the sugar moieties
within the gap are the same as one another. In certain embodiments,
the gap includes one or more nucleoside having a sugar moiety that
differs from the sugar moiety of one or more other nucleosides of
the gap. In certain embodiments, the sugar motifs of the two wings
are the same as one another (symmetric sugar gapmer). In certain
embodiments, the sugar motifs of the 5'-wing differs from the sugar
motif of the 3'-wing (asymmetric sugar gapmer).
i. Certain 5'-Wings
[0598] In certain embodiments, the 5'-wing of a gapmer consists of
1 to 8 linked nucleosides. In certain embodiments, the 5'-wing of a
gapmer consists of 1 to 7 linked nucleosides. In certain
embodiments, the 5'-wing of a gapmer consists of 1 to 6 linked
nucleosides. In certain embodiments, the 5'-wing of a gapmer
consists of 1 to 5 linked nucleosides. In certain embodiments, the
5'-wing of a gapmer consists of 2 to 5 linked nucleosides. In
certain embodiments, the 5'-wing of a gapmer consists of 3 to 5
linked nucleosides. In certain embodiments, the 5'-wing of a gapmer
consists of 4 or 5 linked nucleosides. In certain embodiments, the
5'-wing of a gapmer consists of 1 to 4 linked nucleosides. In
certain embodiments, the 5'-wing of a gapmer consists of 1 to 3
linked nucleosides. In certain embodiments, the 5'-wing of a gapmer
consists of 1 or 2 linked nucleosides. In certain embodiments, the
5'-wing of a gapmer consists of 2 to 4 linked nucleosides. In
certain embodiments, the 5'-wing of a gapmer consists of 2 or 3
linked nucleosides. In certain embodiments, the 5'-wing of a gapmer
consists of 3 or 4 linked nucleosides. In certain embodiments, the
5'-wing of a gapmer consists of 1 nucleoside. In certain
embodiments, the 5'-wing of a gapmer consists of 2 linked
nucleosides. In certain embodiments, the 5'-wing of a gapmer
consists of 3 linked nucleosides. In certain embodiments, the
5'-wing of a gapmer consists of 4 linked nucleosides. In certain
embodiments, the 5'-wing of a gapmer consists of 5 linked
nucleosides. In certain embodiments, the 5'-wing of a gapmer
consists of 6 linked nucleosides.
[0599] In certain embodiments, the 5'-wing of a gapmer comprises at
least one bicyclic nucleoside. In certain embodiments, the 5'-wing
of a gapmer comprises at least two bicyclic nucleosides. In certain
embodiments, the 5'-wing of a gapmer comprises at least three
bicyclic nucleosides. In certain embodiments, the 5'-wing of a
gapmer comprises at least four bicyclic nucleosides. In certain
embodiments, the 5'-wing of a gapmer comprises at least one
constrained ethyl nucleoside. In certain embodiments, the 5'-wing
of a gapmer comprises at least one LNA nucleoside. In certain
embodiments, each nucleoside of the 5'-wing of a gapmer is a
bicyclic nucleoside. In certain embodiments, each nucleoside of the
5'-wing of a gapmer is a constrained ethyl nucleoside. In certain
embodiments, each nucleoside of the 5'-wing of a gapmer is a LNA
nucleoside.
[0600] In certain embodiments, the 5'-wing of a gapmer comprises at
least one non-bicyclic modified nucleoside. In certain embodiments,
the 5'-wing of a gapmer comprises at least one 2'-substituted
nucleoside. In certain embodiments, the 5'-wing of a gapmer
comprises at least one 2'-MOE nucleoside. In certain embodiments,
the 5'-wing of a gapmer comprises at least one 2'-OMe nucleoside.
In certain embodiments, each nucleoside of the 5'-wing of a gapmer
is a non-bicyclic modified nucleoside. In certain embodiments, each
nucleoside of the 5'-wing of a gapmer is a 2'-substituted
nucleoside. In certain embodiments, each nucleoside of the 5'-wing
of a gapmer is a 2'-MOE nucleoside. In certain embodiments, each
nucleoside of the 5'-wing of a gapmer is a 2'-OMe nucleoside.
[0601] In certain embodiments, the 5'-wing of a gapmer comprises at
least one 2'-deoxynucleoside. In certain embodiments, each
nucleoside of the 5'-wing of a gapmer is a 2'-deoxynucleoside. In a
certain embodiments, the 5'-wing of a gapmer comprises at least one
ribonucleoside. In certain embodiments, each nucleoside of the
5'-wing of a gapmer is a ribonucleoside. In certain embodiments,
one, more than one, or each of the nucleosides of the 5'-wing is an
RNA-like nucleoside.
[0602] In certain embodiments, the 5'-wing of a gapmer comprises at
least one bicyclic nucleoside and at least one non-bicyclic
modified nucleoside. In certain embodiments, the 5'-wing of a
gapmer comprises at least one bicyclic nucleoside and at least one
2'-substituted nucleoside. In certain embodiments, the 5'-wing of a
gapmer comprises at least one bicyclic nucleoside and at least one
2'-MOE nucleoside. In certain embodiments, the 5'-wing of a gapmer
comprises at least one bicyclic nucleoside and at least one 2'-OMe
nucleoside. In certain embodiments, the 5'-wing of a gapmer
comprises at least one bicyclic nucleoside and at least one
2'-deoxynucleoside.
[0603] In certain embodiments, the 5'-wing of a gapmer comprises at
least one constrained ethyl nucleoside and at least one
non-bicyclic modified nucleoside. In certain embodiments, the
5'-wing of a gapmer comprises at least one constrained ethyl
nucleoside and at least one 2'-substituted nucleoside. In certain
embodiments, the 5'-wing of a gapmer comprises at least one
constrained ethyl nucleoside and at least one 2'-MOE nucleoside. In
certain embodiments, the 5'-wing of a gapmer comprises at least one
constrained ethyl nucleoside and at least one 2'-OMe nucleoside. In
certain embodiments, the 5'-wing of a gapmer comprises at least one
constrained ethyl nucleoside and at least one
2'-deoxynucleoside.
ii. Certain 3'-Wings
[0604] In certain embodiments, the 3'-wing of a gapmer consists of
1 to 8 linked nucleosides. In certain embodiments, the 3'-wing of a
gapmer consists of 1 to 7 linked nucleosides. In certain
embodiments, the 3'-wing of a gapmer consists of 1 to 6 linked
nucleosides. In certain embodiments, the 3'-wing of a gapmer
consists of 1 to 5 linked nucleosides. In certain embodiments, the
3'-wing of a gapmer consists of 2 to 5 linked nucleosides. In
certain embodiments, the 3'-wing of a gapmer consists of 3 to 5
linked nucleosides. In certain embodiments, the 3'-wing of a gapmer
consists of 4 or 5 linked nucleosides. In certain embodiments, the
3'-wing of a gapmer consists of 1 to 4 linked nucleosides. In
certain embodiments, the 3'-wing of a gapmer consists of 1 to 3
linked nucleosides. In certain embodiments, the 3'-wing of a gapmer
consists of 1 or 2 linked nucleosides. In certain embodiments, the
3'-wing of a gapmer consists of 2 to 4 linked nucleosides. In
certain embodiments, the 3'-wing of a gapmer consists of 2 or 3
linked nucleosides. In certain embodiments, the 3'-wing of a gapmer
consists of 3 or 4 linked nucleosides. In certain embodiments, the
3'-wing of a gapmer consists of 1 nucleoside. In certain
embodiments, the 3'-wing of a gapmer consists of 2 linked
nucleosides. In certain embodiments, the 3'-wing of a gapmer
consists of 31inked nucleosides. In certain embodiments, the
3'-wing of a gapmer consists of 4 linked nucleosides. In certain
embodiments, the 3'-wing of a gapmer consists of 5 linked
nucleosides. In certain embodiments, the 3'-wing of a gapmer
consists of 6 linked nucleosides.
[0605] In certain embodiments, the 3'-wing of a gapmer comprises at
least one bicyclic nucleoside. In certain embodiments, the 3'-wing
of a gapmer comprises at least one constrained ethyl nucleoside. In
certain embodiments, the 3'-wing of a gapmer comprises at least one
LNA nucleoside. In certain embodiments, each nucleoside of the
3'-wing of a gapmer is a bicyclic nucleoside. In certain
embodiments, each nucleoside of the 3'-wing of a gapmer is a
constrained ethyl nucleoside. In certain embodiments, each
nucleoside of the 3'-wing of a gapmer is a LNA nucleoside.
[0606] In certain embodiments, the 3'-wing of a gapmer comprises at
least one non-bicyclic modified nucleoside. In certain embodiments,
the 3'-wing of a gapmer comprises at least two non-bicyclic
modified nucleosides. In certain embodiments, the 3'-wing of a
gapmer comprises at least three non-bicyclic modified nucleosides.
In certain embodiments, the 3'-wing of a gapmer comprises at least
four non-bicyclic modified nucleosides. In certain embodiments, the
3'-wing of a gapmer comprises at least one 2'-substituted
nucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one 2'-MOE nucleoside. In certain embodiments,
the 3'-wing of a gapmer comprises at least one 2'-OMe nucleoside.
In certain embodiments, each nucleoside of the 3'-wing of a gapmer
is a non-bicyclic modified nucleoside. In certain embodiments, each
nucleoside of the 3'-wing of a gapmer is a 2'-substituted
nucleoside. In certain embodiments, each nucleoside of the 3'-wing
of a gapmer is a 2'-MOE nucleoside. In certain embodiments, each
nucleoside of the 3'-wing of a gapmer is a 2'-OMe nucleoside.
[0607] In certain embodiments, the 3'-wing of a gapmer comprises at
least one 2'-deoxynucleoside. In certain embodiments, each
nucleoside of the 3'-wing of a gapmer is a 2'-deoxynucleoside. In a
certain embodiments, the 3'-wing of a gapmer comprises at least one
ribonucleoside. In certain embodiments, each nucleoside of the
3'-wing of a gapmer is a ribonucleoside. In certain embodiments,
one, more than one, or each of the nucleosides of the 5'-wing is an
RNA-like nucleoside.
[0608] In certain embodiments, the 3'-wing of a gapmer comprises at
least one bicyclic nucleoside and at least one non-bicyclic
modified nucleoside. In certain embodiments, the 3'-wing of a
gapmer comprises at least one bicyclic nucleoside and at least one
2'-substituted nucleoside. In certain embodiments, the 3'-wing of a
gapmer comprises at least one bicyclic nucleoside and at least one
2'-MOE nucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one bicyclic nucleoside and at least one 2'-OMe
nucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one bicyclic nucleoside and at least one
2'-deoxynucleoside.
[0609] In certain embodiments, the 3'-wing of a gapmer comprises at
least one constrained ethyl nucleoside and at least one
non-bicyclic modified nucleoside. In certain embodiments, the
3'-wing of a gapmer comprises at least one constrained ethyl
nucleoside and at least one 2'-substituted nucleoside. In certain
embodiments, the 3'-wing of a gapmer comprises at least one
constrained ethyl nucleoside and at least one 2'-MOE nucleoside. In
certain embodiments, the 3'-wing of a gapmer comprises at least one
constrained ethyl nucleoside and at least one 2'-OMe nucleoside. In
certain embodiments, the 3'-wing of a gapmer comprises at least one
constrained ethyl nucleoside and at least one
2'-deoxynucleoside.
[0610] In certain embodiments, the 3'-wing of a gapmer comprises at
least one LNA nucleoside and at least one non-bicyclic modified
nucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one LNA nucleoside and at least one
2'-substituted nucleoside. In certain embodiments, the 3'-wing of a
gapmer comprises at least one LNA nucleoside and at least one
2'-MOE nucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one LNA nucleoside and at least one 2'-OMe
nucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one LNA nucleoside and at least one
2'-deoxynucleoside.
[0611] In certain embodiments, the 3'-wing of a gapmer comprises at
least one bicyclic nucleoside, at least one non-bicyclic modified
nucleoside, and at least one 2'-deoxynucleoside. In certain
embodiments, the 3'-wing of a gapmer comprises at least one
constrained ethyl nucleoside, at least one non-bicyclic modified
nucleoside, and at least one 2'-deoxynucleoside. In certain
embodiments, the 3'-wing of a gapmer comprises at least one LNA
nucleoside, at least one non-bicyclic modified nucleoside, and at
least one 2'-deoxynucleoside.
[0612] In certain embodiments, the 3'-wing of a gapmer comprises at
least one bicyclic nucleoside, at least one 2'-substituted
nucleoside, and at least one 2'-deoxynucleoside. In certain
embodiments, the 3'-wing of a gapmer comprises at least one
constrained ethyl nucleoside, at least one 2'-substituted
nucleoside, and at least one 2'-deoxynucleoside. In certain
embodiments, the 3'-wing of a gapmer comprises at least one LNA
nucleoside, at least one 2'-substituted nucleoside, and at least
one 2'-deoxynucleoside.
[0613] In certain embodiments, the 3'-wing of a gapmer comprises at
least one bicyclic nucleoside, at least one 2'-MOE nucleoside, and
at least one 2'-deoxynucleoside. In certain embodiments, the
3'-wing of a gapmer comprises at least one constrained ethyl
nucleoside, at least one 2'-MOE nucleoside, and at least one
2'-deoxynucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one LNA nucleoside, at least one 2'-MOE
nucleoside, and at least one 2'-deoxynucleoside.
[0614] In certain embodiments, the 3'-wing of a gapmer comprises at
least one bicyclic nucleoside, at least one 2'-OMe nucleoside, and
at least one 2'-deoxynucleoside. In certain embodiments, the
3'-wing of a gapmer comprises at least one constrained ethyl
nucleoside, at least one 2'-OMe nucleoside, and at least one
2'-deoxynucleoside. In certain embodiments, the 3'-wing of a gapmer
comprises at least one LNA nucleoside, at least one 2'-OMe
nucleoside, and at least one 2'-deoxynucleoside.
iii. Certain Central Regions (Gaps)
[0615] In certain embodiments, the gap of a gapmer consists of 6 to
20 linked nucleosides. In certain embodiments, the gap of a gapmer
consists of 6 to 15 linked nucleosides. In certain embodiments, the
gap of a gapmer consists of 6 to 12 linked nucleosides. In certain
embodiments, the gap of a gapmer consists of 6 to 10 linked
nucleosides. In certain embodiments, the gap of a gapmer consists
of 6 to 9 linked nucleosides. In certain embodiments, the gap of a
gapmer consists of 6 to 8 linked nucleosides. In certain
embodiments, the gap of a gapmer consists of 6 or 7 linked
nucleosides. In certain embodiments, the gap of a gapmer consists
of 7 to 10 linked nucleosides. In certain embodiments, the gap of a
gapmer consists of 7 to 9 linked nucleosides. In certain
embodiments, the gap of a gapmer consists of 7 or 8 linked
nucleosides. In certain embodiments, the gap of a gapmer consists
of 8 to 10 linked nucleosides. In certain embodiments, the gap of a
gapmer consists of 8 or 9 linked nucleosides. In certain
embodiments, the gap of a gapmer consists of 6 linked nucleosides.
In certain embodiments, the gap of a gapmer consists of 7 linked
nucleosides. In certain embodiments, the gap of a gapmer consists
of 8 linked nucleosides. In certain embodiments, the gap of a
gapmer consists of 9 linked nucleosides. In certain embodiments,
the gap of a gapmer consists of 10 linked nucleosides. In certain
embodiments, the gap of a gapmer consists of 11 linked nucleosides.
In certain embodiments, the gap of a gapmer consists of 12 linked
nucleosides.
[0616] In certain embodiments, each nucleoside of the gap of a
gapmer is a 2'-deoxynucleoside. In certain embodiments, the gap
comprises one or more modified nucleosides. In certain embodiments,
each nucleoside of the gap of a gapmer is a 2'-deoxynucleoside or
is a modified nucleoside that is "DNA-like." In such embodiments,
"DNA-like" means that the nucleoside has similar characteristics to
DNA, such that a duplex comprising the gapmer and an RNA molecule
is capable of activating RNase H. For example, under certain
conditions, 2'-(ara)-F have been shown to support RNase H
activation, and thus is DNA-like. In certain embodiments, one or
more nucleosides of the gap of a gapmer is not a 2'-deoxynucleoside
and is not DNA-like. In certain such embodiments, the gapmer
nonetheless supports RNase H activation (e.g., by virtue of the
number or placement of the non-DNA nucleosides).
[0617] In certain embodiments, gaps comprise a stretch of
unmodified 2'-deoxynucleoside interrupted by one or more modified
nucleosides, thus resulting in three sub-regions (two stretches of
one or more 2'-deoxynucleosides and a stretch of one or more
interrupting modified nucleosides). In certain embodiments, no
stretch of unmodified 2'-deoxynucleosides is longer than 5, 6, or 7
nucleosides. In certain embodiments, such short stretches is
achieved by using short gap regions. In certain embodiments, short
stretches are achieved by interrupting a longer gap region.
[0618] In certain embodiments, the gap comprises one or more
modified nucleosides. In certain embodiments, the gap comprises one
or more modified nucleosides selected from among cEt, FHNA, LNA,
and 2-thio-thymidine. In certain embodiments, the gap comprises one
modified nucleoside. In certain embodiments, the gap comprises a
5'-substituted sugar moiety selected from among 5'-Me, and
5'-(R)-Me. In certain embodiments, the gap comprises two modified
nucleosides. In certain embodiments, the gap comprises three
modified nucleosides. In certain embodiments, the gap comprises
four modified nucleosides. In certain embodiments, the gap
comprises two or more modified nucleosides and each modified
nucleoside is the same. In certain embodiments, the gap comprises
two or more modified nucleosides and each modified nucleoside is
different.
[0619] In certain embodiments, the gap comprises one or more
modified linkages. In certain embodiments, the gap comprises one or
more methyl phosphonate linkages. In certain embodiments the gap
comprises two or more modified linkages. In certain embodiments,
the gap comprises one or more modified linkages and one or more
modified nucleosides. In certain embodiments, the gap comprises one
modified linkage and one modified nucleoside. In certain
embodiments, the gap comprises two modified linkages and two or
more modified nucleosides.
b. Certain Internucleoside Linkage Motifs
[0620] In certain embodiments, oligonucleotides comprise modified
internucleoside linkages arranged along the oligonucleotide or
region thereof in a defined pattern or modified internucleoside
linkage motif. In certain embodiments, oligonucleotides comprise a
region having an alternating internucleoside linkage motif In
certain embodiments, oligonucleotides of the present disclosure
comprise a region of uniformly modified internucleoside linkages.
In certain such embodiments, the oligonucleotide comprises a region
that is uniformly linked by phosphorothioate internucleoside
linkages. In certain embodiments, the oligonucleotide is uniformly
linked by phosphorothioate internucleoside linkages. In certain
embodiments, each internucleoside linkage of the oligonucleotide is
selected from phosphodiester and phosphorothioate. In certain
embodiments, each internucleoside linkage of the oligonucleotide is
selected from phosphodiester and phosphorothioate and at least one
internucleoside linkage is phosphorothioate.
[0621] In certain embodiments, the oligonucleotide comprises at
least 6 phosphorothioate internucleoside linkages. In certain
embodiments, the oligonucleotide comprises at least 7
phosphorothioate internucleoside linkages. In certain embodiments,
the oligonucleotide comprises at least 8 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least 9 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least 10 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least 11 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least 12 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least 13 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least 14 phosphorothioate
internucleoside linkages.
[0622] In certain embodiments, the oligonucleotide comprises at
least one block of at least 6 consecutive phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least one block of at least 7
consecutive phosphorothioate internucleoside linkages. In certain
embodiments, the oligonucleotide comprises at least one block of at
least 8 consecutive phosphorothioate internucleoside linkages. In
certain embodiments, the oligonucleotide comprises at least one
block of at least 9 consecutive phosphorothioate internucleoside
linkages. In certain embodiments, the oligonucleotide comprises at
least one block of at least 10 consecutive phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least block of at least one 12
consecutive phosphorothioate internucleoside linkages. In certain
such embodiments, at least one such block is located at the 3' end
of the oligonucleotide. In certain such embodiments, at least one
such block is located within 3 nucleosides of the 3' end of the
oligonucleotide.In certain embodiments, the oligonucleotide
comprises less than 15 phosphorothioate internucleoside linkages.
In certain embodiments, the oligonucleotide comprises less than 14
phosphorothioate internucleoside linkages. In certain embodiments,
the oligonucleotide comprises less than 13 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 12 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 11 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 10 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 9 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 8 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 7 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 6 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises less than 5 phosphorothioate
internucleoside linkages.
c. Certain Nucleobase Modification Motifs
[0623] In certain embodiments, oligonucleotides comprise chemical
modifications to nucleobases arranged along the oligonucleotide or
region thereof in a defined pattern or nucleobases modification
motif. In certain such embodiments, nucleobase modifications are
arranged in a gapped motif. In certain embodiments, nucleobase
modifications are arranged in an alternating motif. In certain
embodiments, each nucleobase is modified. In certain embodiments,
none of the nucleobases is chemically modified.
[0624] In certain embodiments, oligonucleotides comprise a block of
modified nucleobases. In certain such embodiments, the block is at
the 3'-end of the oligonucleotide. In certain embodiments the block
is within 3 nucleotides of the 3'-end of the oligonucleotide. In
certain such embodiments, the block is at the 5'-end of the
oligonucleotide. In certain embodiments the block is within 3
nucleotides of the 5'-end of the oligonucleotide.
[0625] In certain embodiments, nucleobase modifications are a
function of the natural base at a particular position of an
oligonucleotide. For example, in certain embodiments each purine or
each pyrimidine in an oligonucleotide is modified. In certain
embodiments, each adenine is modified. In certain embodiments, each
guanine is modified. In certain embodiments, each thymine is
modified. In certain embodiments, each cytosine is modified. In
certain embodiments, each uracil is modified.
[0626] In certain embodiments, some, all, or none of the cytosine
moieties in an oligonucleotide are 5-methyl cytosine moieties.
Herein, 5-methyl cytosine is not a "modified nucleobase."
Accordingly, unless otherwise indicated, unmodified nucleobases
include both cytosine residues having a 5-methyl and those lacking
a 5 methyl. In certain embodiments, the methylation state of all or
some cytosine nucleobases is specified.
[0627] In certain embodiments, chemical modifications to
nucleobases comprise attachment of certain conjugate groups to
nucleobases. In certain embodiments, each purine or each pyrimidine
in an oligonucleotide may be optionally modified to comprise a
conjugate group.
d. Certain Overall Lengths
[0628] In certain embodiments, the present disclosure provides
oligonucleotides of any of a variety of ranges of lengths. In
certain embodiments, oligonucleotides consist of X to Y linked
nucleosides, where X represents the fewest number of nucleosides in
the range and Y represents the largest number of nucleosides in the
range. In certain such embodiments, X and Y are each independently
selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that
X.ltoreq.Y. For example, in certain embodiments, the
oligonucleotide may consist of 8 to 9, 8 to 10, 8 to 11, 8 to 12, 8
to 13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to
20, 8 to 21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27,
8 to 28, 8 to 29, 8 to 30, 9 to 10, 9 to 11, 9 to 12, 9 to 13, 9 to
14, 9 to 15, 9 to 16, 9 to 17, 9 to 18, 9 to 19, 9 to 20, 9 to 21,
9 to 22, 9 to 23, 9 to 24, 9 to 25, 9 to 26, 9 to 27, 9 to 28, 9 to
29, 9 to 30, 10 to 11, 10 to 12, 10 to 13, 10 to 14, 10 to 15, 10
to 16, 10 to 17, 10 to 18, 10 to 19, 10 to 20, 10 to 21, 10 to 22,
10 to 23, 10 to 24, 10 to 25, 10 to 26, 10 to 27, 10 to 28, 10 to
29, 10 to 30, 11 to 12, 11 to 13, 11 to 14, 11 to 15, 11 to 16, 11
to 17, 11 to 18, 11 to 19, 11 to 20, 11 to 21, 11 to 22, 11 to 23,
11 to 24, 11 to 25, 11 to 26, 11 to 27, 11 to 28, 11 to 29, 11 to
30, 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12
to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25,
12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to
15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13
to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28,
13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to
19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14
to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17,
15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to
24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16
to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23,
16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to
30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17
to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30,
18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to
25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19
to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 29,
19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to
24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21
to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28,
21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to
27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23
to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27,
24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to
29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27
to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked
nucleosides. In embodiments where the number of nucleosides of an
oligonucleotide of a compound is limited, whether to a range or to
a specific number, the compound may, nonetheless further comprise
additional other substituents. For example, an oligonucleotide
comprising 8-30 nucleosides excludes oligonucleotides having 31
nucleosides, but, unless otherwise indicated, such an
oligonucleotide may further comprise, for example one or more
conjugate groups, terminal groups, or other substituents.
[0629] Further, where an oligonucleotide is described by an overall
length range and by regions having specified lengths, and where the
sum of specified lengths of the regions is less than the upper
limit of the overall length range, the oligonucleotide may have
additional nucleosides, beyond those of the specified regions,
provided that the total number of nucleosides does not exceed the
upper limit of the overall length range.
5. Certain Antisense Compound Chemistry Motifs
[0630] In certain embodiments, the chemical structural features of
antisense compounds are characterized by their sugar motif,
internucleoside linkage motif, nucleobase modification motif and
overall length. In certain embodiments, such parameters are each
independent of one another. Thus, each internucleoside linkage of
an oligonucleotide having a gapmer sugar motif may be modified or
unmodified and may or may not follow the gapmer modification
pattern of the sugar modifications. Thus, the internucleoside
linkages within the wing regions of a sugar-gapmer may be the same
or different from one another and may be the same or different from
the internucleoside linkages of the gap region. Likewise, such
sugar-gapmer oligonucleotides may comprise one or more modified
nucleobase independent of the gapmer pattern of the sugar
modifications. One of skill in the art will appreciate that such
motifs may be combined to create a variety of oligonucleotides.
[0631] In certain embodiments, the selection of internucleoside
linkage and nucleoside modification are not independent of one
another.
[0632] i. Certain Sequences and Targets
[0633] In certain embodiments, the invention provides antisense
compounds having a sequence complementary to a target nucleic acid.
Such antisense compounds are capable of hybridizing to a target
nucleic acid, resulting in at least one antisense activity. In
certain embodiments, antisense compounds specifically hybridize to
one or more target nucleic acid. In certain embodiments, a
specifically hybridizing antisense compound has a nucleobase
sequence comprising a region having sufficient complementarity to a
target nucleic acid to allow hybridization and result in antisense
activity and insufficient complementarity to any non-target so as
to avoid or reduce non-specific hybridization to non-target nucleic
acid sequences under conditions in which specific hybridization is
desired (e.g., under physiological conditions for in vivo or
therapeutic uses, and under conditions in which assays are
performed in the case of in vitro assays). In certain embodiments,
oligonucleotides are selective between a target and non-target,
even though both target and non-target comprise the target
sequence. In such embodiments, selectivity may result from relative
accessability of the target region of one nucleic acid molecule
compared to the other.
[0634] In certain embodiments, the present disclosure provides
antisense compounds comprising oligonucleotides that are fully
complementary to the target nucleic acid over the entire length of
the oligonucleotide. In certain embodiments, oligonucleotides are
99% complementary to the target nucleic acid. In certain
embodiments, oligonucleotides are 95% complementary to the target
nucleic acid. In certain embodiments, such oligonucleotides are 90%
complementary to the target nucleic acid.
[0635] In certain embodiments, such oligonucleotides are 85%
complementary to the target nucleic acid. In certain embodiments,
such oligonucleotides are 80% complementary to the target nucleic
acid. In certain embodiments, an antisense compound comprises a
region that is fully complementary to a target nucleic acid and is
at least 80% complementary to the target nucleic acid over the
entire length of the oligonucleotide. In certain such embodiments,
the region of full complementarity is from 6 to 14 nucleobases in
length.
[0636] In certain embodiments, oligonucleotides comprise a
hybridizing region and a terminal region. In certain such
embodiments, the hybridizing region consists of 12-30 linked
nucleosides and is fully complementary to the target nucleic acid.
In certain embodiments, the hybridizing region includes one
mismatch relative to the target nucleic acid. In certain
embodiments, the hybridizing region includes two mismatches
relative to the target nucleic acid. In certain embodiments, the
hybridizing region includes three mismatches relative to the target
nucleic acid. In certain embodiments, the terminal region consists
of 1-4 terminal nucleosides. In certain embodiments, the terminal
nucleosides are at the 3' end. In certain embodiments, one or more
of the terminal nucleosides are not complementary to the target
nucleic acid.
[0637] Antisense mechanisms include any mechanism involving the
hybridization of an oligonucleotide with target nucleic acid,
wherein the hybridization results in a biological effect. In
certain embodiments, such hybridization results in either target
nucleic acid degradation or occupancy with concomitant inhibition
or stimulation of the cellular machinery involving, for example,
translation, transcription, or splicing of the target nucleic
acid.
[0638] One type of antisense mechanism involving degradation of
target RNA is RNase H mediated antisense. RNase H is a cellular
endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It
is known in the art that single-stranded antisense compounds which
are "DNA-like" elicit RNase H activity in mammalian cells.
Activation of RNase H, therefore, results in cleavage of the RNA
target, thereby greatly enhancing the efficiency of DNA-like
oligonucleotide-mediated inhibition of gene expression.
D. Antisense
[0639] In certain embodiments, oligomeric compounds of the present
invention are antisense compounds. In such embodiments, the
oligomeric compound is complementary to a target nucleic acid. In
certain embodiments, a target nucleic acid is an RNA. In certain
embodiments, a target nucleic acid is a non-coding RNA. In certain
embodiments, a target nucleic acid encodes a protein. In certain
embodiments, a target nucleic acid is selected from a mRNA, a
pre-mRNA, a microRNA, a non-coding RNA, including small non-coding
RNA, and a promoter-directed RNA. In certain embodiments,
oligomeric compounds are at least partially complementary to more
than one target nucleic acid. For example, oligomeric compounds of
the present invention may be microRNA mimics, which typically bind
to multiple targets.
[0640] In certain embodiments, antisense compounds comprise a
portion having a nucleobase sequence at least 70% complementary to
the nucleobase sequence of a target nucleic acid. In certain
embodiments, antisense compounds comprise a portion having a
nucleobase sequence at least 80% complementary to the nucleobase
sequence of a target nucleic acid. In certain embodiments,
antisense compounds comprise a portion having a nucleobase sequence
at least 90% complementary to the nucleobase sequence of a target
nucleic acid. In certain embodiments, antisense compounds comprise
a portion having a nucleobase sequence at least 95% complementary
to the nucleobase sequence of a target nucleic acid. In certain
embodiments, antisense compounds comprise a portion having a
nucleobase sequence at least 98% complementary to the nucleobase
sequence of a target nucleic acid. In certain embodiments,
antisense compounds comprise a portion having a nucleobase sequence
that is 100% complementary to the nucleobase sequence of a target
nucleic acid. In certain embodiments, antisense compounds are at
least 70%, 80%, 90%, 95%, 98%, or 100% complementary to the
nucleobase sequence of a target nucleic acid over the entire length
of the antisense compound.
[0641] Antisense mechanisms include any mechanism involving the
hybridization of an oligomeric compound with target nucleic acid,
wherein the hybridization results in a biological effect. In
certain embodiments, such hybridization results in either target
nucleic acid degradation or occupancy with concomitant inhibition
or stimulation of the cellular machinery involving, for example,
translation, transcription, or polyadenylation of the target
nucleic acid or of a nucleic acid with which the target nucleic
acid may otherwise interact.
[0642] One type of antisense mechanism involving degradation of
target RNA is RNase H mediated antisense. RNase H is a cellular
endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It
is known in the art that single-stranded antisense compounds which
are "DNA-like" elicit RNase H activity in mammalian cells.
Activation of RNase H, therefore, results in cleavage of the RNA
target, thereby greatly enhancing the efficiency of DNA-like
oligonucleotide-mediated inhibition of gene expression.
[0643] Antisense mechanisms also include, without limitation RNAi
mechanisms, which utilize the RISC pathway. Such RNAi mechanisms
include, without limitation siRNA, ssRNA and microRNA mechanisms.
Such mechanisms include creation of a microRNA mimic and/or an
anti-microRNA.
[0644] Antisense mechanisms also include, without limitation,
mechanisms that hybridize or mimic non-coding RNA other than
microRNA or mRNA. Such non-coding RNA includes, but is not limited
to promoter-directed RNA and short and long RNA that effects
transcription or translation of one or more nucleic acids.
[0645] In certain embodiments, antisense compounds of therapeutic
agents described herein are RNAi compounds. In certain embodiments,
antisense compounds of therapeutic agents described herein are
ssRNA compounds. In certain embodiments, antisense compounds of
therapeutic agents comprise two oligonucleotides which together
form an siRNA. In certain embodiments, a targeting group and/or
therapeutic nucleoside is attached to the antisense strand in an
siRNA compound. In certain embodiments, a targeting group and/or
therapeutic nucleoside is attached to the sense strand in an siRNA
compound. In certain embodiments, a targeting group and/or
therapeutic nucleoside is attached to both the sense strand and the
antisense strand of an siRNA.
D. Target Nucleic Acids, Regions and Segments
[0646] In certain embodiments, antisense compounds of therapeutic
agents target any nucleic acid. In certain embodiments, the target
nucleic acid encodes a target protein that is clinically relevant.
In such embodiments, modulation of the target nucleic acid results
in clinical benefit.
1. Hepatitis B (HBV)
[0647] Hepatitis B is a viral disease transmitted parenterally by
contaminated material such as blood and blood products,
contaminated needles, sexually and vertically from infected or
carrier mothers to their offspring. It is estimated by the World
Health Organization that more than 2 billion people have been
infected worldwide, with about 4 million acute cases per year, 1
million deaths per year, and 350-400 million chronic carriers
(World Health Organization: Geographic Prevalence of Hepatitis B
Prevalence, 2004.
http://www.who.int/vaccines-surveillance/graphics/htmls/hepbprev.htm).
[0648] The virus, HBV, is a double-stranded hepatotropic virus
which infects only humans and non-human primates. Viral replication
takes place predominantly in the liver and, to a lesser extent, in
the kidneys, pancreas, bone marrow and spleen (Hepatitis B virus
biology. Microbiol Mol Biol Rev. 64: 2000; 51-68.). Viral and
immune markers are detectable in blood and characteristic
antigen-antibody patterns evolve over time. The first detectable
viral marker is HBsAg, followed by hepatitis B e antigen (HBeAg)
and HBV DNA. Titers may be high during the incubation period, but
HBV DNA and HBeAg levels begin to fall at the onset of illness and
may be undetectable at the time of peak clinical illness (Hepatitis
B virus infection--natural history and clinical consequences. N
Engl J Med. 350: 2004; 1118-1129). HBeAg is a viral marker
detectable in blood and correlates with active viral replication,
and therefore high viral load and infectivity (Hepatitis B e
antigen--the dangerous end game of hepatitis B. N Engl J Med. 347:
2002; 208-210). The presence of anti-HBsAb and anti-HBcAb (IgG)
indicates recovery and immunity in a previously infected
individual.
[0649] Currently the recommended therapies for chronic HBV
infection by the American Association for the Study of Liver
Diseases (AASLD) and the European Association for the Study of the
Liver (EASL) include interferon alpha (INF.alpha.), pegylated
interferon alpha-2a (Peg-IFN2a), entecavir, and tenofovir. The
nucleoside and nucleobase therapies, entecavir and tenofovir, are
successful at reducing viral load, but the rates of HBeAg
seroconversion and HBsAg loss are even lower than those obtained
using IFN.alpha. therapy. Other similar therapies, including
lamivudine (3TC), telbivudine (LdT), and adefovir are also used,
but for nucleoside/nucleobase therapies in general, the emergence
of resistance limits therapeutic efficacy.
[0650] Thus, there is a need in the art to discover and develop new
anti-viral therapies. Additionally, there is a need for new
anti-HBV therapies capable of increasing HBeAg and HBsAg
seroconversion rates. Recent clinical research has found a
correlation between seroconversion and reductions in HBeAg (Fried
et al (2008) Hepatology 47:428) and reductions in HBsAg (Moucari et
al (2009) Hepatology 49:1151). Reductions in antigen levels may
have allowed immunological control of HBV infection because high
levels of antigens are thought to induce immunological tolerance.
Current nucleoside therapies for HBV are capable of dramatic
reductions in serum levels of HBV but have little impact on HBeAg
and HBsAg levels.
[0651] Antisense compounds targeting HBV have been previously
disclosed in WO2011/047312, WO2012/145674, and WO2012/145697, each
herein incorporated by reference in its entirety. Clinical studies
are planned to assess the effect of antisense compounds targeting
HBV in patients. However, there is still a need to provide patients
with additional and more potent treatment options.
Certain Antisense Compounds Targeted to a HBV Nucleic Acid
[0652] In certain embodiments, antisense compounds of a therapeutic
agent are targeted to a HBV nucleic acid having the sequence of
GENBANK.RTM. Accession No. U95551.1, incorporated herein as SEQ ID
NO: 1. In certain such embodiments, an antisense compound targeted
to SEQ ID NO: 1 is at least 90%, at least 95%, or 100%
complementary to SEQ ID NO: 1.
[0653] In certain embodiments, an antisense compound targeted to
SEQ ID NO: 1 comprises an at least 8 consecutive nucleobase
sequence of SEQ ID NO: 2. In certain embodiments, an antisense
compound targeted to SEQ ID NO: 1 comprises a nucleobase sequence
of SEQ ID NO: 2. In the table below "e" represents 2'-MOE modified
nucleosides, "d" represents deoxynucleosides (e.g. DNA), and "k"
represents cEt modified nucleosides.
TABLE-US-00001 TABLE 12 Antisense Compounds targeted to HBV SEQ ID
NO: 1 Target SEQ Start ID ISIS No Site Sequence (5'-3') Motif NO
505358 1583 GCAGAGGTGAAGCGAAGTGC eeeeeddddddddddeeeee 2 509934 1780
CCAATTTATGCCTACAGCCT eeeddddddddddeeee 3 510100 411
GGCATAGCAGCAGGATG eeeeeeddddddddddeeee 4 552023 1266
AGGAGTTCCGCAGTATGGAT eeeeeeddddddddddeeee 5 552024 1577
GTGAAGCGAAGTGCACACGG eeeeeeddddddddddeeee 6 552032 1585
GTGCAGAGGTGAAGCGAAGT eeeeeeddddddddddeeee 7 552859 1583
AGGTGAAGCGAAGTGC ekkddddddddddkke 8 552925 1264 TCCGCAGTATGGATCG
ekddddddddddeke 9 577119 1780 AATTTATGCCTACAGCCT kdkdkddddddddeeeee
10
HBV Therapeutic Indications
[0654] In certain embodiments, the invention provides methods for
using a therapeutic agent comprising an antisense compound targeted
to a HBV nucleic acid for modulating the expression of HBV in a
subject. In certain embodiments, the expression of HBV is
reduced.
[0655] In certain embodiments, the invention provides methods for
using a therapeutic agent comprising an antisense compound targeted
to a HBV nucleic acid in a pharmaceutical composition for treating
a subject. In certain embodiments, the subject has a HBV-related
condition. In certain embodiments, the HBV-related condition
includes, but is not limited to, chronic HBV infection,
inflammation, fibrosis, cirrhosis, liver cancer, serum hepatitis,
jaundice, liver cancer, liver inflammation, liver fibrosis, liver
cirrhosis, liver failure, diffuse hepatocellular inflammatory
disease, hemophagocytic syndrome, serum hepatitis, and HBV viremia.
In certain embodiments, the HBV-related condition may have which
may include any or all of the following: flu-like illness,
weakness, aches, headache, fever, loss of appetite, diarrhea,
jaundice, nausea and vomiting, pain over the liver area of the
body, clay- or grey-colored stool, itching all over, and
dark-colored urine, when coupled with a positive test for presence
of a hepatitis B virus, a hepatitis B viral antigen, or a positive
test for the presence of an antibody specific for a hepatitis B
viral antigen. In certain embodiments, the subject is at risk for
an HBV-related condition. This includes subjects having one or more
risk factors for developing an HBV-related condition, including
sexual exposure to an individual infected with Hepatitis B virus,
living in the same house as an individual with a lifelong hepatitis
B virus infection, exposure to human blood infected with the
hepatitis B virus, injection of illicit drugs, being a person who
has hemophilia, and visiting an area where hepatitis B is common.
In certain embodiments, the subject has been identified as in need
of treatment for an HBV-related condition.
[0656] In certain embodiments, the invention provides methods for
using a therapeutic agent comprising an antisense compound targeted
to a HBV nucleic acid in the preparation of a medicament.
2. Hepatitis C (HCV)
[0657] In certain embodiments, an antisense compound is for the
treatment of HCV. In certain embodiments, an antisense compound is
targeted to an HCV viral target nucleic acid. In certain
embodiments, an antisense compound is targeted to miR122. In
certain embodiments, an antisense compound is wholly or partially
complementary to the following nucleobase sequence:
5'-uggagugugacaaugguguuug-3'(SEQ ID NO: 11). In certain
embodiments, an antisense compound has the following nucleobase
sequence:
3'-c.sub.Lc.sub.Ltc.sub.Lac.sub.Lact.sub.Lg.sub.Ltta.sub.Lcc.sub.L-5'
(SEQ ID NO: 12), wherein a subscript "L" represents an LNA modified
nucleobase. In certain embodiments, an antisense compound has the
following sequence: 5'ACAAACACCATTGTCACACTCCA-3' (SEQ ID NO:
13).
E. Certain Therapeutic Agents
[0658] In certain embodiments, therapeutic agents have the
following structure:
A.sub.x-B.sub.y-(C-(B).sub.t).sub.z-C.sub.p-D.sub.q-E.sub.r-(F-G).sub.s
[0659] wherein
[0660] A is an oligomeric compound;
[0661] each B is independently a cleavable moiety
[0662] each C is independently a therapeutic nucleoside
[0663] D is a target group linker
[0664] E is a branching group
[0665] each F is a tether;
[0666] each G is a ligand;
[0667] x is 0 or 1;
[0668] y is 0 or 1;
[0669] z is 1-20;
[0670] each t is independently 0 or 1;
[0671] p is 0 or 1;
[0672] q is 0 or 1;
[0673] r is 0 or 1; and
[0674] s is 0-5; and
[0675] provided that if z is 1, then at least one of x and s is
other than 0.
[0676] In the above diagram and in similar diagrams herein, the
branching group branches as many times as necessary to accommodate
the number of tether-ligand groups (indicated by "F-G" in this
diagram) as indicated by the subscript (indicated by "s" in this
diagram). Thus, where r=1 and s=1, the structure comprises:
E-F-G
where r=1 and s=2, the structure comprises:
##STR00093##
where r=1 and s=3, the structure comprises:
##STR00094##
etc.
[0677] In certain embodiments, A is an antisense compound. In
certain embodiments, one or more cleavable moieties is a cleavable
bond. In certain embodiments, one or more cleavable moieties is a
cleavable nucleoside. In certain such embodiments, the cleavable
nucleoside is flanked by one or two cleavable bonds. In certain
embodiments, each cleavable nucleoside is flanked by phosphodiester
bonds on each side.
[0678] In certain embodiments, a therapeutic agent comprises a
structure selected from among the following:
##STR00095##
[0679] In certain embodiments, a therapeutic agent has a structure
selected from among the following:
##STR00096##
[0680] In certain embodiments, a therapeutic agent has a structure
selected from among the following:
##STR00097##
Where Y is at least one therapeutic nucleoside.
F. Certain Uses and Features
[0681] In certain embodiments, therapeutic agents are prodrugs. In
certain embodiments, therapeutic agents are polyprodrugs.
[0682] In certain embodiments, therapeutic agents are a series of
linked therapeutic nucleosides. Such linked therapeutic nucleosides
may be linked with cleavable moieties, such as cleavable bonds,
such as phosphodiester bonds. Such linked therapeutic nucleosides
may be linked with cleavable moieties, such as cleavable
nucleosides, such as cleavable nucleosides linked with
phosphodiester bonds. Thus, the therapeutic agent may comprise or
consist of a portion having any of the following formula:
(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N)
(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(C-
N)
where TN represents a therapeutic nucleoside; CN represent a
cleavable nucleoside; and o represents a phosphodiester bond. Such
compounds could be made to various lengths (e.g., 2 to 50
nucleosides) by increasing or decreasing the number of therapeutic
nucleosides and/or the number of cleavable nucleosides. Without
being bound by any particular mechanism, such therapeutic
nucleosides are expected to cleave into active monomers after
administration to an animal. In certain embodiments, such cleavage
may occur at least in part after the therapeutic agent has entered
a cell. Such a construct may be made using any therapeutic
nucleoside, including, but not limited to, those described herein.
Such linked therapeutic nucleosides may, in certain embodiments,
enter cells more efficiently and result in more potent therapeutic
agents than individual therapeutic nucleosides.
[0683] In certain embodiments, therapeutic agents comprise at least
one targeting group. Such groups, when attached to oligomeric
compounds have demonstrated increased uptake into cells or types of
cells. Such targeting groups may be attached to a single
therapeutic nucleoside or to a linked thereapeutic nucleosides. As
discussed above, such therapeutic nucleosides may be linked
together with cleavable moieties, such as a cleavable bonds and/or
cleavable nucleosides. Likewise, a targeting group may be attached
to one or more therapeutic nucleoside by a cleavable moiety, such
as a cleavable bond or cleavable nucleoside. Certain such
therapeutic agents comprise or consist of a portion having the
following formula:
(TG).sub.o(TN)
(TG).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(TN)
(TG).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(T-
N).sub.o(CN)
(TG).sub.o(CN).sub.o(TN)
(TG).sub.o(CN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(TN).sub.o(TN)
(TG).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(C-
N).sub.o(TN).sub.o(CN)
where TG represents a targeting group; TN represents a therapeutic
nucleoside; CN represent a cleavable nucleoside; and o represents a
phosphodiester bond. Such compounds could be made to various
lengths (e.g., 2 to 50 nucleosides) by increasing or decreasing the
number of therapeutic nucleosides and/or the number of cleavable
nucleosides. Further, in certain embodiments targeting groups are
attached to more than one nucleoside. Targeting groups may be
attached and at any position of any cleavable nucleoside and/or
therapeutic nucleoside. Such therapeutic nucleosides linked to a
targeting group may, in certain embodiments, enter cells more
efficiently and result in more potent therapeutic agents than
individual or linked therapeutic nucleosides lacking such targeting
group.
[0684] In certain embodiments, therapeutic agents comprise at least
one oligomeric compound, such an antisense compound. In certain
embodiments, antisense compounds modulate the amount or activity of
a target nucleic acid. In certain embodiments, antisense compounds
result in cleavage, alternate splicing or translational arrest of a
target nucleic acid. In certain embodiments, therapeutic agents
comprising at least one oligomeric compound comprise or consist of
a portion having the following formula:
(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(OC)
(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(C-
N).sub.o(OC)
(TG).sub.o(TN).sub.o(OC)
(TG).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(TN).sub.o(OC)
(TG).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(T-
N).sub.o(CN).sub.o(OC)
(TG).sub.o(CN).sub.o(TN).sub.o(OC)
(TG).sub.o(CN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(TN).sub.o(TN).sub.o(OC)
(TG).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(C-
N).sub.o(TN).sub.o(CN).sub.o(OC)
(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(CN).sub.o(OC)
(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(C-
N).sub.o(CN).sub.o(OC)
(TG).sub.o(TN) .sub.o(CN).sub.o(OC)
(TG).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(TN).sub.o(CN).sub.o(OC)
(TG).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(T-
N).sub.o(CN).sub.o(CN).sub.o(OC)
(TG).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(OC)
(TG).sub.o(CN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(TN).sub.o(T-
N).sub.o(TN).sub.o(TN).sub.o(CN).sub.o(OC)
(TG).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(CN).sub.o(TN).sub.o(C-
N).sub.o(TN).sub.o(CN).sub.o(CN).sub.o(OC)
where OC represents an oligomeric compound; TG represents a
targeting group; TN represents a therapeutic nucleoside; CN
represent a cleavable nucleoside; and o represents a phosphodiester
bond. Such compounds could be made to various lengths (e.g., 2 to
50 nucleosides) by increasing or decreasing the number of
therapeutic nucleosides and/or the number of cleavable nucleosides.
Further, in certain embodiments targeting groups are attached to
more than one nucleoside. Targeting groups may be attached at any
position of any cleavable nucleoside and/or therapeutic nucleoside.
The oligomeric compound typically comprises 10-30 linked
nucleosides. The oligomeric compound may be attached at its 5'-end,
its 3' end or an internal nucleoside. In certain embodiments, the
oligomeric compound is an antisense compound. In certain such
embodiments, the antisense compound is complementary to a target
nucleic acid, the modulation of which treats a disease or
condition. In certain such embodiments, the disease or condition is
also treated by the therapeutic nucleoside.
[0685] Productive and non-productive uptake of oligonucleotides has
been discussed previously (See e.g. Geary, R. S., E. Wancewicz, et
al. (2009). "Effect of Dose and Plasma Concentration on Liver
Uptake and Pharmacologic Activity of a 2'-Methoxyethyl Modified
Chimeric Antisense Oligonucleotide Targeting PTEN." Biochem.
Pharmacol. 78(3): 284-91; & Koller, E., T. M. Vincent, et al.
(2011). "Mechanisms of single-stranded phosphorothioate modified
antisense oligonucleotide accumulation in hepatocytes." Nucleic
Acids Res. 39(11): 4795-807). Targeting groups described herein may
improve productive uptake of oligonucleotides, including, but not
limited to linked therapeutic nucleosides, antisense
oligonucleotides, and therapeutic agents comprising both one or
more therapeutic nucleosides and one or more antisense
oligonucleotides.
[0686] In certain embodiments, the targeting groups described
herein may further improve potency by increasing the affinity of
therapeutic agents for a particular type of cell or tissue. In
certain embodiments, the targeting groups described herein may
further improve potency by increasing recognition of the targeting
group by one or more cell-surface receptors. In certain
embodiments, the targeting groups described herein may further
improve potency by facilitating endocytosis of a therapeutic
agent.
[0687] In certain embodiments, the cleavable moiety may further
improve potency by allowing the targeting group to be cleaved from
the remainder of the therapeutic agent after the therapeutic agent
has entered a cell. Accordingly, in certain embodiments,
therapeutic agents can be administered at doses lower than would be
necessary for therapeutic nucleosides and/or antisense
oligonucleotides.
G. Certain Pharmaceutical Compositions
[0688] In certain embodiments, the present disclosure provides
pharmaceutical compositions comprising one or more antisense
compound. In certain embodiments, such pharmaceutical composition
comprises a suitable pharmaceutically acceptable diluent or
carrier. In certain embodiments, a pharmaceutical composition
comprises a sterile saline solution and one or more antisense
compound. In certain embodiments, such pharmaceutical composition
consists of a sterile saline solution and one or more antisense
compound. In certain embodiments, the sterile saline is
pharmaceutical grade saline. In certain embodiments, a
pharmaceutical composition comprises one or more antisense compound
and sterile water. In certain embodiments, a pharmaceutical
composition consists of one or more antisense compound and sterile
water. In certain embodiments, the sterile saline is pharmaceutical
grade water. In certain embodiments, a pharmaceutical composition
comprises one or more antisense compound and phosphate-buffered
saline (PBS). In certain embodiments, a pharmaceutical composition
consists of one or more antisense compound and sterile
phosphate-buffered saline (PBS). In certain embodiments, the
sterile saline is pharmaceutical grade PBS.
[0689] In certain embodiments, antisense compounds may be admixed
with pharmaceutically acceptable active and/or inert substances for
the preparation of pharmaceutical compositions or formulations.
Compositions and methods for the formulation of pharmaceutical
compositions depend on a number of criteria, including, but not
limited to, route of administration, extent of disease, or dose to
be administered.
[0690] Pharmaceutical compositions comprising antisense compounds
encompass any pharmaceutically acceptable salts, esters, or salts
of such esters. In certain embodiments, pharmaceutical compositions
comprising antisense compounds comprise one or more oligonucleotide
which, upon administration to an animal, including a human, is
capable of providing (directly or indirectly) the biologically
active metabolite or residue thereof. Accordingly, for example, the
disclosure is also drawn to pharmaceutically acceptable salts of
antisense compounds, prodrugs, pharmaceutically acceptable salts of
such prodrugs, and other bioequivalents. Suitable pharmaceutically
acceptable salts include, but are not limited to, sodium and
potassium salts.
[0691] A prodrug can include the incorporation of additional
nucleosides at one or both ends of an oligonucleotide which are
cleaved by endogenous nucleases within the body, to form the active
antisense oligonucleotide.
[0692] Lipid moieties have been used in nucleic acid therapies in a
variety of methods. In certain such methods, the nucleic acid is
introduced into preformed liposomes or lipoplexes made of mixtures
of cationic lipids and neutral lipids. In certain methods, DNA
complexes with mono- or poly-cationic lipids are formed without the
presence of a neutral lipid. In certain embodiments, a lipid moiety
is selected to increase distribution of a pharmaceutical agent to a
particular cell or tissue. In certain embodiments, a lipid moiety
is selected to increase distribution of a pharmaceutical agent to
fat tissue. In certain embodiments, a lipid moiety is selected to
increase distribution of a pharmaceutical agent to muscle
tissue.
[0693] In certain embodiments, pharmaceutical compositions provided
herein comprise one or more modified oligonucleotides and one or
more excipients. In certain such embodiments, excipients are
selected from water, salt solutions, alcohol, polyethylene glycols,
gelatin, lactose, amylase, magnesium stearate, talc, silicic acid,
viscous paraffin, hydroxymethylcellulose and
polyvinylpyrrolidone.
[0694] In certain embodiments, a pharmaceutical composition
provided herein comprises a delivery system. Examples of delivery
systems include, but are not limited to, liposomes and emulsions.
Certain delivery systems are useful for preparing certain
pharmaceutical compositions including those comprising hydrophobic
compounds. In certain embodiments, certain organic solvents such as
dimethylsulfoxide are used.
[0695] In certain embodiments, a pharmaceutical composition
provided herein comprises one or more tissue-specific delivery
molecules designed to deliver the one or more pharmaceutical agents
of the present disclosure to specific tissues or cell types. For
example, in certain embodiments, pharmaceutical compositions
include liposomes coated with a tissue-specific antibody.
[0696] In certain embodiments, a pharmaceutical composition
provided herein comprises a co-solvent system. Certain of such
co-solvent systems comprise, for example, benzyl alcohol, a
nonpolar surfactant, a water-miscible organic polymer, and an
aqueous phase. In certain embodiments, such co-solvent systems are
used for hydrophobic compounds. A non-limiting example of such a
co-solvent system is the VPD co-solvent system, which is a solution
of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant Polysorbate 80.TM. and 65% w/v polyethylene
glycol 300. The proportions of such co-solvent systems may be
varied considerably without significantly altering their solubility
and toxicity characteristics. Furthermore, the identity of
co-solvent components may be varied: for example, other surfactants
may be used instead of Polysorbate 80.TM.; the fraction size of
polyethylene glycol may be varied; other biocompatible polymers may
replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other
sugars or polysaccharides may substitute for dextrose.
[0697] In certain embodiments, a pharmaceutical composition
provided herein is prepared for oral administration. In certain
embodiments, pharmaceutical compositions are prepared for buccal
administration.
[0698] In certain embodiments, a pharmaceutical composition is
prepared for administration by injection (e.g., intravenous,
subcutaneous, intramuscular, etc.). In certain of such embodiments,
a pharmaceutical composition comprises a carrier and is formulated
in aqueous solution, such as water or physiologically compatible
buffers such as Hanks's solution, Ringer's solution, or
physiological saline buffer. In certain embodiments, other
ingredients are included (e.g., ingredients that aid in solubility
or serve as preservatives). In certain embodiments, injectable
suspensions are prepared using appropriate liquid carriers,
suspending agents and the like. Certain pharmaceutical compositions
for injection are presented in unit dosage form, e.g., in ampoules
or in multi-dose containers. Certain pharmaceutical compositions
for injection are suspensions, solutions or emulsions in oily or
aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing and/or dispersing agents. Certain solvents
suitable for use in pharmaceutical compositions for injection
include, but are not limited to, lipophilic solvents and fatty
oils, such as sesame oil, synthetic fatty acid esters, such as
ethyl oleate or triglycerides, and liposomes. Aqueous injection
suspensions may contain substances that increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran. Optionally, such suspensions may also contain suitable
stabilizers or agents that increase the solubility of the
pharmaceutical agents to allow for the preparation of highly
concentrated solutions.
[0699] In certain embodiments, a pharmaceutical composition is
prepared for transmucosal administration. In certain of such
embodiments penetrants appropriate to the barrier to be permeated
are used in the formulation. Such penetrants are generally known in
the art.
[0700] In certain embodiments, a pharmaceutical composition
provided herein comprises an oligonucleotide in a therapeutically
effective amount. In certain embodiments, the therapeutically
effective amount is sufficient to prevent, alleviate or ameliorate
symptoms of a disease or to prolong the survival of the subject
being treated. Determination of a therapeutically effective amount
is well within the capability of those skilled in the art.
[0701] In certain embodiments, one or more modified oligonucleotide
provided herein is formulated as a prodrug. In certain embodiments,
upon in vivo administration, a prodrug is chemically converted to
the biologically, pharmaceutically or therapeutically more active
form of an oligonucleotide. In certain embodiments, prodrugs are
useful because they are easier to administer than the corresponding
active form. For example, in certain instances, a prodrug may be
more bioavailable (e.g., through oral administration) than is the
corresponding active form. In certain instances, a prodrug may have
improved solubility compared to the corresponding active form. In
certain embodiments, prodrugs are less water soluble than the
corresponding active form. In certain instances, such prodrugs
possess superior transmittal across cell membranes, where water
solubility is detrimental to mobility. In certain embodiments, a
prodrug is an ester. In certain such embodiments, the ester is
metabolically hydrolyzed to carboxylic acid upon administration. In
certain instances the carboxylic acid containing compound is the
corresponding active form. In certain embodiments, a prodrug
comprises a short peptide (polyaminoacid) bound to an acid group.
In certain of such embodiments, the peptide is cleaved upon
administration to form the corresponding active form.
[0702] In certain embodiments, the present disclosure provides
compositions and methods for reducing the amount or activity of a
target nucleic acid in a cell. In certain embodiments, the cell is
in an animal. In certain embodiments, the animal is a mammal. In
certain embodiments, the animal is a rodent. In certain
embodiments, the animal is a primate. In certain embodiments, the
animal is a non-human primate. In certain embodiments, the animal
is a human.
[0703] In certain embodiments, the present disclosure provides
methods of administering a pharmaceutical composition comprising an
oligonucleotide of the present disclosure to an animal. Suitable
administration routes include, but are not limited to, oral,
rectal, transmucosal, intestinal, enteral, topical, suppository,
through inhalation, intrathecal, intracerebroventricular,
intraperitoneal, intranasal, intraocular, intratumoral, and
parenteral (e.g., intravenous, intramuscular, intramedullary, and
subcutaneous). In certain embodiments, pharmaceutical intrathecals
are administered to achieve local rather than systemic exposures.
For example, pharmaceutical compositions may be injected directly
in the area of desired effect (e.g., into the liver).
Nonlimiting Disclosure and Incorporation by Reference While certain
compounds, compositions and methods described herein have been
described with specificity in accordance with certain embodiments,
the following examples serve only to illustrate the compounds
described herein and are not intended to limit the same. Each of
the references, GenBank accession numbers, and the like recited in
the present application is incorporated herein by reference in its
entirety.
[0704] Certain compounds, compositions, and methods herein are
described as "comprising exactly" or "comprises exactly" a
particular number of a particular element or feature. Such
descriptions are used to indicate that while the compound,
composition, or method may comprise additional other elements, the
number of the particular element or feature is the identified
number. For example, "a compound comprising exactly one
cell-targeting ligand" is a compound that contains one and only one
cell-targeting ligand, though it may contain other elements in
addition to the one cell-targeting ligand.
[0705] Although the sequence listing accompanying this filing
identifies each sequence as either "RNA" or "DNA" as required, in
reality, those sequences may be modified with any combination of
chemical modifications. One of skill in the art will readily
appreciate that such designation as "RNA" or "DNA" to describe
modified oligonucleotides is, in certain instances, arbitrary. For
example, an oligonucleotide comprising a nucleoside comprising a
2'-OH sugar moiety and a thymine base could be described as a DNA
having a modified sugar (2'-OH for the natural 2'-H of DNA) or as
an RNA having a modified base (thymine (methylated uracil) for
natural uracil of RNA).
[0706] Accordingly, nucleic acid sequences provided herein,
including, but not limited to those in the sequence listing, are
intended to encompass nucleic acids containing any combination of
natural or modified RNA and/or DNA, including, but not limited to
such nucleic acids having modified nucleobases. By way of further
example and without limitation, an oligonucleotide having the
nucleobase sequence "ATCGATCG" encompasses any oligonucleotides
having such nucleobase sequence, whether modified or unmodified,
including, but not limited to, such compounds comprising RNA bases,
such as those having sequence "AUCGAUCG" and those having some DNA
bases and some RNA bases such as "AUCGATCG" and oligonucleotides
having other modified bases, such as "AT.sup.meCGAUCG," wherein
.sup.meC indicates a cytosine base comprising a methyl group at the
5-position.
EXAMPLES
[0707] The following examples illustrate certain embodiments of the
present disclosure and are not limiting. Moreover, where specific
embodiments are provided, the inventors have contemplated generic
application of those specific embodiments. For example, disclosure
of an oligonucleotide having a particular motif provides reasonable
support for additional oligonucleotides having the same or similar
motif. And, for example, where a particular high-affinity
modification appears at a particular position, other high-affinity
modifications at the same position are considered suitable, unless
otherwise indicated.
Example 1
General Method for the Preparation of Phosphoramidites, Compounds
1, 1a and 2
##STR00098##
[0709] Bx is a heterocyclic base;
[0710] Compounds 1, 1a and 2 were prepared as per the procedures
well known in the art as described in the specification herein (see
Seth et al., Bioorg. Med. Chem., 2011, 21(4), 1122-1125, J. Org.
Chem., 2010, 75(5), 1569-1581, Nucleic Acids Symposium Series,
2008, 52(1), 553-554); and also see published PCT International
Applications (WO 2011/115818, WO 2010/077578, WO2010/036698,
WO2009/143369, WO 2009/006478, and WO 2007/090071), and U.S. Pat.
No. 7,569,686).
Example 2
Preparation of Compound 7
##STR00099##
[0712] Compounds 3
(2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-(.beta.-Dgalactopyranose
or galactosamine pentaacetate) is commercially available. Compound
5 was prepared according to published procedures (Weber et al., J.
Med. Chem., 1991, 34, 2692).
Example 3
Preparation of Compound 11
##STR00100##
[0714] Compounds 8 and 9 are commercially available.
Example 4
Preparation of Compound 18
##STR00101##
[0716] Compound 11 was prepared as per the procedures illustrated
in Example 3. Compound 14 is commercially available. Compound 17
was prepared using similar procedures reported by Rensen et al., J.
Med. Chem., 2004, 47, 5798-5808.
Example 5
Preparation of Compound 23
##STR00102##
[0718] Compounds 19 and 21 are commercially available.
Example 6
Preparation of Compound 24
##STR00103##
[0720] Compounds 18 and 23 were prepared as per the procedures
illustrated in Examples 4 and 5.
Example 7
Preparation of Compound 25
##STR00104##
[0722] Compound 24 was prepared as per the procedures illustrated
in Example 6.
Example 8
General Preparation of Therapeutic Agents Comprising GalNAc.sub.3-1
at the 5' Terminus
##STR00105## ##STR00106## ##STR00107##
[0723] Wherein R.sub.1 and R.sub.2 are independently selected from
H, OH, F, Me, and MOE. As used in the scheme above and throughout
these examples, "Nucleotide(s)" means one or more therapeutic
and/or non-therapeutic nucleotides. Compound 24 is prepared as per
the procedures illustrated in Example 6. The Unylinker.TM. 30 is
commercially available. Compound 34 comprising a GalNAc.sub.3-1
cluster at the 5' terminus is prepared using standard procedures in
automated DNA/RNA synthesis (see Dupouy et al., Angew. Chem. Int.
Ed., 2006, 45, 3623-3627). Phosphoramidite building blocks,
Compounds 1 and 1a were prepared as per the procedures illustrated
in Example 1. The phosphoramidites illustrated are meant to be
representative and not intended to be limiting as other
phosphoramidite building blocks can be used to prepare a compound
having a predetermined sequence or composition. The order and
quantity of phosphoramidites added to the solid support can be
adjusted to prepare gapped oligomeric compounds as described
herein. Such gapped oligomeric compounds can have predetermined
composition and base sequence as dictated by any given target.
Example 9
General Preparation of Therapeutic Agents Comprising GalNAc.sub.3-1
at the 3' terminus
##STR00108## ##STR00109##
[0725] Wherein R.sub.1 and R.sub.2 are independently selected from
H, OH, F, Me, and MOE; and GalNAc.sub.3-1 has the structure:
##STR00110##
[0726] The GalNAc.sub.b 3 cluster portion of the targeting group
GalNAc.sub.3-1 (GalNAc.sub.3-1 .sub.a) can be combined with any
cleavable moiety. Wherein GalNAc.sub.3-1.sub.a has the formula:
##STR00111##
[0727] The solid support bound protected GalNAc.sub.3-1, Compound
25, was prepared as per the procedures illustrated in Example 7.
Compound 29 comprising GalNAc.sub.3-1 at the 3' terminus is
prepared using standard procedures in automated DNA/RNA synthesis
(see Dupouy et al., Angew. Chem. Int. Ed., 2006, 45, 3623-3627).
Phosphoramidite building blocks, Compounds 1 and 1a are prepared as
per the procedures illustrated in Example 1. The phosphoramidites
illustrated are meant to be representative and not intended to be
limiting as other phosphoramidite building blocks can be used to
prepare compounds having a predetermined sequence and composition.
The order and quantity of phosphoramidites added to the solid
support can be adjusted to prepare gapped oligomeric compounds as
described herein. Such gapped oligomeric compounds can have
predetermined composition and base sequence as dictated by any
given target.
Example 10
Preparation of Compound 39
##STR00112##
[0729] Compounds 4, 13 and 23 are prepared as per the procedures
illustrated in Examples 2, 4, and 5. Compound 35 is prepared using
similar procedures published in Rouchaud et al., Eur. J. Org.
Chem., 2011, 12, 2346-2353.
Example 11
Preparation of Compound 40
##STR00113##
[0731] Compound 38 is prepared as per the procedures illustrated in
Example 10.
Example 12
Preparation of Compound 44
##STR00114## ##STR00115##
[0733] Compounds 23 and 36 are prepared as per the procedures
illustrated in Examples 5 and 10. Compound 41 is prepared using
similar procedures published in WO 2009082607.
Example 13
Preparation of Compound 45
##STR00116##
[0735] Compound 43 is prepared as per the procedures illustrated in
Example 12.
Example 14
Preparation of Compound 47
##STR00117##
[0737] Compound 46 is commercially available.
Example 15
Preparation of Compound 53
##STR00118##
[0739] Compounds 48 and 49 are commercially available. Compounds 17
and 47 are prepared as per the procedures illustrated in Examples 4
and 14.
Example 16
Preparation of Compound 54
##STR00119##
[0741] Compound 53 is prepared as per the procedures illustrated in
Example 15.
Example 17
Preparation of Compound 55
##STR00120##
[0743] Compound 53 is prepared as per the procedures illustrated in
Example 15.
Example 18
Compound 56
##STR00121##
[0745] Compound 56 is commercially available from Glen Research or
is prepared according to published procedures reported by
Shchepinov et al., Nucleic Acids Research, 1997, 25(22),
4447-4454.
Example 19
Preparation of Compound 60
##STR00122##
[0747] Compound 4 was prepared as per the procedures illustrated in
Example 2. Compound 57 is commercially available. Compound 60 was
confirmed by structural analysis.
[0748] Compound 57 is meant to be representative and not intended
to be limiting as other monoprotected substituted or unsubstituted
alkyl diols including but not limited to those presented in the
specification herein can be used to prepare phosphoramidites having
a predetermined composition.
Example 20
Preparation of Compound 63
##STR00123##
[0750] Compounds 61 and 62 are prepared using procedures similar to
those reported by Tober et al., Eur. J. Org. Chem., 2013, 3,
566-577; and Jiang et al., Tetrahedron, 2007, 63(19),
3982-3988.
[0751] Alternatively, Compound 63 is prepared using procedures
similar to those reported in scientific and patent literature by
Kim et al., Synlett, 2003, 12, 1838-1840; and Kim et al., published
PCT International Application, WO 2004063208.
Example 21
Preparation of Compound 63b
##STR00124##
[0753] Compound 63a is prepared using procedures similar to those
reported by Hanessian et al., Canadian Journal of Chemistry, 1996,
74(9), 1731-1737.
Example 22
Preparation of Compound 63d
##STR00125##
[0755] Compound 63c is prepared using procedures similar to those
reported by Chen et al., Chinese Chemical Letters, 1998, 9(5),
451-453.
Example 23
Preparation of Compound 67
##STR00126##
[0757] Compound 64 is prepared as per the procedures illustrated in
Example 2. Compound 65 is prepared using procedures similar to
those reported by Or et al., published PCT International
Application, WO 2009003009. The protecting groups used for Compound
65 are meant to be representative and not intended to be limiting
as other protecting groups including but not limited to those
presented in the specification herein can be used.
Example 24
Preparation of Compound 70
##STR00127##
[0759] Compound 64 is prepared as per the procedures illustrated in
Example 2. Compound 68 is commercially available. The protecting
group used for Compound 68 is meant to be representative and not
intended to be limiting as other protecting groups including but
not limited to those presented in the specification herein can be
used.
Example 25
Preparation of Compound 75a
##STR00128##
[0761] Compound 75 is prepared according to published procedures
reported by Shchepinov et al., Nucleic Acids Research, 1997,
25(22), 4447-4454.
Example 26
Preparation of Compound 79
##STR00129##
[0763] Compound 76 is prepared according to published procedures
reported by Shchepinov et al., Nucleic Acids Research, 1997,
25(22), 4447-4454.
Example 27
Preparation of Compound 79a
##STR00130##
[0765] Compound 77 is prepared as per the procedures illustrated in
Example 26.
Example 28
General Method for the Preparation of Therapeutic Agents Comprising
a Phosphodiester Linked GalNAc.sub.3-2 Targeting Group at 5'
Terminus Via Solid Support
##STR00131## ##STR00132##
[0767] The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-2 (GalNAc.sub.3-2.sub.a) can be combined with any
cleavable moiety. Wherein GalNAc.sub.3-2.sub.a has the formula:
##STR00133##
[0768] The VIMAD-bound compound 79b is prepared using standard
procedures for automated DNA/RNA synthesis (see Dupouy et al.,
Angew. Chem. Int. Ed., 2006, 45, 3623-3627). The phosphoramidite
Compounds 56 and 60 were prepared as per the procedures illustrated
in Examples 18 and 19, respectively. The phosphoramidites
illustrated are meant to be representative and not intended to be
limiting as other phosphoramidite building blocks including but not
limited those presented in the specification herein can be used to
prepare a therapeutic agent having a phosphodiester linked
conjugate group at the 5' terminus. The order and quantity of
phosphoramidites added to the solid support can be adjusted to
prepare the compounds as described herein having any predetermined
sequence and composition.
Example 29
General Method for the Preparation of Compound 83h Comprising a
GalNAc.sub.3-3 Targeting Group at the 5' Terminus (GalNAc.sub.3-1
Modified for 5' End Attachment) Via Solid Support
##STR00134## ##STR00135##
[0770] Compound 18 is prepared as per the procedures illustrated in
Example 4. Compounds 83a and 83b are commercially available.
Compound 83e comprising a phosphodiester linked hexylamine is
prepared using standard oligonucleotide synthesis procedures.
Treatment of the protected compound with aqueous ammonia will
provide the 5'-GalNAc.sub.3-3 compound (83h).
[0771] Wherein GalNAc.sub.3-3 has the structure:
##STR00136##
[0772] The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-3 (GalNAc.sub.3-3.sub.a) can be combined with any
cleavable moiety. Wherein GalNAc.sub.3-3.sub.a has the formula:
##STR00137##
Example 30
General Method for the Preparation of Therapeutic Agent 89
Comprising a Phosphodiester Linked GalNAc.sub.3-4 at the 3'
Terminus Via Solid Support
##STR00138## ##STR00139## ##STR00140##
[0774] wherein CM is a cleavable moiety. In certain embodiments,
cleavable moiety is:
##STR00141##
[0775] The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-4 (GalNAc.sub.3-4.sub.a) can be combined with any
cleavable moiety. Wherein GalNAc.sub.3-4.sub.a has the formula:
##STR00142##
[0776] The protected Unylinker functionalized solid support
Compound 30 is commercially available. Compound 84 is prepared
using procedures similar to those reported in the literature (see
Shchepinov et al., Nucleic Acids Research, 1997, 25(22), 4447-4454;
Shchepinov et al., Nucleic Acids Research, 1999, 27, 3035-3041; and
Hornet et al., Nucleic Acids Research, 1997, 25, 4842-4849).
[0777] The phosphoramidite building blocks, Compounds 60 and 79a
are prepared as per the procedures illustrated in Examples 19 and
27, respectively. The phosphoramidites illustrated are meant to be
representative and not intended to be limiting as other
phosphoramidite building blocks can be used to prepare a
therapeutic agent having a phosphodiester linked targeting group at
the 3' terminus and a predetermined sequence and composition. The
order and quantity of phosphoramidites added to the solid support
can be adjusted to prepare the compounds as described herein having
any predetermined sequence and composition.
Example 31
Preparation of PFP Ester, Compound 110a
##STR00143## ##STR00144##
[0779] Compound 4 (9.5g, 28.8 mmoles) was treated with compound
103a or 103b (38 mmoles), individually, and TMSOTf (0.5 eq.) and
molecular sieves in dichloromethane (200 mL), and stirred for 16
hours at room temperature. At that time, the organic layer was
filtered thru celite, then washed with sodium bicarbonate, water
and brine. The organic layer was then separated and dried over
sodium sulfate, filtered and reduced under reduced pressure. The
resultant oil was purified by silica gel chromatography (2%->10%
methanol/dichloromethane) to give compounds 104a and 104b in
>80% yield. LCMS and proton NMR was consistent with the
structure.
[0780] Compounds 104a and 104b were treated to the same conditions
as for compounds 101a-d (Example 33), to give compounds 105a and
105b in >90% yield. LCMS and proton NMR was consistent with the
structure.
[0781] Compounds 105a and 105b were treated, individually, with
compound 90 under the same conditions as for compounds 92a-b, to
give compounds 106a (80%) and 106b (20%). LCMS and proton NMR was
consistent with the structure.
[0782] Compounds 106a and 106b were treated to the same conditions
as for compounds 97a-d (Example 33), to give 107a (60%) and 107b
(20%). LCMS and proton NMR was consistent with the structure.
[0783] Compounds 107a and 107b were treated to the same conditions
as for compounds 100a-d (Example 33), to give compounds 108a and
108b in 40-60% yield. LCMS and proton NMR was consistent with the
structure.
[0784] Compounds 108a (60%) and 108b (40%) were treated to the same
conditions as for compounds 101a-d (Example 33), to give compounds
109a and 109b in >80% yields. LCMS and proton NMR was consistent
with the structure.
[0785] Compound 109a was treated to the same conditions as for
compounds 102a-d (Example 33), to give Compound 110a in 30-60%
yield. LCMS and proton NMR was consistent with the structure.
Alternatively, Compound 110b can be prepared in a similar manner
starting with Compound 109b.
Example 32
General Procedure for Conjugation with PFP Esters
[0786] A 5'-hexylamino modified (oligo)nucleotide is synthesized
and purified using standard solid-phase oligonucleotide procedures.
The 5'-hexylamino modified (oligo)nucleotide is dissolved in 0.1 M
sodium tetraborate, pH 8.5 (200 .mu.L) and 3 equivalents of a
selected PFP esterified GalNAc.sub.3 cluster dissolved in DMSO (50
.mu.L) is added. If the PFP ester precipitates upon addition to the
ASO solution DMSO is added until all PFP ester is in solution. The
reaction is complete after about 16 h of mixing at room
temperature. The resulting solution is diluted with water to 12 mL
and then spun down at 3000 rpm in a spin filter with a mass cut off
of 3000 Da. This process is repeated twice to remove small molecule
impurities. The solution is then lyophilized to dryness and
redissolved in concentrated aqueous ammonia and mixed at room
temperature for 2.5 h followed by concentration in vacuo to remove
most of the ammonia. The conjugated (oligo)nucleotide is purified
and desalted by RP-HPLC and lyophilized to provide the GalNAc.sub.3
conjugated therapeutic agent.
##STR00145##
[0787] Compound 111 is conjugated to GalNAc.sub.3-10. The
GalNAc.sub.3 cluster portion of the targeting group GalNAc.sub.3-10
(GalNAc.sub.3-10.sub.a) can be combined with any cleavable moiety.
In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-10 (GalNAc.sub.3-10.sub.a-CM-) is shown below:
##STR00146##
Example 33
Preparation of Therapeutic Agent 102 Comprising GalNAc.sub.3-8
##STR00147## ##STR00148##
[0789] The triacid 90 (4 g, 14.43 mmol) was dissolved in DMF (120
mL) and N,N-Diisopropylethylamine (12.35 mL, 72 mmoles).
Pentafluorophenyl trifluoroacetate (8.9 mL, 52 mmoles) was added
dropwise, under argon, and the reaction was allowed to stir at room
temperature for 30 minutes. Boc-diamine 91a or 91b (68.87 mmol) was
added, along with N,N-Diisopropylethylamine (12.35 mL, 72 mmoles),
and the reaction was allowed to stir at room temperature for 16
hours. At that time, the DMF was reduced by >75% under reduced
pressure, and then the mixture was dissolved in dichloromethane.
The organic layer was washed with sodium bicarbonate, water and
brine. The organic layer was then separated and dried over sodium
sulfate, filtered and reduced to an oil under reduced pressure. The
resultant oil was purified by silica gel chromatography (2%->10%
methanol/dichloromethane) to give compounds 92a and 92b in an
approximate 80% yield. LCMS and proton NMR were consistent with the
structure.
[0790] Compound 92a or 92b (6.7 mmoles) was treated with 20 mL of
dichloromethane and 20 mL of trifluoroacetic acid at room
temperature for 16 hours. The resultant solution was evaporated and
then dissolved in methanol and treated with DOWEX-OH resin for 30
minutes. The resultant solution was filtered and reduced to an oil
under reduced pressure to give 85-90% yield of compounds 93a and
93b.
[0791] Compounds 7 or 64 (9.6 mmoles) were treated with HBTU (3.7g,
9.6 mmoles) and N,N-Diisopropylethylamine (5 mL) in DMF (20 mL) for
15 minutes. To this was added either compounds 93a or 93b (3
mmoles), and allowed to stir at room temperature for 16 hours. At
that time, the DMF was reduced by >75% under reduced pressure,
and then the mixture was dissolved in dichloromethane. The organic
layer was washed with sodium bicarbonate, water and brine. The
organic layer was then separated and dried over sodium sulfate,
filtered and reduced to an oil under reduced pressure. The
resultant oil was purified by silica gel chromatography (5%->20%
methanol/dichloromethane) to give compounds 96a-d in 20-40% yield.
LCMS and proton NMR was consistent with the structure.
[0792] Compounds 96a-d (0.75 mmoles), individually, were
hydrogenated over Raney Nickel for 3 hours in Ethanol (75 mL). At
that time, the catalyst was removed by filtration thru celite, and
the ethanol removed under reduced pressure to give compounds 97a-d
in 80-90% yield. LCMS and proton NMR were consistent with the
structure. Compound 23 (0.32 g, 0.53 mmoles) was treated with HBTU
(0.2 g, 0.53 mmoles) and N,N-Diisopropylethylamine (0.19 mL, 1.14
mmoles) in DMF (30mL) for 15 minutes. To this was added compounds
97a-d (0.38 mmoles), individually, and allowed to stir at room
temperature for 16 hours. At that time, the DMF was reduced by
>75% under reduced pressure, and then the mixture was dissolved
in dichloromethane. The organic layer was washed with sodium
bicarbonate, water and brine. The organic layer was then separated
and dried over sodium sulfate, filtered and reduced to an oil under
reduced pressure. The resultant oil was purified by silica gel
chromatography (2%->20% methanol/dichloromethane) to give
compounds 98a-d in 30-40% yield. LCMS and proton NMR was consistent
with the structure.
[0793] Compound 99 (0.17 g, 0.76 mmoles) was treated with HBTU
(0.29 g, 0.76 mmoles) and N,N-Diisopropylethylamine (0.35 mL, 2.0
mmoles) in DMF (50 mL) for 15 minutes. To this was added compounds
97a-d (0.51 mmoles), individually, and allowed to stir at room
temperature for 16 hours. At that time, the DMF was reduced by
>75% under reduced pressure, and then the mixture was dissolved
in dichloromethane. The organic layer was washed with sodium
bicarbonate, water and brine. The organic layer was then separated
and dried over sodium sulfate, filtered and reduced to an oil under
reduced pressure. The resultant oil was purified by silica gel
chromatography (5%->20% methanol/dichloromethane) to give
compounds 100a-d in 40-60% yield. LCMS and proton NMR was
consistent with the structure.
[0794] Compounds 100a-d (0.16 mmoles), individually, were
hydrogenated over 10% Pd(OH).sub.2/C for 3 hours in methanol/ethyl
acetate (1:1, 50 mL). At that time, the catalyst was removed by
filtration thru celite, and the organics removed under reduced
pressure to give compounds 101a-d in 80-90% yield. LCMS and proton
NMR was consistent with the structure.
[0795] Compounds 101a-d (0.15 mmoles), individually, were dissolved
in DMF (15 mL) and pyridine (0.016 mL, 0.2 mmoles).
Pentafluorophenyl trifluoroacetate (0.034 mL, 0.2 mmoles) was added
dropwise, under argon, and the reaction was allowed to stir at room
temperature for 30 minutes. At that time, the DMF was reduced by
>75% under reduced pressure, and then the mixture was dissolved
in dichloromethane. The organic layer was washed with sodium
bicarbonate, water and brine. The organic layer was then separated
and dried over sodium sulfate, filtered and reduced to an oil under
reduced pressure. The resultant oil was purified by silica gel
chromatography (2%->5% methanol/dichloromethane) to give
compounds 102a-d in an approximate 80% yield. LCMS and proton NMR
were consistent with the structure.
##STR00149##
[0796] Compound 102, comprising a GalNAc.sub.3-8 targeting group,
is prepared using the general procedures illustrated in Example 32.
The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-8 (GalNAc.sub.3-8.sub.a) can be combined with any
cleavable moiety. In certain embodiments, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--.
[0797] The structure of GalNAc.sub.3-8 (GalNAc.sub.3-8.sub.a-CM-)
is shown below:
##STR00150##
Example 34
Preparation of Therapeutic Agent 119 Comprising GalNAc.sub.3-7
##STR00151## ##STR00152##
[0799] Compound 112 was synthesized following the procedure
described in the literature (J. Med. Chem. 2004, 47,
5798-5808).
[0800] Compound 112 (5 g, 8.6 mmol) was dissolved in 1:1
methanol/ethyl acetate (22 mL/22 mL). Palladium hydroxide on carbon
(0.5 g) was added. The reaction mixture was stirred at room
temperature under hydrogen for 12 h. The reaction mixture was
filtered through a pad of celite and washed the pad with 1:1
methanol/ethyl acetate. The filtrate and the washings were combined
and concentrated to dryness to yield Compound 105a (quantitative).
The structure was confirmed by LCMS.
[0801] Compound 113 (1.25 g, 2.7 mmol), HBTU (3.2 g, 8.4 mmol) and
DIEA (2.8 mL, 16.2 mmol) were dissolved in anhydrous DMF (17 mL)
and the reaction mixture was stirred at room temperature for 5 min.
To this a solution of Compound 105a (3.77 g, 8.4 mmol) in anhydrous
DMF (20 mL) was added. The reaction was stirred at room temperature
for 6 h. Solvent was removed under reduced pressure to get an oil.
The residue was dissolved in CH.sub.2Cl.sub.2 (100 mL) and washed
with aqueous saturated NaHCO.sub.3 solution (100 mL) and brine (100
mL). The organic phase was separated, dried (Na.sub.2SO.sub.4),
filtered and evaporated. The residue was purified by silica gel
column chromatography and eluted with 10 to 20% MeOH in
dichloromethane to yield Compound 114 (1.45 g, 30%). The structure
was confirmed by LCMS and .sup.1H NMR analysis.
[0802] Compound 114 (1.43 g, 0.8 mmol) was dissolved in 1:1
methanol/ethyl acetate (4 mL/4 mL). Palladium on carbon (wet, 0.14
g) was added. The reaction mixture was flushed with hydrogen and
stirred at room temperature under hydrogen for 12 h. The reaction
mixture was filtered through a pad of celite. The celite pad was
washed with methanol/ethyl acetate (1:1). The filtrate and the
washings were combined together and evaporated under reduced
pressure to yield Compound 115 (quantitative). The structure was
confirmed by LCMS and .sup.1H NMR analysis.
[0803] Compound 83a (0.17 g, 0.75 mmol), HBTU (0.31 g, 0.83 mmol)
and DIEA (0.26 mL, 1.5 mmol) were dissolved in anhydrous DMF (5 mL)
and the reaction mixture was stirred at room temperature for 5 min.
To this a solution of Compound 115 (1.22 g, 0.75 mmol) in anhydrous
DMF was added and the reaction was stirred at room temperature for
6 h. The solvent was removed under reduced pressure and the residue
was dissolved in CH.sub.2Cl.sub.2. The organic layer was washed
aqueous saturated NaHCO.sub.3 solution and brine and dried over
anhydrous Na.sub.2SO.sub.4 and filtered. The organic layer was
concentrated to dryness and the residue obtained was purified by
silica gel column chromatography and eluted with 3 to 15% MeOH in
dichloromethane to yield Compound 116 (0.84 g, 61%). The structure
was confirmed by LC MS and .sup.1H NMR analysis.
##STR00153##
[0804] Compound 116 (0.74 g, 0.4 mmol) was dissolved in 1:1
methanol/ethyl acetate (5 mL/5 mL). Palladium on carbon (wet, 0.074
g) was added. The reaction mixture was flushed with hydrogen and
stirred at room temperature under hydrogen for 12 h. The reaction
mixture was filtered through a pad of celite. The celite pad was
washed with methanol/ethyl acetate (1:1). The filtrate and the
washings were combined together and evaporated under reduced
pressure to yield compound 117 (0.73 g, 98%). The structure was
confirmed by LCMS and .sup.1H NMR analysis.
[0805] Compound 117 (0.63 g, 0.36 mmol) was dissolved in anhydrous
DMF (3 mL). To this solution N,N-Diisopropylethylamine (70 .mu.L,
0.4 mmol) and pentafluorophenyl trifluoroacetate (72 .mu.L, 0.42
mmol) were added. The reaction mixture was stirred at room
temperature for 12 h and poured into a aqueous saturated
NaHCO.sub.3 solution. The mixture was extracted with
dichloromethane, washed with brine and dried over anhydrous
Na.sub.2SO.sub.4. The dichloromethane solution was concentrated to
dryness and purified with silica gel column chromatography and
eluted with 5 to 10% MeOH in dichloromethane to yield compound 118
(0.51 g, 79%). The structure was confirmed by LCMS and .sup.1H and
.sup.1H and .sup.19F NMR.
##STR00154##
[0806] Compound 119, comprising a GalNAc.sub.3-7 targeting group,
is prepared using the general procedures illustrated in Example 32.
The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-7 (GalNAc.sub.3-7.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--.
[0807] The structure of GalNAc.sub.3-7 (GalNAc.sub.3-7.sub.a-CM-)
is shown below:
##STR00155##
Example 35
Preparation of Therapeutic Agent 132 Comprising GalNAc.sub.3-5
##STR00156##
[0809] Compound 120 (14.01 g, 40 mmol) and HBTU (14.06 g, 37 mmol)
were dissolved in anhydrous DMF (80 mL). Triethylamine (11.2 mL,
80.35 mmol) was added and stirred for 5 min. The reaction mixture
was cooled in an ice bath and a solution of compound 121 (10 g,
mmol) in anhydrous DMF (20 mL) was added. Additional triethylamine
(4.5 mL, 32.28 mmol) was added and the reaction mixture was stirred
for 18 h under an argon atmosphere. The reaction was monitored by
TLC (ethyl acetate:hexane; 1:1; Rf=0.47). The solvent was removed
under reduced pressure. The residue was taken up in EtOAc (300 mL)
and washed with 1M NaHSO.sub.4 (3.times.150 mL), aqueous saturated
NaHCO.sub.3 solution (3.times.150 mL) and brine (2.times.100 mL).
Organic layer was dried with Na.sub.2SO.sub.4. Drying agent was
removed by filtration and organic layer was concentrated by rotary
evaporation. Crude mixture was purified by silica gel column
chromatography and eluted by using 35-50% EtOAc in hexane to yield
a compound 122 (15.50 g, 78.13%). The structure was confirmed by
LCMS and .sup.1H NMR analysis. Mass m/z 589.3 [M+H].sup.+.
[0810] A solution of LiOH (92.15 mmol) in water (20 mL) and THF (10
mL) was added to a cooled solution of Compound 122 (7.75 g,13.16
mmol) dissolved in methanol (15 mL). The reaction mixture was
stirred at room temperature for 45 min. and monitored by TLC
(EtOAc:hexane; 1:1). The reaction mixture was concentrated to half
the volume under reduced pressure. The remaining solution was
cooled an ice bath and neutralized by adding concentrated HCl. The
reaction mixture was diluted, extracted with EtOAc (120 mL) and
washed with brine (100 mL). An emulsion formed and cleared upon
standing overnight. The organic layer was separated dried
(Na.sub.2SO.sub.4), filtered and evaporated to yield Compound 123
(8.42 g). Residual salt is the likely cause of excess mass. LCMS is
consistent with structure. Product was used without any further
purification. M.W.cal:574.36; M.W.fd:575.3 [M+H].sup.+.
##STR00157##
[0811] Compound 126 was synthesized following the procedure
described in the literature (J. Am. Chem. Soc. 2011, 133,
958-963).
##STR00158## ##STR00159##
[0812] Compound 123 (7.419 g, 12.91 mmol), HOBt (3.49 g, 25.82
mmol) and compound 126 (6.33 g, 16.14 mmol) were dissolved in and
DMF (40 mL) and the resulting reaction mixture was cooled in an ice
bath. To this N,N-Diisopropylethylamine (4.42 mL, 25.82 mmol),
PyBop (8.7 g, 16.7 mmol) followed by Bop coupling reagent (1.17 g,
2.66 mmol) were added under an argon atmosphere. The ice bath was
removed and the solution was allowed to warm to room temperature.
The reaction was completed after 1 h as determined by TLC
(DCM:MeOH:AA; 89:10:1). The reaction mixture was concentrated under
reduced pressure. The residue was dissolved in EtOAc (200 mL) and
washed with 1 M NaHSO.sub.4 (3.times.100 mL), aqueous saturated
NaHCO.sub.3 (3.times.100 mL) and brine (2.times.100 mL). The
organic phase separated dried (Na.sub.2SO.sub.4), filtered and
concentrated. The residue was purified by silica gel column
chromatography with a gradient of 50% hexanes/EtOAC to 100% EtOAc
to yield Compound 127 (9.4 g) as a white foam. LCMS and NMR were
consistent with structure. Mass m/z 778.4 [M+H].sup.+.
[0813] Trifluoroacetic acid (12 mL) was added to a solution of
compound 127 (1.57 g, 2.02 mmol) in dichloromethane (12 mL) and
stirred at room temperature for 1 h. The reaction mixture was
co-evaporated with toluene (30 mL) under reduced pressure to
dryness. The residue obtained was co-evaporated twice with
acetonitrile (30 mL) and toluene (40 mL) to yield Compound 128
(1.67 g) as trifluoro acetate salt and used for next step without
further purification. LCMS and .sup.1H NMR were consistent with
structure. Mass m/z 478.2 [M+H].sup.+.
[0814] Compound 7 (0.43 g, 0.963 mmol), HATU (0.35 g, 0.91 mmol),
and HOAt (0.035 g, 0.26 mmol) were combined together and dried for
4 h over P.sub.2O.sub.5 under reduced pressure in a round bottom
flask and then dissolved in anhydrous DMF (1 mL) and stirred for 5
min. To this a solution of compound 128 (0.20 g, 0.26 mmol) in
anhydrous DMF (0.2 mL) and N,N-Diisopropylethylamine (0.2 mL) was
added. The reaction mixture was stirred at room temperature under
an argon atmosphere. The reaction was complete after 30 min as
determined by LCMS and TLC (7% MeOH/DCM). The reaction mixture was
concentrated under reduced pressure. The residue was dissolved in
DCM (30 mL) and washed with 1 M NaHSO.sub.4 (3.times.20 mL),
aqueous saturated NaHCO.sub.3 (3.times.20 mL) and brine (3.times.20
mL). The organic phase was separated, dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified by silica gel
column chromatography using 5-15% MeOH in dichloromethane to yield
Compound 129 (96.6 mg). LC MS and .sup.1H NMR are consistent with
structure. Mass m/z 883.4 [M+2H].sup.+.
[0815] Compound 129 (0.09 g, 0.051 mmol) was dissolved in methanol
(5 mL) in 20 mL scintillation vial. To this was added a small
amount of 10% Pd/C (0.015 mg) and the reaction vessel was flushed
with H.sub.2 gas. The reaction mixture was stirred at room
temperature under H.sub.2 atmosphere for 18 h. The reaction mixture
was filtered through a pad of Celite and the Celite pad was washed
with methanol. The filtrate washings were pooled together and
concentrated under reduced pressure to yield Compound 130 (0.08 g).
LCMS and .sup.1H NMR were consistent with structure. The product
was used without further purification. Mass m/z 838.3
[M+2H].sup.+.
[0816] To a 10 mL pointed round bottom flask were added compound
130 (75.8 mg, 0.046 mmol), 0.37 M pyridine/DMF (200 .mu.L) and a
stir bar. To this solution was added 0.7 M pentafluorophenyl
trifluoroacetate/DMF (100 .mu.L) drop wise with stirring. The
reaction was completed after 1 h as determined by LC MS. The
solvent was removed under reduced pressure and the residue was
dissolved in CHCl.sub.3 (.about.10 mL). The organic layer was
partitioned against NaHSO.sub.4 (1 M, 10 mL), aqueous saturated
NaHCO.sub.3 (10 mL) and brine (10 mL) three times each. The organic
phase separated and dried over Na.sub.2SO.sub.4, filtered and
concentrated to yield Compound 131 (77.7 mg). LCMS is consistent
with structure. Used without further purification. Mass m/z 921.3
[M+2H].sup.+.
##STR00160##
[0817] Compound 132, comprising a GalNAc.sub.3-5 targeting group,
is prepared using the general procedures illustrated in Example 32.
The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-5 (GalNAc.sub.3-5.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--.
[0818] The structure of GalNAc.sub.3-5 (GalNAc.sub.3-5.sub.a-CM-)
is shown below:
##STR00161##
Example 36
Preparation of Therapeutic Agent 144 Comprising GalNAc.sub.4-11
##STR00162##
[0820] Synthesis of Compound 134. To a Merrifield flask was added
aminomethyl VIMAD resin (2.5 g, 450 .mu.mol/g) that was washed with
acetonitrile, dimethylformamide, dichloromethane and acetonitrile.
The resin was swelled in acetonitrile (4 mL). Compound 133 (where
from) was pre-activated in a 100 mL round bottom flask by adding 20
(1.0 mmol, 0.747 g), TBTU (1.0 mmol, 0.321 g), acetonitrile (5 mL)
and DIEA (3.0 mmol, 0.5 mL). This solution was allowed to stir for
5 min and was then added to the Merrifield flask with shaking. The
suspension was allowed to shake for 3 h. The reaction mixture was
drained and the resin was washed with acetonitrile, DMF and DCM.
New resin loading was quantitated by measuring the absorbance of
the DMT cation at 500 nm (extinction coefficient=76000) in DCM and
determined to be 238 .mu.mol/g. The resin was capped by suspending
in an acetic anhydride solution for ten minutes three times.
[0821] The solid support bound compound 141 was synthesized using
iterative Fmoc-based solid phase peptide synthesis methods. A small
amount of solid support was withdrawn and suspended in aqueous
ammonia (28-30 wt %) for 6 h. The cleaved compound was analyzed by
LC-MS and the observed mass was consistent with structure. Mass m/z
1063.8 [M+2H].sup.+.
[0822] The solid support bound compound 142 was synthesized using
solid phase peptide synthesis methods.
##STR00163##
[0823] The solid support bound compound 143 is synthesized using
standard solid phase synthesis on a DNA synthesizer.
[0824] The GalNAc.sub.4 cluster portion of the targeting group
GalNAc.sub.4-11 (GalNAc.sub.4-11 .sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--.
[0825] The structure of GalNAc.sub.4-11 (GalNAc.sub.4-11.sub.a-CM)
is shown below:
##STR00164##
Example 37
Preparation of Therapeutic Agent 155 Comprising GalNAc.sub.3-6
##STR00165##
[0827] Compound 146 was synthesized as described in the literature
(Analytical Biochemistry 1995, 229, 54-60).
##STR00166##
[0828] Compound 4 (15 g, 45.55 mmol) and compound 35b (14.3 grams,
57 mmol) were dissolved in CH.sub.2Cl.sub.2 (200 ml). Activated
molecular sieves (4 A. 2 g, powdered) was added, and the reaction
was allowed to stir for 30 minutes under nitrogen atmosphere.
TMS-OTf was added (4.1 ml, 22.77 mmol) and the reaction was allowed
to stir at room temp overnight. Upon completion, the reaction was
quenched by pouring into solution of saturated aqueous NaHCO.sub.3
(500 ml) and crushed ice (.about.150 g). The organic layer was
separated, washed with brine, dried over MgSO.sub.4, filtered, and
was concentrated to an orange oil under reduced pressure. The crude
material was purified by silica gel column chromatography and
eluted with 2-10% MeOH in CH.sub.2C;.sub.2to yield Compound 112
(16.53 g, 63%). LCMS and .sup.1H NMR were consistent with the
expected compound.
[0829] Compound 112 (4.27 g, 7.35 mmol) was dissolved in 1:1
MeOH/EtOAc (40 ml). The reaction mixture was purged by bubbling a
stream of argon through the solution for 15 minutes. Pearlman's
catalyst (palladium hydroxide on carbon, 400 mg) was added, and
hydrogen gas was bubbled thru the solution for 30 minutes. Upon
completion (TLC 10% MeOH in CH.sub.2Cl.sub.2, and LCMS), the
catalyst was removed by filtration through a pad of celite. The
filtrate was concentrated by rotary evaporation, and was dried
briefly under high vacuum to yield Compound 105a (3.28 g). LCMS and
1H NMR were consistent with desired product.
[0830] Compound 147 (2.31 g, 11 mmol) was dissolved in anhydrous
DMF (100 mL). N,N-Diisopropylethylamine (DIEA, 3.9 mL, 22 mmol) was
added, followed by HBTU (4 g, 10.5 mmol). The reaction mixture was
allowed to stir for .about.15 minutes under nitrogen. To this a
solution of compound 105a (3.3 g, 7.4 mmol) in dry DMF was added
and stirred for 2 h under nitrogen atmosphere. The reaction was
diluted with EtOAc and washed with saturated aqueous NaHCO.sub.3
and brine. The organics phase was separated, dried (MgSO.sub.4),
filtered, and concentrated to an orange syrup. The crude material
was purified by column chromatography 2-5% MeOH in
CH.sub.2Cl.sub.2to yield Compound 148 (3.44 g, 73%). LCMS and
.sup.1H NMR were consistent with the expected product.
[0831] Compound 148 (3.3 g, 5.2 mmol) was dissolved in 1:1
MeOH/EtOAc (75 ml). The reaction mixture was purged by bubbling a
stream of argon through the solution for 15 minutes. Pearlman's
catalyst (palladium hydroxide on carbon) was added (350 mg).
Hydrogen gas was bubbled through the solution for 30 minutes. Upon
completion (TLC 10% MeOH in DCM, and LCMS), the catalyst was
removed by filtration through a pad of celite. The filtrate was
concentrated by rotary evaporation, and was dried briefly under
high vacuum to yield Compound 149 (2.6 g). LCMS was consistent with
desired product. The residue was dissolved in dry DMF (10 ml) was
used immediately in the next step.
##STR00167##
[0832] Compound 146 (0.68 g, 1.73 mmol) was dissolved in dry DMF
(20 ml). To this DIEA (450 .mu.L, 2.6 mmol, 1.5 eq.) and HBTU (1.96
g, 0.5.2 mmol) were added. The reaction mixture was allowed to stir
for 15 minutes at room temperature under nitrogen. A solution of
compound 149 (2.6 g) in anhydrous DMF (10 mL) was added. The pH of
the reaction was adjusted to pH=9-10 by addition of DIEA (if
necessary). The reaction was allowed to stir at room temperature
under nitrogen for 2 h. Upon completion the reaction was diluted
with EtOAc (100 mL), and washed with aqueous saturated aqueous
NaHCO.sub.3, followed by brine. The organic phase was separated,
dried over MgSO.sub.4, filtered, and concentrated. The residue was
purified by silica gel column chromatography and eluted with 2-10%
MeOH in CH.sub.2Cl.sub.2to yield Compound 150 (0.62 g, 20%). LCMS
and .sup.1H NMR were consistent with the desired product.
[0833] Compound 150 (0.62 g) was dissolved in 1:1 MeOH/EtOAc (5 L).
The reaction mixture was purged by bubbling a stream of argon
through the solution for 15 minutes. Pearlman's catalyst (palladium
hydroxide on carbon) was added (60 mg). Hydrogen gas was bubbled
through the solution for 30 minutes. Upon completion (TLC 10% MeOH
in DCM, and LCMS), the catalyst was removed by filtration (syringe
tip Teflon filter, 0.45 .mu.m). The filtrate was concentrated by
rotary evaporation, and was dried briefly under high vacuum to
yield Compound 151 (0.57 g). The LCMS was consistent with the
desired product. The product was dissolved in 4 mL dry DMF and was
used immediately in the next step.
##STR00168##
[0834] Compound 83a (0.11 g, 0.33 mmol) was dissolved in anhydrous
DMF (5 mL) and N,N-Diisopropylethylamine (75 .mu.L, 1 mmol) and
PFP-TFA (90 .mu.L, 0.76 mmol) were added. The reaction mixture
turned magenta upon contact, and gradually turned orange over the
next 30 minutes. Progress of reaction was monitored by TLC and
LCMS. Upon completion (formation of the PFP ester), a solution of
compound 151 (0.57 g, 0.33 mmol) in DMF was added. The pH of the
reaction was adjusted to pH=9-10 by addition of
N,N-Diisopropylethylamine (if necessary). The reaction mixture was
stirred under nitrogen for .about.30 min. Upon completion, the
majority of the solvent was removed under reduced pressure. The
residue was diluted with CH.sub.2Cl.sub.2 and washed with aqueous
saturated NaHCO.sub.3, followed by brine. The organic phase
separated, dried over MgSO.sub.4, filtered, and concentrated to an
orange syrup. The residue was purified by silica gel column
chromatography (2-10% MeOH in CH.sub.2Cl.sub.2) to yield Compound
152 (0.35 g, 55%). LCMS and .sup.1H NMR were consistent with the
desired product.
[0835] Compound 152 (0.35 g, 0.182 mmol) was dissolved in 1:1
MeOH/EtOAc (10 mL). The reaction mixture was purged by bubbling a
stream of argon thru the solution for 15 minutes. Pearlman's
catalyst (palladium hydroxide on carbon) was added (35 mg).
Hydrogen gas was bubbled thru the solution for 30 minutes. Upon
completion (TLC 10% MeOH in DCM, and LCMS), the catalyst was
removed by filtration (syringe-tip Teflon filter, 0.45 .mu.m). The
filtrate was concentrated by rotary evaporation, and was dried
briefly under high vacuum to yield Compound 153 (0.33 g,
quantitative). The LCMS was consistent with desired product.
[0836] Compound 153 (0.33 g, 0.18 mmol) was dissolved in anhydrous
DMF (5 mL) with stirring under nitrogen. To this
N,N-Diisopropylethylamine (65 .mu.L, 0.37 mmol) and PFP-TFA (35
.mu.L, 0.28 mmol) were added. The reaction mixture was stirred
under nitrogen for .about.30 min. The reaction mixture turned
magenta upon contact, and gradually turned orange. The pH of the
reaction mixture was maintained at pH=9-10 by adding more
N,-Diisopropylethylamine. The progress of the reaction was
monitored by TLC and LCMS. Upon completion, the majority of the
solvent was removed under reduced pressure. The residue was diluted
with CH.sub.2Cl.sub.2 (50 mL), and washed with saturated aqueous
NaHCO.sub.3, followed by brine. The organic layer was dried over
MgSO.sub.4, filtered, and concentrated to an orange syrup. The
residue was purified by column chromatography and eluted with 2-10%
MeOH in CH.sub.2Cl.sub.2 to yield Compound 154 (0.29 g, 79%). LCMS
and .sup.1H NMR were consistent with the desired product.
##STR00169##
[0837] Compound 155, comprising a GalNAc.sub.3-6 targeting group,
is prepared using the general procedures illustrated in Example 32.
The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-6 (GalNAc.sub.3-6.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--.
[0838] The structure of GalNAc.sub.3-6 (GalNAc.sub.3-6.sub.a-CM-)
is shown below:
##STR00170##
Example 38
Preparation of Therapeutic Agent 160 Comprising GalNAc.sub.3-9
##STR00171##
[0840] Compound 156 was synthesized following the procedure
described in the literature (J. Med. Chem. 2004, 47, 5798-5808).
Compound 156, (18.60 g, 29.28 mmol) was dissolved in methanol (200
mL). Palladium on carbon (6.15 g, 10 wt %, loading (dry basis),
matrix carbon powder, wet) was added. The reaction mixture was
stirred at room temperature under hydrogen for 18 h. The reaction
mixture was filtered through a pad of celite and the celite pad was
washed thoroughly with methanol. The combined filtrate was washed
and concentrated to dryness. The residue was purified by silica gel
column chromatography and eluted with 5-10% methanol in
dichloromethane to yield Compound 157 (14.26 g, 89%). Mass m/z
544.1 [M-H].sup.+.
[0841] Compound 157 (5 g, 9.17 mmol) was dissolved in anhydrous DMF
(30 mL). HBTU (3.65 g, 9.61 mmol) and N,N-Diisopropylethylamine
(13.73 mL, 78.81 mmol) were added and the reaction mixture was
stirred at room temperature for 5 minutes. To this a solution of
compound 47 (2.96 g, 7.04 mmol) was added. The reaction was stirred
at room temperature for 8 h. The reaction mixture was poured into a
saturated NaHCO.sub.3 aqueous solution. The mixture was extracted
with ethyl acetate and the organic layer was washed with brine and
dried (Na.sub.2SO.sub.4), filtered and evaporated. The residue
obtained was purified by silica gel column chromatography and
eluted with 50% ethyl acetate in hexane to yield compound 158
(8.25g, 73.3%). The structure was confirmed by MS and .sup.1H NMR
analysis.
[0842] Compound 158 (7.2 g, 7.61 mmol) was dried over
P.sub.2O.sub.5 under reduced pressure. The dried compound was
dissolved in anhydrous DMF (50 mL). To this 1H-tetrazole (0.43 g,
6.09 mmol) and N-methylimidazole (0.3 mL, 3.81 mmol) and
2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphorodiamidite (3.65 mL,
11.50 mmol) were added. The reaction mixture was stirred t under an
argon atmosphere for 4 h. The reaction mixture was diluted with
ethyl acetate (200 mL). The reaction mixture was washed with
saturated NaHCO.sub.3 and brine. The organic phase was separated,
dried (Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by silica gel column chromatography and eluted with 50-90%
ethyl acetate in hexane to yield Compound 159 (7.82 g, 80.5%). The
structure was confirmed by LCMS and .sup.31P NMR analysis.
##STR00172##
[0843] Compound 160, comprising a GalNAc.sub.3-9 targeting group,
is prepared using standard oligonucleotide synthesis procedures.
Three units of compound 159 are coupled to the solid support,
followed by nucleotide phosphoramidite(s). Treatment of the
protected compound with aqueous ammonia yields compound 160. The
GalNAc.sub.3 cluster portion of the targeting group GalNAc.sub.3-9
(GalNAc.sub.3-9.sub.a) can be combined with any cleavable moiety.
In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-9 (GalNAc.sub.3-9.sub.a-CM) is shown below:
##STR00173##
Example 39
Alternate Procedure for Preparation of Compound 18 (GalNAc.sub.3-1a
and GalNAc.sub.3-3a)
##STR00174##
[0845] Lactone 161 was reacted with diamino propane (3-5 eq) or
Mono-Boc protected diamino propane (1 eq) to provide alcohol 162a
or 162b. When unprotected propanediamine was used for the above
reaction, the excess diamine was removed by evaporation under high
vacuum and the free amino group in 162a was protected using CbzCl
to provide 162b as a white solid after purification by column
chromatography. Alcohol 162b is further reacted with compound 4 in
the presence of TMSOTf to provide 163a which is converted to 163b
by removal of the Cbz group using catalytic hydrogenation. The
pentafluorophenyl (PFP) ester 164 was prepared by reacting triacid
113 with PFPTFA (3.5 eq) and pyridine (3.5 eq) in DMF (0.1 to 0.5
M). The triester 164 is directly reacted with the amine 163b (3-4
eq) and DIPEA (3-4 eq) to provide Compound 18. The above method
greatly facilitates purification of intermediates and minimizes the
formation of byproducts which are formed using the procedure
described in Example 4.
Example 40
Alternate Procedure for Preparation of Compound 18 (GalNAc.sub.3-1a
and GalNAc.sub.3-3a)
##STR00175##
[0847] The triPFP ester 164 was prepared from acid 113 using the
procedure outlined in example 31 and reacted with mono-Boc
protected diamine to provide 165 in essentially quantitative yield.
The Boc groups are removed with hydrochloric acid or
trifluoroacetic acid to provide the triamine which is reacted with
the PFP activated acid 166 in the presence of a suitable base such
as DIPEA to provide Compound 18.
[0848] The PFP protected Gal-NAc acid 166 is prepared from the
corresponding acid by treatment with PFPTFA (1-1.2 eq) and pyridine
(1-1.2 eq) in DMF. The precursor acid in turn was prepared from the
corresponding alcohol by oxidation using TEMPO (0.2 eq) and BAIB in
acetonitrile and water. The precursor alcohol was prepared from
sugar intermediate 4 by reaction with 1,6-hexanediol (or
1,5-pentanediol or other diol for other n values) (2-4 eq) and
TMSOTf using the conditions described previously in example 47.
Example 41
Preparation of Therapeutic Agent 175 Comprising GalNAc.sub.3-12
##STR00176## ##STR00177## ##STR00178##
[0850] Compound 169 is commercially available. Compound 172 was
prepared by addition of benzyl (perfluorophenyl) glutarate to
compound 171. The benzyl (perfluorophenyl) glutarate was prepared
by adding PFP-TFA and DIEA to 5-(benzyloxy)-5-oxopentanoic acid in
DMF. Compound 175, comprising a GalNAc.sub.3-12 targeting group, is
prepared from compound 174 using the general procedures illustrated
in Example 32. The GalNAc.sub.3 cluster portion of the targeting
group GalNAc.sub.3-12 (GalNAc.sub.3-12.sub.a) can be combined with
any cleavable moiety. In a certain embodiment, the cleavable moiety
is --P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-12 (GalNAc.sub.3-12.sub.a-CM-) is shown below:
##STR00179##
Example 42
Preparation of Therapeutic agent 180 Comprising GalNAc.sub.3-13
##STR00180##
[0852] Compound 176 was prepared using the general procedure
described in Example 40. Compound 180, comprising a GalNAc.sub.3-13
targeting group, is prepared from compound 177 using the general
procedures illustrated in Example 35. The GalNAc.sub.3 cluster
portion of the targeting group GalNAc.sub.3-13
(GalNAc.sub.3-13.sub.a) can be combined with any cleavable moiety.
In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-13 (GalNAc.sub.3-13.sub.a-CM-) is shown below:
##STR00181##
Example 43
Preparation of Therapeutic agent 188 Comprising GalNAc.sub.3-14
##STR00182## ##STR00183##
[0854] Compounds 181 and 185 are commercially available. Compound
188, comprising a GalNAc.sub.3-14 targeting group, is prepared from
compound 186 using the general procedures illustrated in Example
32. The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-14 (GalNAc.sub.3-14.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-14 (GalNAc.sub.3-14.sub.a-CM-) is shown below:
##STR00184##
Example 44
Preparation of Therapeutic Agent 197 Comprising GalNAc.sub.3-15
##STR00185##
[0856] Compound 189 is commercially available. Compound 195 was
prepared using the general procedure shown in Example 21. Compound
197, comprising a GalNAc.sub.3-15 targeting group, is prepared from
compounds 194 and 195 using standard oligonucleotide synthesis
procedures. The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-15 (GalNAc.sub.3-15.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-15 (GalNAc.sub.3-15.sub.a-CM-) is shown below:
##STR00186##
Example 45
Preparation of Therapeutic Agent 199 Comprising GalNAc.sub.3-16
##STR00187##
[0858] Compound 199, comprising a GalNAc.sub.3-16 targeting group,
is prepared using the general procedures illustrated in Examples 7
and 9. The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-16 (GalNAc.sub.3-16.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-16 (GalNAc.sub.3-16.sub.a-CM-) is shown below:
##STR00188##
Example 46
Preparation of Therapeutic Agent 200 Comprising GalNAc.sub.3-17
##STR00189##
[0860] Compound 200, comprising a GalNAc.sub.3-17 targeting group,
is prepared using the general procedures illustrated in Example 32.
The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-17 (GalNAc.sub.3-17.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-17 (GalNAc.sub.3-17.sub.a-CM-) is shown below:
##STR00190##
Example 47
Preparation of Therapeutic Agent 201 Comprising GalNAc.sub.3-18
##STR00191##
[0862] Compound 201, comprising a GalNAc.sub.3-18 targeting group,
is prepared using the general procedures illustrated in Example 32.
The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-18 (GalNAc.sub.3-18.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-18 (GalNAc.sub.3-18.sub.a-CM-) is shown below:
##STR00192##
Example 48
Preparation of Therapeutic Agent 204 Comprising GalNAc.sub.3-19
##STR00193##
[0864] Compound 204, comprising a GalNAc.sub.3-19 targeting group,
is prepared from compound 64 using the general procedures
illustrated in Example 38. The GalNAc.sub.3 cluster portion of the
targeting group GalNAc.sub.3-19 (GalNAc.sub.3-19.sub.a) can be
combined with any cleavable moiety. In a certain embodiment, the
cleavable moiety is --P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The
structure of GalNAc.sub.3-19 (GalNAc.sub.3-19.sub.a-CM-) is shown
below:
##STR00194##
Example 49
Preparation of Therapeutic Agent 210 Comprising GalNAc.sub.3-20
##STR00195## ##STR00196##
[0866] Compound 205 was prepared by adding PFP-TFA and DIEA to
6-(2,2,2-trifluoroacetamido)hexanoic acid in acetonitrile. The
6-(2,2,2-trifluoroacetamido)hexanoic acid was prepared by adding
triflic anhydride to 6-aminohexanoic acid. The reaction mixture was
heated to 80 .degree. C., then lowered to rt. Compound 210,
comprising a GalNAc.sub.3-20 targeting group, is prepared from
compound 208 using the general procedures illustrated in Example
38. The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-20 (GalNAc.sub.3-20.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-20 (GalNAc.sub.3-20.sub.a-CM-) is shown below:
##STR00197##
Example 50
Preparation of Therapeutic Agent 215 Comprising GalNAc.sub.3-21
##STR00198##
[0868] Compound 211 is commercially available. Compound 215,
comprising a GalNAc.sub.3-21 targeting group, is prepared from
compound 213 using the general procedures illustrated in Example
38. The GalNAc.sub.3 cluster portion of the targeting group
GalNAc.sub.3-21 (GalNAc.sub.3-21.sub.a) can be combined with any
cleavable moiety. In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-21 (GalNAc.sub.3-21.sub.a-CM-) is shown below:
##STR00199##
Example 51
Preparation of Therapeutic Agent 221 Comprising GalNAc.sub.3-22
##STR00200##
[0870] Compound 220 was prepared from compound 219 using
diisopropylammonium tetrazolide. Compound 221, comprising a
GalNAc.sub.3-21 targeting group, is prepared from compound 220
using the general procedure illustrated in Example 38. The
GalNAc.sub.3 cluster portion of the targeting group GalNAc.sub.3-22
(GalNAc.sub.3-22.sub.a) can be combined with any cleavable moiety.
In a certain embodiment, the cleavable moiety is
--P(.dbd.O)(OH)-A.sub.d-P(.dbd.O)(OH)--. The structure of
GalNAc.sub.3-22 (GalNAc.sub.3-22.sub.a-CM-) is shown below:
##STR00201##
Example 52
Preparation of Therapeutic agent 230 Comprising GalNAc.sub.3-23
##STR00202##
[0872] Compound 222 is commercially available. 44.48 ml (0.33 mol)
of compound 222 was treated with tosyl chloride (25.39 g, 0.13 mol)
in pyridine (500mL) for 16 hours. The reaction was then evaporated
to an oil, dissolved in EtOAc and washed with water, sat.
NaHCO.sub.3, brine, and dried over Na.sub.2SO.sub.4. The ethyl
acetate was concentrated to dryness and purified by column
chromatography, eluted with EtOAc/hexanes (1:1) followed by 10%
methanol in CH.sub.2Cl.sub.2 to give compound 223 as a colorless
oil. LCMS and NMR were consistent with the structure. 10 g (32.86
mmol) of 1-Tosyltriethylene glycol (compound 223) was treated with
sodium azide (10.68 g, 164.28 mmol) in DMSO (100mL) at room
temperature for 17 hours. The reaction mixture was then poured onto
water, and extracted with EtOAc. The organic layer was washed with
water three times and dried over Na.sub.2SO.sub.4. The organic
layer was concentrated to dryness to give 5.3g of compound 224
(92%). LCMS and NMR were consistent with the structure.
1-Azidotriethylene glycol (compound 224, 5.53 g, 23.69 mmol) and
compound 4 (6 g, 18.22 mmol) were treated with 4A molecular sieves
(5 g), and TMSOTf (1.65 ml, 9.11 mmol) in dichloromethane (100mL)
under an inert atmosphere. After 14 hours, the reaction was
filtered to remove the sieves, and the organic layer was washed
with sat. NaHCO.sub.3, water, brine, and dried over
Na.sub.2SO.sub.4. The organic layer was concentrated to dryness and
purified by column chromatography, eluted with a gradient of 2 to
4% methanol in dichloromethane to give compound 225. LCMS and NMR
were consistent with the structure. Compound 225 (11.9 g, 23.59
mmol) was hydrogenated in EtOAc/Methanol (4:1, 250mL) over
Pearlman's catalyst. After 8 hours, the catalyst was removed by
filtration and the solvents removed to dryness to give compound
226. LCMS and NMR were consistent with the structure.
[0873] In order to generate compound 227, a solution of
nitromethanetrispropionic acid (4.17 g, 15.04 mmol) and Hunig's
base (10.3 ml, 60.17 mmol) in DMF (100mL) were treated dropwise
with pentaflourotrifluoro acetate (9.05 ml, 52.65 mmol). After 30
minutes, the reaction was poured onto ice water and extracted with
EtOAc. The organic layer was washed with water, brine, and dried
over Na.sub.2SO.sub.4. The organic layer was concentrated to
dryness and then recrystallized from heptane to give compound 227
as a white solid. LCMS and NMR were consistent with the structure.
Compound 227 (1.5 g, 1.93 mmol) and compound 226 (3.7 g, 7.74 mmol)
were stirred at room temperature in acetonitrile (15 mL) for 2
hours. The reaction was then evaporated to dryness and purified by
column chromatography, eluting with a gradient of 2 to10% methanol
in dichloromethane to give compound 228. LCMS and NMR were
consistent with the structure. Compound 228 (1.7 g, 1.02 mmol) was
treated with Raney Nickel (about 2 g wet) in ethanol (100 mL) in an
atmosphere of hydrogen. After 12 hours, the catalyst was removed by
filtration and the organic layer was evaporated to a solid that was
used directly in the next step. LCMS and NMR were consistent with
the structure. This solid (0.87 g, 0.53 mmol) was treated with
benzylglutaric acid (0.18 g, 0.8 mmol), HBTU (0.3 g, 0.8 mmol) and
DIEA (273.7 .mu.L 1.6 mmol) in DMF (5 mL). After 16 hours, the DMF
was removed under reduced pressure at 65.degree. C. to an oil, and
the oil was dissolved in dichloromethane. The organic layer was
washed with sat. NaHCO.sub.3, brine, and dried over
Na.sub.2SO.sub.4. After evaporation of the organic layer, the
compound was purified by column chromatography and eluted with a
gradient of 2 to 20% methanol in dichloromethane to give the
coupled product. LCMS and NMR were consistent with the structure.
The benzyl ester was deprotected with Pearlman's catalyst under a
hydrogen atmosphere for 1 hour. The catalyst was them removed by
filtration and the solvents removed to dryness to give the acid.
LCMS and NMR were consistent with the structure. The acid (486 mg,
0.27 mmol) was dissolved in dry DMF (3 mL). Pyridine (53.61 .mu.L
0.66 mmol) was added and the reaction was purged with argon.
Pentaflourotriflouro acetate (46.39 .mu.L 0.4 mmol) was slowly
added to the reaction mixture. The color of the reaction changed
from pale yellow to burgundy, and gave off a light smoke which was
blown away with a stream of argon. The reaction was allowed to stir
at room temperature for one hour (completion of reaction was
confirmed by LCMS). The solvent was removed under reduced pressure
(rotovap) at 70 .degree. C. The residue was diluted with DCM and
washed with 1N NaHSO.sub.4, brine, saturated sodium bicarbonate and
brine again. The organics were dried over Na.sub.2SO.sub.4,
filtered, and were concentrated to dryness to give 225 mg of
compound 229 as a brittle yellow foam. LCMS and NMR were consistent
with the structure.
[0874] Compound 230, comprising a GalNAc.sub.3-23 conjugate group,
is prepared from compound 229 using the general procedure
illustrated in Example 32. The GalNAc.sub.3 cluster portion of the
GalNAc.sub.3-23 conjugate group (GalNAc.sub.3-23.sub.a) can be
combined with any cleavable moiety to provide a variety of
conjugate groups. The structure of GalNAc.sub.3-23
(GalNAc.sub.3-23.sub.a-CM) is shown below:
##STR00203##
Example 53
Preparation of Therapeutic Agents Comprising a 5'-GalNAc.sub.2
Conjugate
##STR00204## ##STR00205##
[0876] Compound 120 is commercially available, and the synthesis of
compound 126 is described in Example 35. Compound 120 (1 g, 2.89
mmol), HBTU (0.39 g, 2.89 mmol), and HOBt (1.64 g, 4.33 mmol) were
dissolved in DMF (10 mL) and N,N-diisopropylethylamine (1.75 mL,
10.1 mmol) were added. After about 5 min, aminohexanoic acid benzyl
ester (1.36 g, 3.46 mmol) was added to the reaction. After 3h, the
reaction mixture was poured into 100 mL of 1 M NaHSO.sub.4 and
extracted with 2.times.50 mL ethyl acetate. Organic layers were
combined and washed with 3.times.40 mL sat NaHCO.sub.3 and 2.times.
brine, dried with Na.sub.2SO.sub.4, filtered and concentrated. The
product was purified by silica gel column chromatography
(DCM:EA:Hex, 1:1:1) to yield compound 231. LCMS and NMR were
consistent with the structure. Compounds 231 (1.34 g, 2.438 mmol)
was dissolved in dichloromethane (10 mL) and trifluoracetic acid
(10 mL) was added. After stirring at room temperature for 2 h, the
reaction mixture was concentrated under reduced pressure and
co-evaporated with toluene (3.times.10 mL). The residue was dried
under reduced pressure to yield compound 232 as the trifuloracetate
salt. The synthesis of compound 166 is described in Example 40.
Compound 166 (3.39 g, 5.40 mmol) was dissolved in DMF (3 mL). A
solution of compound 232 (1.3 g, 2.25 mmol) was dissolved in DMF (3
mL) and N,N-diisopropylethylamine (1.55 mL) was added. The reaction
was stirred at room temperature for 30 minutes, then poured into
water (80 mL) and the aqueous layer was extracted with EtOAc
(2.times.100 mL). The organic phase was separated and washed with
sat. aqueous NaHCO.sub.3 (3.times.80 mL), 1 M NaHSO.sub.4
(3.times.80 mL) and brine (2.times.80 mL), then dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The residue was
purified by silica gel column chromatography to yield compound 233.
LCMS and NMR were consistent with the structure. Compound 233 (0.59
g, 0.48 mmol) was dissolved in methanol (2.2 mL) and ethyl acetate
(2.2 mL). Palladium on carbon (10 wt % Pd/C, wet, 0.07 g) was
added, and the reaction mixture was stirred under hydrogen
atmosphere for 3 h. The reaction mixture was filtered through a pad
of Celite and concentrated to yield the carboxylic acid. The
carboxylic acid (1.32 g, 1.15 mmol, cluster free acid) was
dissolved in DMF (3.2 mL). To this N,N-diisopropylehtylamine (0.3
mL, 1.73 mmol) and PFPTFA (0.30 mL, 1.73 mmol) were added. After 30
min stirring at room temperature the reaction mixture was poured
into water (40 mL) and extracted with EtOAc (2.times.50 mL). A
standard work-up was completed as described above to yield compound
234. LCMS and NMR were consistent with the structure. Compound 235
is prepared using the general procedure described in Example 32.
The GalNAc.sub.2 cluster portion (GalNAc.sub.2-24.sub.a) of the
conjugate group GalNAc.sub.2-24 can be combined with any cleavable
moiety present on the therapeutic agent to provide a variety of
conjugate groups. The structure of GalNAc.sub.2-24
(GalNAc.sub.2-24.sub.a-CM) is shown below:
##STR00206##
Example 54
Preparation of Therapeutic Agents Comprising a GalNAc.sub.1-25
Conjugate
##STR00207##
[0878] The synthesis of compound 166 is described in Example 40.
Compound 236 is prepared using the general procedure described in
Example 32.
[0879] Alternatively, compound 236 is synthesized using the scheme
shown below, and compound 238 is used to form compound 236.
##STR00208##
[0880] The GalNAc.sub.1 cluster portion (GalNAc.sub.1-25.sub.a) of
the conjugate group GalNAc.sub.1-25 can be combined with any
cleavable moiety present on the therapeutic agent to provide a
variety of conjugate groups. The structure of GalNAc.sub.1-25
(GalNAc.sub.1-25.sub.a-CM) is shown below:
##STR00209##
Example 55
Preparation of Therapeutic Agents Comprising a GalNAc.sub.1-26 or
GalNAc.sub.1-27 Conjugate
##STR00210##
[0882] Compound 239 is synthesized via coupling of compound 47 (see
Example 14) to acid 64 (see Example 23) using HBTU and DIEA in DMF.
The resulting amide containing compound is phosphitylated, then
added to the 5'-end of a nucleotide(s). The GalNAci cluster portion
(GalNAc.sub.1-26.sub.a) of the conjugate group GalNAc.sub.1-26 can
be combined with any cleavable moiety present on the therapeutic
agent to provide a variety of conjugate groups. The structure of
GalNAc.sub.1-26 (GalNAc.sub.1-26.sub.a-CM) is shown below:
##STR00211##
[0883] In order to add the GalNAc.sub.1 conjugate group to the
3'-end of a nucleotide(s), the amide formed from the reaction of
compounds 47 and 64 is added to a solid support. The
oligonucleotide synthesis is then completed in order to form
compound 240.
##STR00212##
[0884] The GalNAc.sub.1 cluster portion (GalNAc.sub.1-27.sub.a) of
the conjugate group GalNAc-27 can be combined with any cleavable
moiety present on the therapeutic agent to provide a variety of
conjugate groups. The structure of GalNAc.sub.1-27
(GalNAc.sub.1-27.sub.a-CM) is shown below:
##STR00213##
Example 56
Preparation of Therapeutic Agents Comprising a GalNAc.sub.1-28 or
GalNAc.sub.1-29 Conjugate
##STR00214##
[0886] Compound 241 is synthesized using procedures similar to
those described in Example 49 to form the phosphoramidite
intermediate, which is then linked to the nucleotide(s). The
GalNAc.sub.1 cluster portion (GalNAc.sub.1-28.sub.a) of the
conjugate group GalNAc.sub.1-28 can be combined with any cleavable
moiety present on the therapeutic agent to provide a variety of
conjugate groups. The structure of GalNAc.sub.1-28
(GalNAc.sub.1-28.sub.a-CM) is shown below:
[0887] In order to add the GalNAc.sub.1 conjugate group to the
3'-end of a nucleotide(s), procedures similar to
##STR00215##
those described in Example 49 are used to form the hydroxyl
intermediate, which is then added to the solid support. Standard
oligonucleotide synthesis is then completed in order to form
compound 242.
##STR00216##
[0888] The GalNAc.sub.1 cluster portion (GalNAc.sub.1-29.sub.a) of
the conjugate group GalNAc.sub.1-29 can be combined with any
cleavable moiety present on the nucleotide(s) to provide a variety
of conjugate groups. The structure of GalNAc.sub.1-29
(GalNAc.sub.1-29.sub.a-CM) is shown below:
##STR00217##
Example 57
Preparation of Therapeutic Agents Comprising a GalNAc.sub.1-30
Conjugate
##STR00218##
[0890] Compound 246 comprising a GalNAc.sub.1-30 conjugate group,
wherein Y is selected from O, S, a substituted or unsubstituted
C.sub.1-C.sub.10 alkyl, amino, substituted amino, azido, alkenyl or
alkynyl, is synthesized as shown above. The GalNAc.sub.1 cluster
portion (GalNAc.sub.1-30.sub.a) of the conjugate group
GalNAc.sub.1-30 can be combined with any cleavable moiety to
provide a variety of conjugate groups. In certain embodiments, Y is
part of the cleavable moiety. In certain embodiments, Y is part of
a stable moiety, and the cleavable moiety is present on the
oligonucleotide. The structure of GalNAc.sub.1-30.sub.a is shown
below:
##STR00219##
Example 58
Synthesis of Oligonucleotides comprising a GalNAc.sub.2-31 or
GalNAc.sub.2-32 Conjugate
##STR00220##
[0892] Compound 250 comprising a GalNAc.sub.2-31 conjugate group,
wherein Y is selected from O, S, a substituted or unsubstituted
C.sub.1-C.sub.10 alkyl, amino, substituted amino, azido, alkenyl or
alkynyl, is synthesized as shown above. The GalNAc.sub.2 cluster
portion (GalNAc.sub.2-3 1 .sub.a) of the conjugate group
GalNAc.sub.2-31 can be combined with any cleavable moiety to
provide a variety of conjugate groups. In certain embodiments, the
Y-containing group directly adjacent to the 5' position of the
nucleotide(s) is part of the cleavable moiety. In certain
embodiments, the Y-containing group directly adjacent to the 5'
position of the nucleotide(s) is part of a stable moiety, and the
cleavable moiety is present on the nucleotide(s). The structure of
GalNAc.sub.2-31.sub.a is shown below:
##STR00221##
[0893] The synthesis of an oligonucleotide comprising a
GalNAc.sub.2-32 conjugate is shown below.
##STR00222##
[0894] Compound 252 comprising a GalNAc.sub.2-32 conjugate group,
wherein Y is selected from O, S, a substituted or unsubstituted
C.sub.1-C.sub.10 alkyl, amino, substituted amino, azido, alkenyl or
alkynyl, is synthesized as shown above. The GalNAc.sub.2 cluster
portion (GalNAc.sub.2-32.sub.a) of the conjugate group
GalNAc.sub.2-32 can be combined with any cleavable moiety to
provide a variety of conjugate groups. In certain embodiments, the
Y-containing group directly adjacent to the 5' position of the
nucleotide(s) is part of the cleavable moiety. In certain
embodiments, the Y-containing group directly adjacent to the 5'
position of the nucleotide(s) is part of a stable moiety, and the
cleavable moiety is present on the oligonucleotide. The structure
of GalNAc.sub.2-32.sub.a is shown below:
##STR00223##
Example 59
Synthesis of Therapeutic Nucleosides Comprising a Targeting Moiety
at the 3' Position
##STR00224##
[0896] Synthesis of the therapeutic nucleoside is performed as in
Cho et al., Tetrahedron, 2011, 67, 5498-5493. The carboxylic acid
of the targeting group is activated and conjugated to the
3'-hydroxyl group of the therapeutic nucleoside.
Example 60
Synthesis of Therapeutic Nucleosides Comprising a Targeting Moiety
at the 5' Position
##STR00225##
[0898] Following addition of a hexylamino linker to a therapeutic
nucleoside, the pentafluorophenyl ester of the targeting group is
coupled to the amino group of the linker to form the final product.
Sequence CWU 1
1
1313182DNAHepatitis B virus 1aattccacaa cctttcacca aactctgcaa
gatcccagag tgagaggcct gtatttccct 60gctggtggct ccagttcagg agcagtaaac
cctgttccga ctactgcctc tcccttatcg 120tcaatcttct cgaggattgg
ggaccctgcg ctgaacatgg agaacatcac atcaggattc 180ctaggacccc
ttctcgtgtt acaggcgggg tttttcttgt tgacaagaat cctcacaata
240ccgcagagtc tagactcgtg gtggacttct ctcaattttc tagggggaac
taccgtgtgt 300cttggccaaa attcgcagtc cccaacctcc aatcactcac
caacctcctg tcctccaact 360tgtcctggtt atcgctggat gtgtctgcgg
cgttttatca tcttcctctt catcctgctg 420ctatgcctca tcttcttgtt
ggttcttctg gactatcaag gtatgttgcc cgtttgtcct 480ctaattccag
gatcctcaac caccagcacg ggaccatgcc gaacctgcat gactactgct
540caaggaacct ctatgtatcc ctcctgttgc tgtaccaaac cttcggacgg
aaattgcacc 600tgtattccca tcccatcatc ctgggctttc ggaaaattcc
tatgggagtg ggcctcagcc 660cgtttctcct ggctcagttt actagtgcca
tttgttcagt ggttcgtagg gctttccccc 720actgtttggc tttcagttat
atggatgatg tggtattggg ggccaagtct gtacagcatc 780ttgagtccct
ttttaccgct gttaccaatt ttcttttgtc tttgggtata catttaaacc
840ctaacaaaac aaagagatgg ggttactctc tgaattttat gggttatgtc
attggaagtt 900atgggtcctt gccacaagaa cacatcatac aaaaaatcaa
agaatgtttt agaaaacttc 960ctattaacag gcctattgat tggaaagtat
gtcaacgaat tgtgggtctt ttgggttttg 1020ctgccccatt tacacaatgt
ggttatcctg cgttaatgcc cttgtatgca tgtattcaat 1080ctaagcaggc
tttcactttc tcgccaactt acaaggcctt tctgtgtaaa caatacctga
1140acctttaccc cgttgcccgg caacggccag gtctgtgcca agtgtttgct
gacgcaaccc 1200ccactggctg gggcttggtc atgggccatc agcgcgtgcg
tggaaccttt tcggctcctc 1260tgccgatcca tactgcggaa ctcctagccg
cttgttttgc tcgcagcagg tctggagcaa 1320acattatcgg gactgataac
tctgttgtcc tctcccgcaa atatacatcg tatccatggc 1380tgctaggctg
tgctgccaac tggatcctgc gcgggacgtc ctttgtttac gtcccgtcgg
1440cgctgaatcc tgcggacgac ccttctcggg gtcgcttggg actctctcgt
ccccttctcc 1500gtctgccgtt ccgaccgacc acggggcgca cctctcttta
cgcggactcc ccgtctgtgc 1560cttctcatct gccggaccgt gtgcacttcg
cttcacctct gcacgtcgca tggagaccac 1620cgtgaacgcc caccgaatgt
tgcccaaggt cttacataag aggactcttg gactctctgc 1680aatgtcaacg
accgaccttg aggcatactt caaagactgt ttgtttaaag actgggagga
1740gttgggggag gagattagat taaaggtctt tgtactagga ggctgtaggc
ataaattggt 1800ctgcgcacca gcaccatgca actttttcac ctctgcctaa
tcatctcttg ttcatgtcct 1860actgttcaag cctccaagct gtgccttggg
tggctttggg gcatggacat cgacccttat 1920aaagaatttg gagctactgt
ggagttactc tcgtttttgc cttctgactt ctttccttca 1980gtacgagatc
ttctagatac cgcctcagct ctgtatcggg aagccttaga gtctcctgag
2040cattgttcac ctcaccatac tgcactcagg caagcaattc tttgctgggg
ggaactaatg 2100actctagcta cctgggtggg tgttaatttg gaagatccag
catctagaga cctagtagtc 2160agttatgtca acactaatat gggcctaaag
ttcaggcaac tcttgtggtt tcacatttct 2220tgtctcactt ttggaagaga
aaccgttata gagtatttgg tgtctttcgg agtgtggatt 2280cgcactcctc
cagcttatag accaccaaat gcccctatcc tatcaacact tccggaaact
2340actgttgtta gacgacgagg caggtcccct agaagaagaa ctccctcgcc
tcgcagacga 2400aggtctcaat cgccgcgtcg cagaagatct caatctcggg
aacctcaatg ttagtattcc 2460ttggactcat aaggtgggga actttactgg
tctttattct tctactgtac ctgtctttaa 2520tcctcattgg aaaacaccat
cttttcctaa tatacattta caccaagaca ttatcaaaaa 2580atgtgaacag
tttgtaggcc cacttacagt taatgagaaa agaagattgc aattgattat
2640gcctgctagg ttttatccaa aggttaccaa atatttacca ttggataagg
gtattaaacc 2700ttattatcca gaacatctag ttaatcatta cttccaaact
agacactatt tacacactct 2760atggaaggcg ggtatattat ataagagaga
aacaacacat agcgcctcat tttgtgggtc 2820accatattct tgggaacaag
atctacagca tggggcagaa tctttccacc agcaatcctc 2880tgggattctt
tcccgaccac cagttggatc cagccttcag agcaaacaca gcaaatccag
2940attgggactt caatcccaac aaggacacct ggccagacgc caacaaggta
ggagctggag 3000cattcgggct gggtttcacc ccaccgcacg gaggcctttt
ggggtggagc cctcaggctc 3060agggcatact acaaactttg ccagcaaatc
cgcctcctgc ctccaccaat cgccagacag 3120gaaggcagcc taccccgctg
tctccacctt tgagaaacac tcatcctcag gccatgcagt 3180gg
3182220DNAArtificial sequenceSynthetic oligonucleotide 2gcagaggtga
agcgaagtgc 20320DNAArtificial sequenceSynthetic oligonucleotide
3ccaatttatg cctacagcct 20417DNAArtificial sequenceSynthetic
oligonucleotide 4ggcatagcag caggatg 17520DNAArtificial
sequenceSynthetic oligonucleotide 5aggagttccg cagtatggat
20620DNAArtificial sequenceSynthetic oligonucleotide 6gtgaagcgaa
gtgcacacgg 20720DNAArtificial sequenceSynthetic oligonucleotide
7gtgcagaggt gaagcgaagt 20816DNAArtificial sequenceSynthetic
oligonucleotide 8aggtgaagcg aagtgc 16916DNAArtificial
sequenceSynthetic oligonucleotide 9tccgcagtat ggatcg
161018DNAArtificial sequenceSynthetic oligonucleotide 10aatttatgcc
tacagcct 181122RNAArtificial sequenceSynthetic oligonucleotide
11uggaguguga caaugguguu ug 221215DNAArtificial sequenceSynthetic
oligonucleotide 12cctcacactg ttacc 151323DNAArtificial
sequenceSynthetic oligonucleotide 13acaaacacca ttgtcacact cca
23
* * * * *
References